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Part I. Introduction
Chapter 1
Current understanding of meningeal and cerebral 
vascular function underlying migraine headache
Based on: Cephalalgia, 2018, In press.
Levy D, Labastida-Ramírez A and MaassenVanDenBrink A.
Abstract
Background: The exact mechanisms underlying the onset of a migraine attack are not 
completely understood. It is, however, now well accepted that the onset of the excruciating 
headache of migraine is mediated by the activation and increased mechanosensitivity 
(i.e. sensitization) of trigeminal nociceptive afferents that innervate the cranial meninges 
and their related large blood vessels. 
Objective: To provide a critical summary of current understanding of the role that the cranial 
meninges, their associated vasculature, and immune cells play in meningeal nociception 
and the ensuing migraine headache.
Methods: We discuss the anatomy of the cranial meninges, their associated vasculature, 
innervation and immune cell population. We then debate the meningeal neurogenic 
inflammation hypothesis of migraine and its putative contribution to migraine pain. Finally, 
we provide insights into potential sources of meningeal inflammation and nociception 
beyond neurogenic inflammation and their potential contribution to migraine headache.
Background
Migraine is a complex, multifactorial neurological disorder affecting about 10% of the adult 
population worldwide [1]. It is the second most prevalent neurological disorder [1] and 
the first cause of disability in under 50s [2, 3]. While the exact mechanisms underlying the 
onset of a migraine attack remain unclear, it is now accepted that the development of the 
excruciating throbbing headache of migraine requires the initial activation and increased 
mechanosensitivity (i.e. sensitization) of trigeminal nociceptive afferents that innervate 
the cranial meninges and their related large blood vessels [4–7]. The goal of this review is 
to summarize current knowledge and understanding of the role that the cranial meninges 
and their related vasculature and cellular constituents play in the meningeal nociceptive 
processes underlying the onset of migraine headache.
(i) Anatomical features of the cranial meninges and their associated vasculature
The cranial meninges are comprised of two main distinct layers: the dura mater, or 
pachymeninx, a thick layer of connective tissue apposing to the cranium, and the 
leptomeninges. The latter can be further separated into the arachnoid and pia mater. The 
dura mater can be divided anatomically into three layers, the endosteal (periosteal) layer, 
the inner meningeal layer, and the dural border cell layer, or subdural neurothelium [8]. 
The dural layers are fused in most places, but separate to form the venous sinuses and 
at the Falx cerebri. The dural border cell layer is attached to the outer layer of the 
arachnoid – the arachnoid barrier cell layer – by occasional cell junctions, or desmosomes. 
Under various pathological conditions, such as in the case of subdural hematoma, damage 
to the dural border cell layer can lead to separation of the dura from the arachnoid 
and the formation of a ‘‘subdural space’’ [8]. The arachnoid layer connects to the thin 
piamater via collagen trabeculae to form the subarachnoid space, which is filled with 
cerebrospinal fluid (CSF). The pia mater, the most inner meningeal layer, abuts a cortical 
barrier layer made of astrocyte endfoot processes (i.e. the glia limitans, Figure 1(a)). 
Blood vessels within the subarachnoid space are coated by a pia mater layer (hence the 
name pial vessels). As arteries penetrate the brain, a single-layered sheath of pial cells 
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Figure 1. Overview of the cranial meninges and their associated constituents.
(a) Schematic illustration of meningeal innervation components in relation to superficial cortical 
constituents and their mediators (red and yellow, denoting molecules released from neurons and 
astrocytes respectively), which upon reaching the subarachnoid space via diffusion or bulk flow, could 
underlie the cortical to meninges signaling in migraine with aura and perhaps also in migraine without 
aura. (b) Postulated crosstalk between meningeal autonomic and sensory nerves, resident immune 
cells, fibroblasts and vessels that have been suggested to contribute to meningeal nociception and 
headache and receptor systems that have been (i) implicated in the genesis of migraine pain in clinical 
studies (black font), (ii) suggested to activate and/or sensitize the meningeal sensory system based 
on preclinical studies (blue font), or with questionable contribution to meningeal nociception and 
headache pain (red font). CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-
activating polypeptide; NO: nitric oxide; NA: noradrenaline; ACh: acetylcholine; NGF: nerve growth 
factor; BDNF: brain-derived neurotrophic factor; TNF-a: tumor necrosis factor; IL-1: interleukin-1; IL-6: 
interleukin 6; ATP: adenosine triphosphate; SP: substance P; NPY: neuropeptide Y; VIP: vasoactive 
intestinal peptide; ET: endothelin.
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is maintained for a short distance and separates between the vessel wall and the glia 
limitans [9, 10]. Upon entering the cortex, the pial layer that surrounds the arterioles 
becomes fenestrated. Penetrating veins lack a continuous pial layer [9]. The dura mater is 
highly vascularized. The arterial supply of the supratentorial dura mater comes primarily 
from branches of the posterior, middle (the largest), and anterior meningeal arteries, which 
arise from the occipital, maxillary, and ophthalmic arteries respectively. Meningeal arteries 
lie predominantly in the endosteal layer.
 The intracranial middle meningeal artery, which enters the cranium through the 
foramen spinosum, runs in grooves in the inner table of the calvarium, surrounded almost 
on three sides by bone [11]. A dense capillary network occurs in the inner meningeal 
layer of the dura. The major dural veins, which run primarily parallel to the path of the 
meningeal arteries, drain into efferent vessels in the periosteal layer or the dural venous 
sinuses. The dural venous sinuses absorb CSF from the subarachnoid space via arachnoid 
granulations. Studies in rodents also identified a dural lymphatic vascular network alongside 
blood vessels, primarily the middle meningeal artery, superior sagittal sinus, and transverse 
sinuses [12-15]. A recent study in non-human primates and humans has shown that the dural 
lymphatic system drains macromolecules from the dura [15]. In rodents, dural lymphatics 
drain CSF and parenchymal interstitial fluid [13, 14], but whether such lymphatic drainage 
also occurs in humans remains to be determined [16].
Innervation of the cranial meninges
The cranial meninges are innervated by sensory and autonomic nerves (Figure 1(b)). The 
sensory innervation of the dura mater originates primarily in the ophthalmic branch of 
the trigeminal ganglion but also from the mandibular and maxillary branches. Studies on 
samples obtained from humans, cats, and rodents have demonstrated nerve fibers in the 
supratentorial dura, along arteries, as well as at the tentorium cerebelli, and the 
venous sinuses [12, 17–20]. Using immunohistochemistry in animal and human tissue, axons 
innervating the cranial dura, cranial arteries and venous sinuses have been shown to express 
the sensory neuropeptides CGRP (the most abundant) and substance P [19, 21–23]. Pituitary 
adenylate cyclase-activating polypeptide (PACAP) was recently found to be co-expressed 
with CGRP in some dural nerve fibers [24]. Glutamate was also identified in trigeminal 
ganglion cells of rats, albeit primarily in neurons that do not express CGRP [25]. While there 
is no available data to suggest expression of glutamate in meningeal afferents, a recent 
retrograde tracing study in the mouse identified vesicular glutamate transporter 3 in a 
subpopulation of small diameter dural afferents [26]. 
 The dura mater is also innervated by autonomic fibers that express PACAP, 
neuronal nitric oxide synthase (nNOS), vasoactive intestinal polypeptide (VIP), tyrosine 
hydroxylase (TH), acetylcholine (ACh), and neuropeptide Y (NPY) [18, 21–24, 27–31]. 
Ultrastructural studies conducted in the rat localized some peptidergic fibers’ termination 
in the vicinity, or walls, of dural blood vessels including lymphatics; axon terminations on 
collagen bundles in the dural connective tissue have been shown to be more abundant, 
however [12, 18]. Within the leptomeningeal, which lack their own blood supply, the cerebral 
(pial) arteries are the primary sites that receive sensory and autonomic innervations by 
fibers that originate from sympathetic, parasympathetic, and sensory trigeminal ganglia 
(Figure 1(a)). 
 
Immunohistochemistry studies together with denervation and tracing studies identified 
trigeminal nerves expressing substance P and CGRP, as well as autonomic nerves that 
express NPY, VIP, nNOS, ACh, and tryptophan-5-hydroxylase [28, 32–39]. The sensory and 
autonomic innervation of cerebral pial vessels is primarily localized to the subarachnoid 
space and does not follow the vessels when they penetrate the cortex; the loss of pial sheath 
in the penetrating arteriole is also accompanied by the loss of perivascular innervation. 
Ultra-structurally, cerebral pial arteries are innervated by peptidergic sensory afferents 
that terminate either in the outer layer of the adventitia (substance P) or in the inner layer 
of the adventitia (CGRP), close to arterial smooth muscle cells [40].
Meningeal immune cells 
Cytochemical and immunohistochemical studies in naive rats and mice localized resident 
immune cells to the dura mater (Figure 1(b)). Macrophages, which express numerous 
antigens (e.g. CD163, CD68) [41, 42] can be found along dural vessels, but also remotely 
from large vessels. In rodents, resident macrophages that express the chemokine receptor 
CX3CR1 were also localized to the dura and near pial vessels [43, 44]. The dura mater 
also harbors a sizeable population of mast cells (MCs) [19, 45–47]. Dural MCs are found in 
the endosteal/periosteal layer and are associated with blood vessels, dural sensory axons 
expressing CGRP, or substance P, and sympathetic fibers [27, 47, 48]. In the rat, dural MCs 
can also be found in a distinctive ‘‘linear arrays’’ arrangement [19, 46]. In the rat, a unique 
and much denser population of dural MCs is also found immediately caudal to the transverse 
sinus and medial to the superior cerebellar veins, which empty into the sinus, on either side 
of the midline [19]. 
 Studies on human dural tissue also identified perivascular MCs in the periosteal 
dura [49]. In rats and mice, there is also a small population of MCs localized to the pia [50, 51]. 
Meningeal MCs can be classified based on their histochemical properties, using alcian blue 
and safranin staining [50, 52, 53]. Using these staining properties, it has been shown that 
the densities of subsets of dural MCs undergo dynamic changes in female rats during the 
estrous cycle that are estrogen-dependent [53]. Dendritic cells – antigen presenting cells 
expressing MHC class II and CD11c markers – are localized to the inner layer and connective 
tissue of the dura, in the arachnoid membrane, and pia mater layer [41, 42, 44, 54, 55]. 
Studies in naive mice demonstrated a small number of T lymphocytes also in the dura, with 
females showing higher numbers [13, 54, 55]. Memory CD4+ and CD3 T cells can also be 
found in the subarachnoid space [56, 57].
(ii) The meningeal neurogenic inflammation hypothesis of migraine
In vivo electrophysiological studies provided important information about the basic response 
properties of trigeminal dural afferents [58]. Knowledge about the response properties of 
leptomeningeal afferents is poor, however. Furthermore, knowledge of the endogenous 
processes that drive the activation and increased sensitivity of both dural and leptomeningeal 
afferents during a clinically occurring headache attack such as that of migraine is also 
limited. Tissue injury associated with local inflammation is a major driver of nociceptors’ 
activation, sensitization and pain. However, frank tissue injury or pathology has yet to be 
demonstrated in migraine (or any other primary headache condition). Nevertheless, a major 
hypothesis implicates local sterile meningeal inflammation as a key event that mediates the 
prolonged activation and sensitization of meningeal afferents and the origin of migraine 
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headache [59, 60] (see below for further discussion on the contribution of meningeal 
neurogenic inflammation to meningeal nociception). Numerous clinical findings gathered 
over the years provided key, yet indirect, support for this inflammatory hypothesis of 
migraine. Among those are increased levels of inflammatory mediators in the cephalic venous 
outflow [61, 62] and the ability of corticosteroids and non-steroidal-anti-inflammatory drugs 
to abort migraine pain [63, 64]. Landmark preclinical studies in rodents provided indirect 
support for this hypothesis by showing that meningeal afferents are inflammatory sensors 
and can become persistently activated and sensitized to mechanical stimuli following local 
stimulation with mediators found in inflammatory exudates [59, 65–69].
 The origin of such meningeal inflammatory response in primary headaches, and 
particularly in migraine, remains nevertheless elusive. In their hypothesis paper, Moskowitz 
and colleagues [70] proposed that ‘‘the headache phase of migraine may develop as a result of 
an abnormal interaction (and perhaps an abnormal release) of vasoactive neurotransmitters 
from the terminals of the trigeminal nerve with large intracranial and extracranial blood 
vessels’’. The meningeal process implicated in this hypothesis was neurogenic inflammation, 
a peripheral response comprised of (i) increased capillary permeability leading to plasma 
protein extravasation (PPE), (ii) arterial vasodilatation, and (iii) activation of resident 
immune cells. Neurogenic inflammation results from activity-dependent release of 
vasoactive substances, in particular substance P and CGRP from peripheral nerve endings of 
primary afferent nociceptors: this release occurs through an ‘‘axon reflex’’ process, where 
action potentials from acutely activated afferents are conducted antidromically and invade 
peripheral end branches [71]. The finding that dural and pial blood vessels are innervated 
by sensory nerves that express these vasoactive neuropeptides (see above) provided key 
support for the neurogenic inflammation hypothesis of migraine, which further led to the 
conceptualization of the trigeminovascular system and its role in migraine headache [72].
Increased meningeal vascular permeability
An early study in animals described the development of meningeal PPE in the dura mater 
following electrical stimulation of the trigeminal ganglion [73]. The subsequent findings that 
antimigraine drugs, including ergot alkaloids and triptans, could block this experimental 
meningeal PPE [74, 75] provided additional indirect support for the role of meningeal 
neurogenic inflammation in migraine headache. The inability to resolve the meningeal 
tissue and its vasculature in humans using imaging techniques remains a major hurdle in 
assessing meningeal PPE during migraine headache. However, one imaging study, conducted 
on a single migraine patient, suggested an increase in meningeal vascular permeability 
during an attack [76]. Current technical improvements in meningeal imaging [15] may be 
able to provide more clues into this process. In agreement with studies on non-cranial 
tissues [77], animal studies also implicated substance P and its neurokinin 1 receptor (NK1-R) 
in mediating meningeal neurogenic PPE [78, 79]. However, available data does not support 
a role for NK1 signaling in migraine pain. In clinical trials, NK1-R antagonists failed to abort 
migraine headache [80, 81]. While such negative data argues against the involvement of 
substance P signaling and meningeal neurogenic PPE in migraine pain, the possibility that 
the doses of NK1-R antagonists used in those studies were suboptimal and thus did not 
reach biologically-active plasma levels were considered [81, 82]. The possibility that during 
migraine, substance P does play a role in mediating a meningeal PPE response, but only 
during the early stages of the attack, may also be entertained. However, a small study 
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reported the absence of substance P release into the internal jugular vein prior to the onset 
of the headache phase of a migraine with aura attack induced by intracarotid Xenon-133 
injection [83], suggesting lack of substance P involvement in the triggering mechanisms of 
migraine headache. 
Meningeal vasodilatation
Arterial vasodilation – another major characteristic of experimental meningeal neurogenic 
inflammation – has also been advocated for many years as a key cause of migraine headache. 
The theory that vasodilatation plays a role in migraine headache was largely based on the 
early observations of Graham and Wolff [84], who described a close relationship between 
the decrease in pulsation amplitude of the temporal artery and the decline of headache 
intensity following treatment with the vasoconstrictor (and antimigraine drug) ergotamine. 
The later observations that intracranial arteries (mainly the dural branches of the middle 
meningeal artery) are sensitive to painful stimuli [85] extended the extracranial vascular 
hypothesis to the intracranial vasculature. Moreover, when distending these arteries, a 
throbbing headache accompanied with nausea was induced, while neither constriction of 
the artery lumen nor stimulation of the dura mater 2 mm away from such vessels produced 
headache pain. These findings have led to the notion that dilatation and distention of 
intracranial dural meningeal arteries are a major source of migraine headache [86]. Thus, 
it was hypothesized that selective cranial vasoconstrictors would be more efficient and 
safe antimigraine drugs than ergotamine, which has affinity for a wide array of receptors, 
including 5-HT and dopamine [87]. 
 On this basis, in the beginning of the 1970s, Humphrey et al. aimed at identifying 
novel antimigraine agents capable of mimicking the beneficial effects of 5-HT without its 
side-effects [88]. As a result, more selective vasoconstrictors of the cranial extra-cerebral 
circulation were developed, which allowed the identification of the 5-HT1B receptor (at 
the time of the development designated as 5-HT1-like receptor) as responsible for this 
vasoconstriction. Subsequently, one of those agents, the antimigraine drug sumatriptan, 
has been shown to produce selective cranial vasoconstriction in dogs, and to display much 
less activity in other vascular beds [89]. In accordance with the hypothesis on which its 
development was based, migraine-related changes in the middle cerebral artery blood 
flow, congruent with vasodilation, were reversed by sumatriptan [83]. Unfortunately, 
the vasoconstrictor effects of sumatriptan were not entirely selective for the cranial 
circulation (i.e. 5-HT1B receptors were also localized in coronary arteries), suggesting that 
the antimigraine effect of sumatriptan may not be entirely related to meningeal arterial 
vasoconstriction. Whether meningeal vasodilatation plays a causative role in migraine, or 
is merely an epiphenomenon – a secondary event arising from the activation of intracranial 
trigeminal afferents and the ensuing meningeal release of vasodilatory neuropeptides – 
remains a hotly debated subject [90]. However, neuroimaging studies have revealed that 
triptans produce cranial vasoconstriction; this may well contribute to their antimigraine 
effects [91, 92]. 
 Assuming that receptor density expression in the cranial vasculature and the 
trigeminal ganglion have a close similarity, it could indeed be that triptans’ antimigraine 
effects are not only mediated via the blood vessels, but via other structures, such as peripheral 
nerve endings of meningeal afferents [93] (but see also 94), their trigeminal ganglion cell 
bodies or central nerve endings in the trigemino-cervical complex [95]. According to the 
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‘‘vascular theory’’, intracranial vasodilatation (but possibly also extracranial) leads to the 
activation of trigeminal afferents that innervate these vessels, with ensuing headache [96]. 
A key process that could hypothetically mediate the activation of meningeal afferents by 
arterial vasodilatation is the stimulation of mechanosensitive stretch receptors located 
within the dilated vessels’ walls. While electrophysiological studies indicate that meningeal 
afferents that innervate the dura mater are mechanosensitive [58, 59], anatomical studies 
in animals suggest that most of the sensory innervation of the dura mater terminates in the 
connective tissue, far from the vessels [18]. Animal studies showing that administration of 
vasoactive agents, including CGRP and NO, failed to activate afferents with perivascular 
dural receptive fields [97–99], which further suggests that dural vasodilation alone is not 
sufficient to activate mechanosensitive meningeal afferents.
 As indicated above, the sensory innervation of intracranial pial vessels, which may 
also be mechanosensitive, terminates in the outer layer of the adventitia (substance P) or 
in the inner layer of the adventitia (CGRP), close to arterial smooth muscle cells [40]; but it 
is unclear whether pial afferents can be directly activated by arterial dilatation per se. The 
finding of only a slight dilatation of intracranial arteries during migraine attacks that was 
not reduced by effective treatment with sumatriptan [100] argues against the activation 
of meningeal afferents in responses to such intracranial vasodilatation in migraine (and 
see also 101). Moreover, headache provocation studies in healthy subjects revealed that 
migraine-like headaches can be induced by oral sildenafil, a phosphodiesterase 5 inhibitor, 
while no cerebral arterial vasodilation was detected. On the other hand, experimentally-
induced headache in migraine patients revealed that the vasodilator adrenomedullin did 
not induce migraine headaches or changes in mean blood flow velocity of the middle 
cerebral artery. To properly interpret these studies, it should be taken into account that, 
due to technical limitations, only extracranial parts of the meningeal vasculature [100] or 
intracerebral vessels [102, 103] were measured and thus potentially do not always exactly 
reflect changes that occur in the meningeal vasculature [104]. 
 Further, although sildenafil is strictly not a vasodilator per se, it is quite likely 
that its phosphodiesterase 5 inhibitory activity may lead to vasodilatation depending on the 
levels of cGMP in a blood vessel. Indeed, in isolated meningeal arteries from rats or patients 
undergoing neurosurgery, VIP, SNP, CGRP and PACAP, as well as sildenafil, can promote 
vasorelaxation. Interestingly, infusion of PACAP38 causes headache and vasodilation in both 
healthy subjects and migraine patients. In contrast, infusion of VIP in people with migraine 
evoked a marked cephalic vasodilation, but not a migrainous headache [105], which is also 
congruent with the notion that a provoked intracranial vasodilation alone is not sufficient 
to activate meningeal afferents. On the other hand, the above-mentioned discrepancy 
between VIP and PACAP may also be assigned to the shorter-lasting vasodilatory response 
evoked by VIP compared to that by PACAP (M Ashina, personal communication). Studies 
investigating the effects of VIP infusions over a longer period of time may explain whether 
the discrepancy between VIP and PACAP is due to different pharmacokinetics, or whether 
provoked vasodilatation is indeed not sufficient to provoke a migraine-like headache.
 Intriguingly, the receptors mediating dilatation in the meningeal circulation 
closely resemble many of the receptors expressed on the trigeminal ganglion, hampering a 
dissection between pure vascular and trigeminal effects. Increased diameter of meningeal 
vessels, whether dural or pial, may however lead to meningeal tissues’ stretching that could 
activate mechanosensitive afferents, in particular during a sensitized state [59, 101, 106]. 
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Key studies in rodents have led researchers to suggest that trigeminal nerve endings of 
activated perivascular meningeal afferents release CGRP, and this is the primary driver of 
neurogenic meningeal vasodilation in migraine [107]. The view that cephalic vasodilatation 
in migraine is neurogenically mediated received strong support from the findings of Goadsby 
and colleagues [108, 109], who demonstrated elevated levels of CGRP in the extra-cerebral 
circulation during a migraine attack. While these findings could not be replicated in a later 
study [110], the validity of its methodology was questioned subsequently [111]. Despite 
the inconclusive findings of increased CGRP levels within the intracranial circulation during 
a migraine attack [83, 112], the finding that sumatriptan normalized the elevated CGRP 
levels observed in the extra-jugular vein, concomitant with headache relief [109] further 
promoted the notion that trigeminal release of CGRP and the ensuing cranial neurogenic 
vasodilatation contribute to migraine headache. 
 Moreover, a human experimental model of neurogenic vasodilation, where 
capsaicin is applied to a trigeminal (V1) dermatome in the human forehead to release 
endogenous CGRP (via activation of TRPV1 channels), confirmed that sumatriptan, most 
likely via 5 -HT1D/1F receptors, pre-synaptically inhibits CGRP release from trigeminal nerve 
endings [113]. The key findings that exogenous CGRP infusions could trigger delayed migraine-
like headaches accompanied by a unilateral dilatation of the middle meningeal artery, and 
no dilation of the middle cerebral artery [114, 115] suggested a peripheral role for CGRP 
and its related meningeal vasodilation in migraine headache, especially since CGRP, like 
substance P, is unlikely to pass readily into the brain, due to its large molecular weight. 
It should be noted, however, that in chronic migraine an elevated CGRP level was also 
detected in the CSF [116], pointing to the possibility that CGRP released also from cortical 
parenchymal cells [117] (or possibly from pial afferents) is also involved in migraine. 
 In a recent preliminary study, peripheral administration of CGRP to mice 
overexpressing the CGRP receptor subunit RAMP1 in smooth muscle cells (including in 
vascular smooth muscle cells) promoted light aversion (a rodent behavior suggested to 
be linked to the photophobia phenomenon of migraine), pointing to the possibility that 
over-activation of dural arterial cells can promote migraine headache [118]. Whether such 
migraine-related response is mediated via enhanced meningeal vasodilatation or augmented 
release of algesic mediators from meningeal vascular smooth muscle cells (VSMCs, see also 
below) remain to be determined. Taken together, the abovementioned studies demonstrate 
a complex bidirectional cross-talk between cranial blood vessels and their trigeminal nerve 
endings in migraine pathogenesis. 
Neurogenic activation of meningeal immune cells
Another major feature of neurogenic inflammation is the activation of immune cells [119]. 
Of particular interest to migraine are meningeal MCs [106]. Activated MCs are 
proinflammatory and release a host of pro-nociceptive mediators [120] that can lead to 
the activation and sensitization of meningeal afferents [66, 67, 121, 122]. Clinical studies 
reported elevated plasma levels of the MC mediator’s histamine, tryptase and TNF-alpha 
during migraine [61, 123, 124], supporting the involvement of MCs in migraine. A role for MCs 
in meningeal neurogenic inflammation was initially supported by the finding that stimulation 
of the trigeminal ganglion to produce dural PPE also promoted morphological changes in 
dural MCs suggestive of degranulation [52, 125]. The anatomical localization of dural MCs in 
close apposition to terminals of dural afferents that express substance P and CGRP provided 
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indirect support for the ability of trigeminal axon reflex to activate intracranial dural MCs. 
The activation of MCs’ NK1-R is thought to promote their degranulation by substance P [126]. 
However, the presumed lack of involvement of NK1 signaling in migraine headache suggests 
that if dural MCs are degranulated in response to meningeal axon reflex, and this process 
contributes to the headache of migraine (see also below), it is unlikely to involve substance P 
receptor signaling. Release of CGRP from activated meningeal afferents may also promote MC 
degranulation in experimental animals, although with less potency than substance P [127]. 
  In vitro stimulation of rodent’s meningeal MCs with CGRP induced 5-HT and histamine 
release [128, 129]. The MC degranulating effect of CGRP may be nonetheless rodent specific. 
Rodent MCs express the required components of the CGRP receptor system, calcitonin receptor-
like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) [24, 130, 131]. Human 
dural MCs, however, express only RAMP1 [24]. Nonetheless, the possibility that CGRP signals 
via the calcitonin (CTR)/RAMP1 receptor complex [132] in these cells should not be ignored. 
Meningeal release of PACAP may also promote MC degranulation [133, 134]. A recent 
clinical study demonstrated the expression of the PACAP receptor VPAC1 on human skin 
MCs [135]. Whether PACAP can promote the degranulation of human dural MCs is currently 
unknown. Meningeal MCs have been shown to become activated after exposure to 
carbachol [47, 136, 137], suggesting that activation of meningeal parasympathetic efferents 
could promote meningeal neurogenic inflammation [138]. While cranial parasympathetic 
activation has been implicated in trigeminal autonomic cephalalgias [139], and may 
accompany migraine attacks in some patients [140], its role in promoting meningeal 
nociception and migraine headache is less clear. Taken together, whether meningeal 
neurogenic inflammation, either mediated by release of sensory or autonomic transmitters, 
promotes a sufficient dural MC degranulation response that can lead to the activation and 
sensitization of meningeal afferents with ensuing headache remains to be determined. 
Perivascular meningeal macrophages may play a role in meningeal nociception and 
potentially in headache.
 Macrophages can release a host of inflammatory and nociceptive mediators 
including prostaglandins, cytokines, chemokines, and high levels of NO that can act 
directly, or indirectly, on meningeal afferents to promote their activation and mechanical 
sensitization [68, 69, 97, 99, 121]. The finding that systemic administration of the headache 
and migraine trigger nitroglycerin upregulates proinflammatory cytokines and the inducible 
(and pro-inflammatory) isoform of nitric oxide synthase (iNOS) in rat dural macrophages, as 
well as promoting dural inflammation [141], further suggests a role for these immune cells 
in headache. While functional interactions between sensory or autonomic transmitters, 
and meningeal macrophages are yet to be defined, in other tissues CGRP rather inhibits 
proinflammatory macrophage function [142–144]. A role for resident DCs and circulating 
T cells in meningeal neurogenic inflammation remains unknown. While studies in other 
tissues suggest that CGRP downregulates the expression of the nociceptive cytokine 
TNF-alpha in DCs, activation of peptidergic nociceptive afferents can drive DC production of 
the proinflammatory and nociceptive cytokine IL-23 with subsequent tissue PPE [145, 146]. 
T cells have been shown to mediate neuropathic pain in rodent models [147], but a role 




How might meningeal neurogenic inflammation be triggered during migraine? 
One critical unknown aspect of the neurogenic inflammation hypothesis of migraine is 
the identity of the endogenous processes that lead to the initial activation of meningeal 
afferents and the ensuing release of neuropeptides. One event that has been hypothesized 
to trigger meningeal neurogenic inflammation is cortical spreading depression (CSD), a 
wave of neural and glial depolarizations (followed by neuronal silencing) that is thought to 
underlie the aura phase of migraine [72]. In rats and rabbits, induction of a single CSD event 
gives rise to a brief dilatation of pial arteries and increase in cerebral blood flow [148]. 
The induction of CSD-evoked cortical hyperemia in the mouse [148] (and also in human 
subjects [149]), however, is less clear. The dilation of pial vessels in response to CSD has 
been shown to be mediated in part by CGRP receptor signaling [150–152], suggesting a short-
lasting activation of peptidergic leptomeningeal afferents. The mechanisms underlying the 
pial afferent response to CSD are incompletely understood, but presumably involve the 
release of small nociceptive molecules, such as nitric oxide, potassium ions and ATP in 
the superficial cortical parenchyma during the passage of the CSD wave, their diffusion or 
bulk flow into the subarachnoid space and subsequent action upon leptomeningeal afferent 
nerve endings [153] (Figure 1(a)). 
 A key part of the meningeal neurogenic inflammation theory of migraine posits 
that leptomeningeal afferents have additional branches that terminate in the dura mater 
(Figure 1(a)), and that activation of leptomeningeal afferents can promote the release of 
proinflammatory peptides also in the dura mater with ensuing local sterile inflammatory 
responses [154]. Anatomical support for this hypothesis comes from rodent studies 
demonstrating a sizable number of single trigeminal ganglion neurons that project to both 
the middle cerebral, and middle meningeal arteries, or other dural sites [17], and a small 
number of dural fibers that issue collateral branches to the pia at the frontal part of the 
brain [155]. The finding of prolonged dural vasodilatation and PPE following a single CSD 
event that were dependent upon an intact trigeminal nerve and activation of NK1-R [154] 
provided further support for this theory. In that study, CSD evoked prolonged dilatation 
of the dural middle meningeal artery that was also dependent on parasympathetic 
outflow from sphenopalatine ganglion neurons, highlighting the additional contribution of 
trigemino-parasympathetic reflex to meningeal NI. More recently, an electrophysiological 
single unit recording in a rat model provided direct evidence for the acute activation 
of a subpopulation of dural afferents during the passage of the CSD wave [156, 157]. 
 A direct link between CSD, meningeal neurogenic inflammation and the activation 
of dural or leptomeningeal afferents, remains to be established. CSD has been shown to 
promote meningeal MC degranulation [158] and conformational changes in meningeal 
macrophages, reminiscent of an inflammatory response [44]. CSD also leads to arrested 
migration of meningeal DCs, suggesting inflammatory activation [44]. It is unknown, 
however, whether these inflammatory changes occur in response to the activation of 
meningeal afferents (i.e. via the release of neuropeptides). Nonetheless, the finding that 
CSD (which likely contributes to the headache in migraine with aura) leads to meningeal 
inflammatory changes involving MCs and macrophages, similar to those provoked by other 
migraine triggers such as GTN and F38 (which trigger migraine without aura), suggest that 
meningeal inflammation (whether this involves the release of sensory neuropeptides or not) 
serves as a common mechanism of migraine headache onset. 
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Can meningeal neurogenic inflammation actually promote meningeal nociception? 
Despite the indirect evidence for meningeal neurogenic inflammation in animal models 
of migraine, a critical question remains as to whether this event actually contributes 
to meningeal nociception and headache. Previous studies examined the effect of acute 
stimulation of primary afferent neurons that innervate other tissues on the sensitivity of 
primary afferent nociceptive neurons, but have yielded conflicting data. For example, 
studies in monkeys [159] and rats [160] have shown that stimulation of cutaneous nociceptive 
afferents did not subsequently alter their ongoing activity, mechanosensitivity, or heat 
sensitivity. A study in rabbits, however, reported the development of heat sensitization 
of nociceptive afferents following antidromic afferent stimulation [161]. A rat study that 
employed local capsaicin stimulation to evoke acute excitation of cutaneous afferents 
documented a delayed and prolonged increase in the afferents’ ongoing activity and 
mechanosensitivity that were suggested to involve CGRP signaling [162]. Finally, we have 
shown recently that brief meningeal application with potassium levels, similar to that 
expected during CSD, can lead to prolonged activation of dural afferents [163].
 The finding that in addition to their acute activation, CSD also gives rise to prolonged 
activation and enhanced mechanosensitivity of meningeal afferents [156, 157, 164] may 
point to neurogenic inflammation as a nociceptive event. Nevertheless, numerous finding 
suggests meningeal nociception in response to CSD is not directly mediated by neurogenic 
inflammation. For example, persistent meningeal afferent activation still occurs following 
excision of the parasympathetic sphenopalatine ganglion [156], whose activation was 
critical to the CSD-evoked meningeal neurogenic vasodilatation. In addition, persistent 
meningeal afferent activation following CSD can occur in the absence of acute NI-mediated 
dural MC degranulation, as was observed in craniotomized animals, a preparation in which 
the majority of dural MCs are already in a state of degranulation prior to the induction 
of CSD [165]. As indicated above, studies in naive rats suggest that acute activation of 
meningeal CGRP receptors is not sufficient to activate or sensitize meningeal afferents [98]. 
While there is some evidence in rats and humans for the expression of the CGRP receptors 
components CLR and RAMP1 in the cytoplasm of some thick myelinated dural axons [24], 
these receptors were also reported to be localized specifically to the axons’ Schwann 
cells [130]. It also remains unclear whether these CLR/RAMP1 expressing dural afferents 
play a role in meningeal nociception as they are not co-localized with CGRP [24]. 
 The possibility that CGRP receptors are preferentially expressed on non-nociceptive, 
myelinated dural fast A fibers, which comprise about one-third of the myelinated axons in 
the nerves supplying the dura, and exhibit the highest thresholds and the lowest firing 
rates, as well as the lowest incidence of mechanosensitivity [12, 166] should be considered. 
Recent data further suggests that acute blockade of meningeal CGRP receptors, using 
systemic administration of olcegepant (BIBN4096), does not inhibit the prolonged activation 
and mechano-sensitization of meningeal afferents, in the wake of CSD, despite diminishing 
the related cerebral vasodilatation [163]. This data is congruent with the observations that 
CSD does not alter dural CGRP release [167] or leads to CGRP release into the external 
jugular vein [168]. However, the finding that a prolonged sequestering of CGRP, using a 
monoclonal antibody approach, can inhibit the prolonged activation of slow conducting 
A-delta afferents following CSD [169] points to the possibility that the basal CGRP level 
somehow modulates the responsiveness of a subpopulation of meningeal afferents.
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Such effects are likely to be restricted to the dura mater, as antibodies, due to their 
large molecular size, are unlikely to gain access to the leptomeningeal space (i.e. CSF). 
Finally, the finding that acute CGRP receptor blockade can inhibit prolonged meningeal 
afferent activation in response to their local stimulation with high physiological levels of 
potassium [163] further suggests that the indirect, pro-nociceptive effect of CGRP, likely 
mediated through its signaling on non-neural cells and in tandem with other nociceptive 
factors, may play a role in mediating meningeal nociception. However, whether the 
antimigraine prophylactic effects of monoclonal antibodies that target CGRP or its receptor 
are linked to acute inhibition of dural NI or other, unrelated peripheral effects of CGRP 
remains unknown.
 
(iii) Potential sources of meningeal nociception beyond neurogenic inflammation 
Activation of meningeal MCs
Beyond neurogenic inflammation, are there other mechanisms that could lead to prolonged 
activation of meningeal afferents and the ensuing headache? As indicated above, release of 
MC mediators in the vicinity of meningeal afferents could potentially lead to their activation 
and sensitization. While not directly related to meningeal neurogenic inflammation, a 
causative role for MCs in migraine headache was already considered more than 50 years 
ago [170]. In that study, injection of an MC degranulating agent, compound 48/80, into the 
cranial circulation gave rise to a headache resembling that of migraine. Levy et al. [165] 
have shown that degranulation of dural MCs, using compound 48/80 as in Sicuteri’s study, 
promoted persistent activation of the majority of meningeal afferents, as well as of 
nociceptive neurons in the trigeminal nucleus caudalis. This work suggested that extensive 
dural MC degranulation could serve as a powerful peripheral pro-nociceptive stimulus 
capable of triggering the activation of the peripheral and central components of the 
migraine pain pathway. The finding that activation of dural MCs was also associated with 
the development of cephalic tactile hypersensitivity [6] provided further indirect evidence 
for their role in meningeal nociception and migraine headache pain.
 The identity of non-neurogenic inflammation mechanisms that could lead to dural 
MC degranulation with ensuing enhanced meningeal nociception are unclear at present. 
Because there is no blood-dura barrier, it is conceivable that circulating factors, reaching 
the dural circulation, could lead to the degranulation of a sizable population of dural MCs. 
The finding that migraine is comorbid with MC-related conditions such as allergies and 
asthma [171, 172] points to a potential link between MC-related events and migraine. 
The involvement of peripherally-acting MCs in migraine is also congruent with the recent 
finding that migraine is genetically and environmentally similar to peripheral inflammatory 
conditions that also involve MCs, such as irritable bowel syndrome and cystitis [173]. 
Finally, it has been suggested that some migraine events may be triggered by various food 
ingredients acting upon MCs, a notion that gained support from studies showing potent 
migraine prophylactic action of the MC stabilizing agent cromoglycate in a subset of patients 
with food-related attacks [174, 175]. It remains unclear, however, what level of meningeal 
MC degranulation is actually nociceptive. A relatively low level of dural MC degranulation 
induced by systemic infusion of the migraine trigger nitroglycerin [141, 176] was not 
sufficient to promote activation of meningeal afferents in a rodent model [99]. However, 
in migraineurs, a higher density of meningeal MCs, potentially due to endocrine changes, 
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such as fluctuation in female sex hormones [53] or increased propensity of these immune 
cells to become activated in response to a given trigger, could potentially result in a robust 
proinflammatory that promotes the activation of meningeal afferents and lead to headache. 
Beyond vasodilatation: release of algesic mediators 
Vascular endothelial cells (ECs) and VSMCs are potentially important sources of algesic 
mediators that can activate and sensitize meningeal afferents. The vascular endothelium has 
been suggested to promote peripheral enhancement in pain (i.e. hyperalgesia) through the 
release of endothelin-1 [177] and ATP [178]. While a direct role for endothelin-1 in migraine 
has been questioned based on the lack of efficacy of endothelin receptor antagonism [179], 
its release from leptomeningeal vessels could potentially trigger CSD [180], and thus 
indirectly promote meningeal nociception. The genetic association between migraine, 
endothelin expression and vascular mechanisms [181, 182], as well as with the endothelin A 
receptor [183], also suggests a rather complex role for endothelin in migraine. Local release 
of ATP from the meningeal vasculature (but also from other meningeal cells) could promote 
acute activation of meningeal afferents [157], potentially via activation of afferent P2X2 
and P2X3 purinergic receptors [184]. Prolonged activation and/or sensitization of meningeal 
afferents mediated by these, and potentially other purinergic receptors localized to 
meningeal afferent nerve endings, remains, however, to be established.
 Indirect meningeal nociceptive effects of ATP, promoted by its action upon 
proinflammatory P2X7 receptors localized to resident meningeal immune cells, such as 
macrophages [185] may also be of importance to headache and migraine mechanisms. 
Release of NO and prostacyclin (PGI2) from the vascular endothelium may lead to meningeal 
nociception [66, 121]. The release of COX-2-derived prostanoids, as well as high levels of 
NO and proinflammatory cytokines, such as IL-1β from VSMCs could activate and sensitize 
meningeal afferents [68]. Finally, the finding that the migraine trigger nitroglycerin, which 
leads to delayed migraine attacks, evokes a delayed mechanical sensitization of meningeal 
afferents that depends upon inflammatory signaling (i.e. ERK phosphorylation) in meningeal 
arteries [99] further points to the role of non-vasodilating meningeal vascular mechanisms 
in migraine headache. Recent work suggests that dural fibroblasts, which serve as key 
building blocks of this meningeal tissue, can release algesic mediators such as IL-6 that can 
act upon meningeal afferents and promote migraine-like behaviors in rodents [186, 187] 
(Figure 1(b)). 
The role of cortical mediators 
The finding that CSD, an event that is primarily restricted to the cortex, can lead to the 
activation and mechanical sensitization of meningeal afferents points to the possibility that 
algesic factors, such as ATP, prostaglandins and NO that are released into the parenchymal 
interstitial fluid, gain access to the subarachnoid space, where they can act upon 
leptomeningeal afferents. The presence of the dura-arachnoid interface layer, however, is 
likely to impede the passage of these cortical mediators into the cranial dura mater and 
their nociceptive action on dural afferents. Are there any routes by which cortical-derived 
algesic factors could reach the dura and interact with its nociceptive afferents?
 CSF in the subarachnoid space enters the bloodstream in the dural venous sinuses, 
via arachnoid granulation. Afferents localized to the dural sinus walls, in particular to the 
sinus lumen [23], could potentially sense these mediators. However, this implies that these 
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afferents also sample venous blood – an unlikely occurrence – since blood itself has been 
shown to exert a nociceptive effect [188]. Alternatively, sensory nerve fiber terminals in the 
arachnoid granulations [189], which protrude through the dura, may become activated by 
CSF-derived nociceptive mediators. 
Conclusions and future perspectives 
While migraine is considered as a brain disorder, peripheral meningeal components 
including the sensory innervation of the cranial meninges and immune and vascular cells 
are likely to play a major role. A better understanding of the brain dysfunction processes 
and the nature of the cortical to meningeal signaling cascades that promote the activation 
and increased responsiveness of trigeminal nociceptive afferents is essential for the 
development of effective antimigraine prophylactic therapies. The finding that, genetically 
and environmentally, migraine is much closer to immune system diseases such as irritable 
bowel syndrome and cystitis/urethritis rather than to central nervous system specific 
conditions [173] further implies that migraine has a peripheral inflammatory origin that is 
not nervous system-specific. 
 The concept of neurogenic inflammation undoubtedly had a tremendous impact on 
migraine research and provided an important roadmap for the development of neuropeptide 
and receptor driven therapies for migraine. While meningeal neurogenic inflammation 
continues to be regarded as a causal factor in migraine headache, direct evidence for the 
occurrence of neurogenic inflammation during migraine and its role in meningeal nociception 
is limited at best. Future studies may provide better direct evidence for the presence of the 
various features of meningeal neurogenic inflammation or lack thereof during a migraine 
attack and, most importantly, whether they constitute active players in driving migraine 
pain rather than simply epiphenomena. The advent of monoclonal antibodies against CGRP 
or its receptor, which are too large in molecular size to cross the blood brain barrier, may 
serve as a pharmacological tool to decipher the role of peripheral inflammatory mechanisms 
that involve CGRPergic signaling. While the success of treatment with antibodies that curtail 
CGRP signaling in preventing migraine attacks points to a peripheral, likely meningeal origin 
of migraine, the failure of such treatments in a subpopulation of patients [190] may point 
to a larger role for trigeminal leptomeningeal afferents, which cannot be targeted with 
systemically-administered antibodies, in mediating migraine pain, or to CGRP-independent 
processes. Thus, the role of other substances, including neuropeptides such as PACAP 
but certainly also immuno-active substances and numerous meningeal receptor systems 
(Figure 1(b)), should be explored and selective pharmacological tools developed. The 
availability of such tools will help to further unravel the pathophysiology of migraine and 
thus to ultimately provide a more effective and safe treatment for migraine patients.
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Aims of the Thesis
1. Thirty years after the discovery of the triptans (5-HT1B/1D receptor agonists), and about 
fifteen years after the proof-of-concept that CGRP receptor antagonists are effective, 
their precise antimigraine site and mechanism of action remain unknown. In Chapter 3 
an overview is given of the effects of these drugs on the cranial vasculature, focusing on 
their specific relevance to migraine treatment. 
2. Migraine is a neurovascular disorder recently interconnected with an overall increased risk 
of cardiovascular disease, while current specific drugs used for its acute treatment activate 
vascular receptors, a fact that potentially contraindicates these drugs in patients with 
cardiovascular disease. Therefore, in Chapter 4 we investigated in rats the cardiovascular 
effects and the pharmacological profile of two novel isometheptene enantiomers developed 
for the acute treatment of migraine. In Chapter 5, we investigated the vasoactive effects 
of these drugs on human blood vessels and their modulation of CGRP-induced neurogenic 
dural vasodilation as a pharmacological mechanism of action.
3. Adenosine has been shown to increase in plasma during migraine attacks and to induce 
vasodilation; however, it remains unknown whether purinergic receptors can interact with 
the trigeminovascular system. Therefore, in Chapter 6 we evaluated the involvement 
of adenosine A2A receptors as prejunctional modulators of trigeminal CGRPergic sensory 
fibers. In Chapter 7 we explored additional purinergic (P2Y and P2X) receptors as potential 
antimigraine targets.
4. Some of the triptans display affinity for the 5-HT1F receptor, which is located in trigeminal 
afferent fibers and it is believed to contribute to their antimigraine efficacy. Hence, 
in Chapter 8 we assessed whether a selective 5-HT1F receptor agonist is capable of inhibiting 
CGRP release from the peripheral and central components of the trigeminovascular system 
of mice and rats.
5. Familial hemiplegic migraine type 1 (FHM1) is a rare migraine subtype. Whereas 
transgenic knock-in mice with the human pathogenic FHM1 mutation reveal overall neuronal 
hyperexcitability, the effects of this mutation on the trigeminovascular system and CGRP 
receptor are largely unknown. In Chapter 9, we compared the trigeminovascular system of 
wild-type and FHM1 mice.
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Part II. Vascular (side) effects of antimigraine drugs
Chapter 3
Triptans and CGRP blockade – impact on the cranial vasculature
Based on: The Journal of Headache and Pain, 2017, 18: 103.
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Abstract
The trigeminovascular system plays a key role in the pathophysiology of migraine. The 
activation of this system causes release of various neurrotrasmitters and neuropeptides, 
including serotonin and calcitonin gene-related peptide (CGRP), which modulate nociceptive 
transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B 
and 5-HT1D receptors (triptans) and less than fifteen after the proof-of-concept of the 
gepant class of CGRP receptor antagonists, we are still a long way from understanding 
their precise site and mode of action in migraine. The effect on cranial vasculature is 
relevant, because all specific antimigraine drugs and migraine pharmacological triggers may 
act in the perivascular space. This review reports the effects of triptans and CGRP blocking 
molecules on cranial vasculature in humans, focusing on their specific relevance to migraine 
treatment.
Background
Over the last century, controversies have raised around the vascular, neural or neurovascular 
origin of migraine [1]. From Galen original conjecture [2], with a meningeal involvement 
in the throbbing pain, several centuries passed before Willis, in 1672, hinted for the first 
time at a “vascular hypothesis” of migraine [3]. Throughout the 1930s and early 1940s 
headache science has emerged from studies by Graham, Ray and Wolff, who reported head 
pain after in vivo stimulation of dural and cerebral arteries, hypothesizing perivascular 
space as the possible site of migraine pain [4–7]. Pial, dural and extracranial vessels are 
part of the trigeminovascular system, a functional pathway that, on one side, releases 
vasoactive neuropeptides from perivascular nerve fibers and, on the other, reacts to 
them with nociception and vasodilation [8]. Pursuing the vascular hypothesis, several 
pharmacological triggers (such as glyceryl trinitrate (GTN), calcitonin gene-related 
peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) were 
found to induce attacks phenotypically indistinguishable from spontaneous migraine in 
migraine patients [9–11]. The fact that all migraine-provoking molecules are vasoactive and 
sumatriptan constricts arteries [12, 13], further granted a key role of cranial vasculature in 
migraine pathophysiology [14].
 Cranial arteries dilation has been shown, with different techniques, in both 
provocation and spontaneous migraine studies. Since the early 1990s, ultrasonography has 
been used to measure blood flow velocity in intracranial arteries [15] and extracranial artery 
diameter [16] during migraine attacks. Blood flow velocity correlates to vessel autoregulation 
and reactivity. Moreover, if cerebral blood flow does not change during an attack, blood flow 
velocity may be a surrogate marker of artery diameter (i.e. decreased blood flow velocity 
means increased middle cerebral artery lumen) [17]. In the last decade, investigation 
techniques have moved from ultrasonography to magnetic resonance angiography (MRA), 
allowing researchers to directly measure artery circumference [18–22]. MRA studies reported 
modest artery dilation during attacks, which was inhibited by triptans [12, 18, 21, 23]. 
Similar results, with prevention of superficial temporal artery dilation, were reported with 
the CGRP receptor antagonist olcegepant [24], hence suggesting that the modulation of 
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Despite the above mentioned evidence, the heated debate about the role of cranial vasculature 
in migraine pathophysiology is still open, and some authors have questioned whether cranial 
arteries play a significant role or only represent a negligible epiphenomenon [25, 26]. Even 
though the precise site where migraine origin still remains elusive, consistent evidence 
suggests that initial mechanisms may dilate intra- and extra-cerebral arteries, and cranial 
vasoconstriction may mediate at least a part of the effects of specific acute antimigraine 
drugs [8]. Thus, considering treatments on the verge of entering the clinical practice, such 
as CGRP blocking molecules, cranial arteries are undoubtedly of major interest in migraine.
 This review reports the effects of triptans and CGRP (receptor) blocking molecules 
on cranial vasculature in humans, focusing on their specific relevance to migraine treatment. 
The classification of cranial vessels as intracranial – intracerebral and extracerebral – and 
extracranial, is shown in Table 1. 
Cranial vessels Division Example
Extracranial -
Superficial temporal artery





Cavernous part of the internal carotid 
artery (ICA)
Middle cerebral artery 
Cerebral part of the ICA
Table 1. Cranial vessels according to current imaging techniques resolution. *Importantly, the middle 
meningeal artery has an intracranial and heavily innervated portion that may even be of more relevance 
in the pathophysiology of migraine than the extracranial portion. However, throughout the text and in 
accordance with current imaging detection limitations, the text considers the middle meningeal artery 
as an extracranial vessel.
Triptans 
The development and consequent introduction of triptans represented an unprecedented 
revolution in migraine history, being the first successful attempt of rational and mechanism-
driven treatment of migraine attacks. Compared to ergot alkaloids (ergotamine, 
dihydroergotamine and methysergide) that are non-specific serotonin type 1 (5-HT1) receptor 
agonists, that also target 5-HT2, adrenergic and dopaminergic receptors; triptans act as 
selective agonists at 5-HT1B and 5-HT1D subtypes, displaying a more favorable risk profile to 
ergots [27, 28].
 The rationale for triptans development has been based on the vascular theory 
of migraine, together with the hypothesis that serotonin and serotonin receptors are 
involved in migraine pathophysiology. It has been shown that during a migraine attack high 
levels of hydroxyindoleacetic acid, a serotonin metabolite, are excreted [29] and that 
monoamine depletors induce migraine attacks that are aborted by intravenous infusion of 
serotonin [30]. To develop selective cranial vasoconstrictors and to avoid risky side-effects 
of ergot alkaloids (i.e. a marked and long-lasting vasoconstriction in peripheral vessels), 
Humphrey and colleagues identified the 5-HT1-like receptor, later discovered to consist of 
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both the 5-HT1B and the 5-HT1D receptor subtypes, mostly located in cranial vessels, and 
then developed the first triptan, known as sumatriptan (GR43175) [31, 32]. Because of its 
efficacy and relative safety, sumatriptan has become a landmark in the treatment of migraine 
attacks [33]. Nevertheless, some peculiarities, such as the low oral bioavailability and short 
half-life [34], have favoured the development of new molecules, the so-called “second-
generation” triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan), with 
an optimization of the pharmacokinetic profile [35].
 Triptans are 5-HT1B/1D receptor agonists, most of them showing a moderate to high 
affinity for 5-HT1F receptors as well [35]. Immunohistochemical studies have shown that 
5-HT1B receptors are mainly located within the smooth muscle and in the endothelium of 
human middle meningeal [36, 37] and cerebral [38] arteries. Importantly, in in vitro studies, 
triptans constrict these arteries [37–39]. The 5-HT1B receptors, together with the 5-HT1D 
and 5-HT1F receptors, are also located within the trigeminal nerve endings and trigeminal 
nucleus, suggesting that their stimulation could inhibit the release of proinflammatory 
neuropeptides (e.g. CGRP) and consequently nociceptive transmission [40]. In a randomized 
placebo-controlled study, the administration of PNU142633, a selective 5-HT1D receptor 
agonist, failed to acutely alleviate migraine headache, suggesting a secondary role of the 
5-HT1D receptors [41]. On the other side, selective non-vasoconstrictive 5-HT1F receptor 
agonists, LY334370 [42] and LY573144 (i.e. lasmiditan) [43] demonstrated clinical 
efficacy, even though it remains to be confirmed whether these molecules, at therapeutic 
concentrations, are devoid of any activity on 5-HT1B receptors. Interestingly, lasmiditan 
did not exert vasoactive effects in supratherapeutic concentrations [44]. Importantly, the 
high cranial (i.e. middle meningeal artery) 5-HT1B receptor density compared to peripheral 
(i.e. coronary artery) blood vessels probably renders the triptans relatively selective for 
producing cranial vasoconstriction [36, 45].
 Human experimental data about vessel responses to triptans have refined our 
comprehension of triptan antimigraine effects and, indirectly, of the migraine mechanism. 
Differently from what observed in vitro [46], a placebo-controlled single-photon emission 
computed tomography (SPECT) study on healthy volunteers showed that sumatriptan 
infusion did not modify total and regional cerebral perfusion [47]. Interestingly, contrasting 
data in migraine patients have been initially reported about the correspondence between 
sumatriptan-related blood velocity modifications, measured by Doppler sonography, and 
the resolution of migraine attacks [12, 48, 49]. Importantly, combining the measurement 
of the regional cerebral blood flow and the blood velocity in the middle cerebral arteries, 
sumatriptan infusion has been shown to reverse the abnormal dilation of the middle cerebral 
artery in the headache side [12]. This finding suggests that the sumatriptan-induced 
vasoconstriction occurs only in the dilated vessels, without affecting normal ones.
Triptans and cranial vasculature
A key feature of migraine is that attacks can be provoked by pharmacological triggers, 
including glyceryl trinitrate (GTN) [50] and, as detailed below, provocation migraine models 
have provided important data on the role of cranial vasculature in migraine. The efficacy of 
triptans in GTN-induced headache was investigated in healthy volunteers in double-blind, 
placebo-controlled, crossover studies. Sumatriptan (6 mg) administered subcutaneously 
20 min before GTN (0.12 μg/kg/min) infusion, relieved pain and decreased temporal artery 
diameter without affecting blood velocity of the middle cerebral artery (MCA) [51]. 
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On the other hand, zolmitriptan (5 mg), administered orally during ongoing GTN infusion 
(0.2 μg/kg/min) had no effects on the induced-headache [52]. 
 Oral triptans (rizatriptan 10 mg, sumatriptan 50 mg and zolmitriptan 2.5 mg) 
were also tested in migraine patients, in which they have been shown to both decrease 
diameter and increase resistance of temporal artery, although to a different extent [53]. 
More recently, the triptan effect was examined after the experimental administration of 
vasoactive neuropeptides such as CGRP, PACAP38 and VIP, in healthy volunteers and migraine 
patients. In a first study, 18 healthy volunteers were randomized to receive an intravenous 
infusion of human α-CGRP (1.5 μg/min) or placebo, for 20 min [18]. After 45 min, a single 
dose of subcutaneous sumatriptan (6 mg) was administered to each patient. A high-resolution 
MRA was performed at baseline, before and after the sumatriptan injection, to measure the 
changes in the circumference of the MCA and middle meningeal artery (MMA). Compared to 
placebo, CGRP caused significant dilation of MMA but not of MCA, and sumatriptan reduced 
the MMA circumference after CGRP pre-treatment by 25% and to a lesser extent on MCA, 
suggesting that sumatriptan exerts part of its antinociceptive effect primarily acting on 
the MMA. 
 A second study was performed in 24 patients with migraine without aura [23], in 
which the CGRP intravenous infusion always resulted in a delayed headache, which fulfilled 
the criteria for migraine-like attacks in 18 patients (75%). MRA was performed in 15 of 18 
patients, and of these, 10 (67%) patients reported unilateral head pain. MMA and MCA were 
dilated only on the painful side. The other 5 patients (33%) reported bilateral head pain, 
accompanied by a bilateral dilatation of both MMA and MCA. Sumatriptan subcutaneous 
injection reversed the dilatation of MMA and aborted the migraine attacks, without affecting 
the MCA circumference [23]. These data show that migraine is associated with dilatation of 
extracerebral and intracerebral arteries, but only the contraction of extracerebral arteries 
is associated with amelioration of headache.
 PACAP38 is a vasoactive neuropeptide that belongs to the secretin/glucagon/VIP 
family and it is used to provoke experimental headache and migraine [10]. PACAP38 is 
reported to cause delayed headache in healthy volunteers, associated with a significant and 
long-lasting dilatation of the MMA (up to 23%), but no change in the MCA circumference [19]. 
In comparison, sumatriptan induced a contraction of the MMA by 12.3% and reversed the 
delayed headache attack, but no effects on the MCA were observed. The role of PACAP38 was 
further investigated in a double-blind crossover study [22] conducted in 22 female migraine 
patients without aura. Sixteen patients (73%) after PACAP38 infusion, but only four patients 
(18%) after VIP infusion (8 pmol/kg/min), reported migraine-like attacks. Both peptides 
induced a marked dilatation of the extracranial arteries, but not of the intracranial arteries. 
The subcutaneous injection of sumatriptan reversed migraine attacks simultaneously to the 
constriction of the dilated extracerebral arteries, but not the intracerebral arteries.
 To date, only one MRA study has explicitly investigated cranial arteries during 
spontaneous migraine attacks [20]. Migraine attacks, with a median time from pain onset 
to scan of 5 h 45 min, are not accompanied by extracranial arterial dilation on the pain 
side, but only by slight dilation of intracerebral arteries, MCA and internal carotid (ICA). 
In addition, the dilatation of the intracerebral arteries persisted after subcutaneous injection 
of sumatriptan, which however relieved migraine pain and reduced the circumference of 
not-dilated extracranial arteries. These data suggested that the vasoconstrictor action of 






be relevant to relief migraine (Figure 1). However, these findings do not refuse possible 
nociceptive input from other extracranial structures, in the absence of dilatation, such 
as CGRP-releasing sensitized perivascular afferents. Interestingly, recent data in humans 
suggested that the decrease of capsaicin-induced dermal blood flow may be mediated by 
the inhibition of CGRP release [54].
Figure 1. Effects of sumatriptan and olcegepant on cranial vessels in migraine patients.
The intracerebral vessels, the middle cerebral artery (MCA) and the cerebral part of the internal 
carotid artery (ICAcerebral), are both shown in yellow. The extracerebral artery, the cavernous part 
of the internal carotid artery (ICAcavernous), is shown in blue. The extracranial vessels, the middle 
meningeal artery (MMA) and the superficial temporal artery (STA), are both shown in purple. Boxes 
include description of vessel reactivity during spontaneous and/or CGRP induced attacks, as well as 
vessel response to sumatriptan and/or olcegepant. Imaging modality indicated in parentheses in boxes; 
magnetic resonance angiography (MRA) or transcranial ultrasound Doppler (Doppler). Image from MRA 
of healthy volunteer kindly provided by Faisal M Amin.
CGRP and cranial vasculature
CGRP is a potent vasodilator expressed and released in the perivascular space by trigeminal 
sensory neurons with a central role in neurogenic inflammation [55]. CGRP receptor consists 
of three components: calcitonin-receptor-like receptor (CLR), receptor component protein 
(RCP) and a specific chaperone called receptor activity modifying protein 1 (RAMP1) [56]. 
Importantly, CLR and RAMP1 expression has been shown in human middle meningeal [57], 
middle cerebral, pial and superficial temporal arteries [58], demonstrating the presence of 
all essential components required for a functional CGRP receptor in these districts.
 Several small molecule antagonists targeting the CGRP receptor have been 
developed [59] for the treatment of acute migraine attack and have shown efficacy in 
clinical trials. Olcegepant (BIBN4096BS) was the first selective and hydrophilic non-peptide 
CGRP receptor antagonist with an extremely high affinity and specificity for the human CGRP 
receptor [60] showing clinical efficacy in migraine attacks [61]. In comparison to triptans, 
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which have been extensively studied in humans, most data on vascular effects of “gepants” 
come from preclinical studies and this has been previously reviewed [62]. Olcegepant, which 
inhibits dose-dependent relaxation of isolated human cerebral arteries [63], blocks MMA 
vasodilation following systemic administration of α-CGRP and β-CGRP, without significantly 
affecting pial artery dilation or the local cortical cerebral blood flow increase [64]. 
In contrast to the pial vessels, the meningeal arteries have no blood-brain barrier [65], 
suggesting that olcegepant likely acts outside of the blood-brain barrier [66]. 
 In humans, olcegepant per se had no constrictor effect on the middle cerebral, 
radial, and superficial temporal artery [24], and no influence on global and regional cerebral 
blood flow [67]. Nevertheless, olcegepant effectively antagonizes the extracerebral vascular 
effect (e.g. temporal artery dilation) induced by CGRP intravascular administration [24]. 
A series of orally bioavailable small molecule CGRP receptor antagonists, including MK-0974 
(telcagepant), have been then developed giving rise to the pharmacological class of 
“gepants”. Telcagepant has been shown to be able to abort CGRP-induced vasodilatation on 
human cerebral and meningeal arteries ex vivo [68]. However, notwithstanding efficacy in 
clinical trials [69], clinical development of early gepants has been discontinued [70], and 
accordingly their use in migraine models has been withdrawn.
 There are currently four monoclonal antibodies (mAb) in clinical development for 
migraine prophylaxis: three humanized mAb targeting CGRP (LY2951742/galcanezumab, 
Eli Lilly and Company; ALD403/eptinezumab, Alder Biopharmaceuticals; and TEV-48215/
fremanezumab, TEVA Pharmaceuticals) and one fully human mAb targeting the CGRP 
receptor (AMG 334/erenumab, Amgen). These biological drugs have shown efficacy, 
tolerability and few adverse effects in phase 2 randomized control trials [71–76]. However, 
their exact site and mechanism of action is not completely understood. The new CGRP 
mAbs are macromolecules (around 150,000 Da) that are unlikely to cross the blood-brain 
barrier [66]. In line with this, few preclinical studies revealed that humanized CGRP mAb 
are (i) unable to penetrate the blood-brain barrier in the perfused MCA [77]; (ii) ineffective 
in inhibiting the responses to CGRP-induced neurogenic vasodilation of the pial artery [78]; 
and (iii) capable of inhibiting CGRP-induced neurogenic vasodilation of the MMA, which 
as mentioned above lacks blood-brain barrier [65, 79]. Importantly, it has been recently 
shown that there is no blood-brain barrier disruption during migraine attacks [80]. All these 
findings taken into account suggest a peripheral vascular site of action of the mAbs.
 A similar alternative under development for the preventive treatment of migraine 
is blocking CGRP-induced receptor activation through a RNA-Spiegelmer (NOX-C89). This 
single-strand mirror-image oligonucleotide binds to circulating CGRP and is highly resistant 
to endogenous nuclease degradation, hence inhibiting its function. Interestingly, this drug 
could not inhibit neurogenic vasodilation of pial arteries in vivo, which suggested that it is 
unlikely to penetrate the blood-brain barrier readily [78].
 Targeting peripheral CGRP may reduce or prevent the phenomenon (i.e. vasodilation) 
that has been advocated as a mechanism of headache and associated symptoms, whereas 
long-term inhibition of CGRP outside of the blood-brain barrier induces modulation of 
central pathways remains unknown. Further studies are needed to fully clarify the exact 









From Galen’s quote about meninges and vessels as mediators, together with other structures 
and mechanisms of migraine pain, long time has passed. In the last years, notwithstanding 
many detractors, cranial vasculature involvement in the pathogenesis of migraine pain has 
benefited from experimental data acquired by modern imaging techniques, such as MRA, 
and specific pharmacological tools, such as triptans. Recently developed human migraine 
models have suggested that attention should be paid to cranial extracerebral arteries 
(i.e. MMA) in addition to intracerebral vessels, which were the major focus at the dawn 
of vascular migraine research. On the basis of current knowledge [20, 23], future studies 
should investigate whether there are differences in how the perivascular nerves innervate 
the different sections of the MMA, including dural branches, because it is likely that it is 
activation or inhibition of the perivascular nerves that is associated with migraine pain 
relief. In addition, future advanced brain imaging methods will allow to investigate possible 
dilatation of dural branches of the MMA that are very difficult to visualise with current 
method, without injection of contrast agents [20]. The availability of innovative migraine-
specific drugs, such as CGRP-targeted compounds [69], will further increase our ability to 
investigate the involvement of cranial vasculature in migraine pain, and will finally allow to 
properly balance the weight of vessel contribution to the neurovascular theory of migraine.
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Abstract
Background: Isometheptene is a sympathomimetic drug effective in acute migraine 
treatment. It is composed of two enantiomers with diverse pharmacological properties. 
This study investigated in pithed rats the cardiovascular effects of (S)-isometheptene and 
(R)-isometheptene, and the pharmacological profile of the more potent enantiomer.
Methods: The effects of i.v. bolus injections (0.03, 0.1, 0.3, 1 and 3 mg/kg) of isometheptene 
racemate, (S)-isometheptene or (R)-isometheptene on heart rate and blood pressure were 
analysed in control experiments. The enantiomer producing more pronounced tachycardic 
and/or vasopressor responses was further analysed in rats receiving i.v. injections of 
prazosin (0.1 mg/kg), rauwolscine (0.3 mg/kg), propranolol (1 mg/kg) or intraperitoneal 
reserpine (5 mg/kg, -24 hr). 
Results: Compared to (R)-isometheptene, (S)-isometheptene produced greater vasopressor 
responses, whilst both compounds equipotently increased heart rate. The tachycardic 
responses to (S)-isometheptene were abolished after propranolol, but remained unaffected 
by the other antagonists. In contrast, the vasopressor responses to (S)-isometheptene 
were practically abolished after prazosin. Interestingly, after reserpine, the tachycardic 
responses to (S)-isometheptene were abolished, whereas its vasopressor responses were 
attenuated and subsequently abolished by prazosin. 
Conclusion: The different cardiovascular effects of the isometheptene enantiomers 
are probably due to differences in their mechanism of action, namely: (i) a mixed 
sympathomimetic action for (S)-isometheptene (a tyramine-like action and a direct 
stimulation of α1-adrenoceptors); and (ii) exclusively a tyramine like action for 
(R)-isometheptene. Thus, (R)-isometheptene may represent a superior therapeutic benefit 
as an antimigraine agent.
Background
Isometheptene racemate is a sympathomimetic amine that has been used for decades 
in the acute treatment of moderate primary headaches (i.e. migraine and tension-type 
headaches) [1–2], but its exact mechanisms of action have not been comprehensively 
explored. In this respect, our group has demonstrated in pithed rats [3] and anesthetized 
dogs [4] that isometheptene racemate behaves as a dual-acting sympathomimetic agent 
producing: (i) an indirect vasoconstrictor tyramine-like action (attenuated by reserpine) 
that involves the displacement of endogenous noradrenaline from sympathetic nerves; 
and (ii) a direct vasoconstriction that results in either rat vasopressor responses mediated 
by α1-adrenoceptors [3] or decreases in canine external carotid blood flow/conductance 
mediated by α2A/2C-adrenoceptors [4].
 These properties have linked isometheptene’s therapeutic effectiveness with 
the vascular theory of migraine [5], so that its cranial vasoconstriction may reduce the 
phenomenon (i.e. vasodilatation) that has been advocated as a mechanism of  headache and 
associated symptoms [6]. Interestingly, sumatriptan (a 5-HT1B/1D receptor agonist with acute 
antimigraine properties) seems to exert part of its antinociceptive action by constricting the 
human middle meningeal artery (MMA) [7, 8]. In contrast, isometheptene racemate failed 








supports its vasoactive action on dilated cranial and cerebral arterioles [12,13].
 Tonix Pharmaceuticals has separated isometheptene racemate into its two 
enantiomers (R)-isometheptene and (S)-isometheptene, in order to explore their efficacy 
in the acute treatment of primary headaches [14]. Isometheptene racemate binds with 
high affinity (Ki=42 nM) to the I1-imidazoline receptor (I1-R), suggesting that this receptor, 
along with α-adrenoceptors, could be involved in its antimigraine action [15]. Moreover, 
(R)-isometheptene binds to the I1-R (Ki=18 nM) with about 60-fold greater affinity than 
(S)-isometheptene (Ki=1100 nM) [15]. Notably, other studies have described: (i) a decreased 
pain threshold in I1-R knockout mice [16]; and (ii) that treatment with (R)-isometheptene 
relieved trigeminal sensitivity in the inflammatory soup and in spontaneous trigeminal 
allodynia rat models, two different models of chronic migraine [17]. This study investigated 
the cardiovascular effects produced by these novel compounds in an experimental model 
predictive of systemic (cardio) vascular side-effects.
Materials and Methods
Animals 
Seventy-four male normotensive Wistar rats (250-300 g, 8-10 weeks of age) were maintained 
at a 12/12-hr light-dark cycle (with light beginning at 07:00 hr) and housed in a special room 
at a constant temperature (22±2°C) and humidity (50%), with food and water ad libitum in 
their cages. All animal protocols of this investigation were approved by our Institutional 
Ethics Committee (CICUAL-Cinvestav; permission protocol number 507-12) and followed the 
regulations established by the Mexican Official Norm (NOM-062-ZOO-1999), in accordance 
with  ARRIVE (Animal Research: Reporting In Vivo Experiments) reporting guidelines for the 
care and use of laboratory animals.
General Methods
After anaesthesia with sodium pentobarbital (60 mg/kg, i.p.) and cannulation of the trachea, 
all rats were pithed by inserting a stainless steel rod through the orbit and foramen magnum 
and down the vertebral foramen, as previously reported [18,19]. The animals were then 
artificially ventilated with room air using a model 7025 Ugo Basile pump (56 strokes/min.; 
stroke volume: 20 ml/kg), as previously established [20]. After cervical bilateral vagotomy, 
catheters were placed in: (i) the right femoral vein, for the administration of antagonists, 
isometheptene racemate, (R)-isometheptene or (S)-isometheptene; and (ii) the left carotid 
artery, connected to a Grass pressure transducer (P23XL), for the recording of arterial blood 
pressure. Heart rate was measured with a tachograph (7P4F, Grass Instrument Co., Quincy, 
MA, U.S.A.) triggered from the blood pressure signal. Both heart rate and blood pressure 
were recorded simultaneously by a model 7D Grass polygraph (Grass Instrument Co., Quincy, 
MA, U.S.A.). The body temperature of each pithed rat was maintained at 37°C by a lamp 
and monitored with a rectal thermometer.
Experimental protocols
After a stable hemodynamic condition during at least 30 min, baseline values of heart rate 
and diastolic blood pressure (a more accurate indicator of peripheral vascular resistance 
than mean blood pressure) were determined. Subsequently, the 74 rats were randomly 
assigned into three main sets (n=24, 40 and 10) for performing the following dose-response 
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protocols. We a priori decided to investigate the pharmacological characteristics of the 
responses to the most potent enantiomer in more detail, since this enantiomer would most 
likely be responsible for the side-effects induced by isometheptene. In addition, we planned 
to study for the least potent enantiomer to which extent the cardiovascular responses were 
mediated by a direct or indirect, tyramine-like, mechanism of action. 
Protocol I. Comparative analysis of the effects produced by the isometheptene 
enantiomers
The first set of animals (n=24) was divided into four groups (n=6 each) that received consecutive 
i.v. bolus injections (0.03, 0.1, 0.3, 1 and 3 mg/kg) of, respectively: (i) isometheptene 
racemate; (ii) (S)-isometheptene; (iii) (R)-isometheptene; and (iv) equivalent volumes of 
physiological saline (1 ml/kg given 5 consecutive times; vehicle for dissolving isometheptene). 
The peak effects produced by each dose of the above compounds on heart rate and diastolic 
blood pressure were measured and compared, as previously reported [3]. The dose-intervals 
between the different doses of isometheptene (racemate and enantiomers) ranged between 
5 and 15 min, as in each case we waited with the administration of the next dose until heart 
rate and diastolic blood pressure had returned to baseline values.
Protocol II. Analysis of the pharmacological profile of the more potent enantiomer
The second set of animals (n=40) was divided into three subsets (n=25, 10 and 5). The first 
subset (untreated; n=25) received consecutive i.v. bolus injections of the more potent 
isometheptene enantiomer (0.03, 0.1, 0.3, 1 and 3 mg/kg). Then, this subset was divided into 
five groups (n=5 each) that received i.v. bolus injections of, respectively: (i) physiological 
saline (1 ml/kg; vehicle for dissolving the antagonists); (ii) prazosin (0.1 mg⁄kg; 
α1-adrenoceptor antagonist); (iii) rauwolscine (0.3 mg/kg; α2-adrenoceptor antagonist); 
(iv) the combination of prazosin (0.1 mg/kg) plus rauwolscine (0.3 mg/kg); and (v) propranolol 
(1 mg/kg; nonselective β-adrenoceptor antagonist). The doses of the antagonists used were 
sufficient to completely block their corresponding receptors, as previously reported [3]. 
Subsequently, the responses to the above doses of the isometheptene enantiomer were 
elicited again 15 min after administration of the aforementioned compounds.
 The second subset (reserpinized; n=10) was pretreated with reserpine (5 mg⁄kg, i.p.) 
24 hr before the start of the experiments, as previously reported by our group [3], in order 
to eliminate the potential tyramine-like action exerted by the more potent isometheptene 
enantiomer. Then, this subset received sequential i.v. bolus injections of the isometheptene 
enantiomer (0.03-3 mg/kg) and was subsequently divided into two groups (n=5 each) 
that were given i.v. bolus injections of, respectively: (i) physiological saline (1 ml/kg); 
and (ii) prazosin (0.1 mg/kg). After 15 min, the responses to the above isometheptene 
enantiomer doses were elicited again.
 The third subset (sham; n=5) was pretreated with the vehicle of reserpine (1 ml⁄kg 
of 5% ascorbic acid; i.p.) 24 hr before the start of the experiments. Then, this subset 
received i.v. bolus injections of the isometheptene enantiomer as previously described.
Protocol III. Effects of reserpine pretreatment on the effects of the less potent 
enantiomer
Finally, the third set of animals (n=10) was divided into two groups (n=5 each) that were 
pretreated i.p. (24 hr before the start of the experiments) with, respectively: (i) 1 ml/kg 
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of 5% ascorbic acid; and (ii) 5 mg/kg reserpine. Then, both groups received sequential i.v. 
bolus injections of the less potent isometheptene enantiomer (0.03-3 mg/kg).
Data presentation and statistical evaluation
The number of animals was justified by statistical power calculation based on our previous 
studies with similar methodology [3]. All data in the text and figures are presented as 
mean ± S.E.M. The peak changes in the baseline values of heart rate and diastolic blood 
pressure elicited by the administration of isometheptene (racemate and enantiomers) 
were determined. The difference between the tachycardic and vasopressor responses to 
isometheptene within one subset/group of animals as well as between two groups (i.e. the 
more potent isometheptene enantiomer in reserpine- and vehicle-pretreated animals) 
were evaluated with the Student-Newman-Keuls’ test, once a two-way repeated measures 
analysis of variance had revealed that the samples represented different populations. 
Statistical significance was accepted at p<0.05.
Drugs
Apart from the anaesthetic (sodium pentobarbital), the drugs used in the present study were: 
isometheptene racemate (Carnick Laboratories, Cedar Knolls, NJ, U.S.A.); (R)-isometheptene 
and (S)-isometheptene (Tonix Pharmaceuticals Inc., New York, NY, U.S.A.); prazosin 
hydrochloride, rauwolscine hydrochloride, propranolol hydrochloride and reserpine (Sigma 
Chemical Co., St. Louis, MO, U.S.A.) All compounds were dissolved in physiological saline 
with the exception of reserpine, which was dissolved in 5% (w/v) ascorbic acid. A short 
period of heating was needed to dissolve prazosin. These vehicles had no significant effects 
on baseline heart rate or diastolic blood pressure, as previously reported by our group [3]. 
The doses mentioned in the text refer to the free base of substances in all cases.
Results
Systemic hemodynamic variables
The baseline values of heart rate and diastolic blood pressure in the pithed rats without 
reserpine were 260±6 beats/min and 64±1 mmHg, respectively. These variables did not 
significantly differ (p>0.05) from those obtained in the animals pretreated with reserpine, 
i.e. 269±4 beats/min and 67±2 mmHg. Moreover, these hemodynamic variables remained 
without significant changes (p>0.05) after administration of the i.v. bolus injections of 
saline, prazosin, rauwolscine, the combination prazosin plus rauwolscine or propranolol 
(not shown), as previously reported [3]. 
Effects of isometheptene enantiomers on heart rate and diastolic blood pressure
Figure 1 shows the effects produced by i.v. administration of isometheptene racemate, 
(R)-isometheptene and (S)-isometheptene on heart rate and diastolic blood pressure. These 
compounds produced: (i) dose-dependent tachycardic responses (left panel), with 3 mg/kg of 
these compounds representing the effects of a supramaximal dose; and (ii) dose-dependent 
vasopressor responses in the case of isometheptene racemate and (S)-isometheptene, while 
only smaller vasopressor responses (not dose-dependent; p<0.05 vs. the corresponding dose 
of saline) were produced by the last two doses of (R)-isometheptene.
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Figure 1. Effects of i.v. bolus injections of isometheptene enantiomers (0.03-3 mg/kg) or saline 
(1 ml⁄kg, given 5 times) on (a) heart rate; and (b) diastolic blood pressure (DBP) in pithed rats. Full 
symbols represent significant differences (p<0.05) vs saline (vehicle). *p<0.05 vs. the corresponding 
dose to (R)-isometheptene; n=6 for each group.
Effect of antagonists on (S)-isometheptene-induced tachycardic and vasopressor 
responses
Figure 2 illustrates the tachycardic responses produced by (S)-isometheptene before and 
after different treatments. Indeed, these responses appeared to be tachyphylactic as they 
were significantly attenuated (p<0.05) in control animals when repeating the dose-response 
curve after 1 ml/kg physiological saline (Figure 2a). Furthermore, as compared to the 
tachycardic responses to (S)-isometheptene produced after saline, these responses were 
practically abolished after 1 mg/kg propranolol (Figure 2e), but remained unaffected after 
administration of the other compounds (Figures 2b, 2c and 2d).
Figure 2. Effects of i.v. bolus injections of: (a) saline; (b) prazosin (Praz); (c) rauwolscine (Rauw); (d) the 
combination of Praz plus Rauw; or (e) propranolol (Prop) on the increases in heart rate (∆ Heart rate) 
produced by (S)-isometheptene (0.03-3 mg/kg, i.v.) in pithed rats. *p<0.05 vs. the corresponding dose 
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 In contrast, as shown in Figure 3, the vasopressor responses to (S)-isometheptene 
were: (i) reproducible as they remained practically unchanged after 1 ml/kg saline 
(Figure 3a); (ii) similarly and markedly blocked (p<0.05) after 0.1 mg/kg prazosin (Figure 3b) 
or the combination of 0.1 mg/kg prazosin plus 0.3 mg/kg rauwolscine (Figure 3d); and 
(ii) unaffected (p>0.05) after 0.3 mg/kg rauwolscine (Figure 3c) or 1 mg/kg propranolol 
(Figure 3e). It is noteworthy that the blockade produced by the combination of prazosin plus 
rauwolscine did not significantly differ (p>0.05) from that produced by prazosin alone.
Figure 3. Effects of i.v. bolus injections of: (a) saline; (b) prazosin (Praz); (c) rauwolscine (Rauw); 
(d) the combination of Praz plus Rauw; or (e) propranolol (Prop) on the increases in diastolic blood 
pressure (∆ DBP) produced by (S)-isometheptene (0.03-3 mg/kg, i.v.) in pithed rats. *p<0.05 vs. the 
corresponding dose in the control curve; n=5 for each group.
Cardiovascular effects of (S)-isometheptene in rats pretreated i.p. with reserpine or 
its vehicle
Figure 4 shows the effects of i.p. pretreatment with vehicle (5% ascorbic acid; 1 ml/kg), 
reserpine (5 mg/kg), reserpine followed by i.v. saline (1 ml/kg) or reserpine followed by 
i.v. prazosin (Praz; 0.1 mg/kg) on the increases in heart rate and diastolic blood pressure 
produced by (S)-isometheptene. Hence, in the vehicle-pretreated animals, (S)-isometheptene 
produced dose-dependent increases in heart rate (Figures 4a and 4b) and diastolic blood 
pressure (Figures 4c and 4d) as described above. In contrast, in the reserpine-pretreated 
animals: (i) (S)-isometheptene-induced tachycardic responses were practically abolished 
(as compared to the respective responses in vehicle-pretreated animals; p<0.05), and 
the subsequent administration of saline (Figure 4a) or prazosin (Figure 4b) produced no 
further effect; and (ii) (S)-isometheptene-induced vasopressor responses were significantly 
attenuated (p<0.05, but not abolished) and the subsequent administration of saline produced 
no further effect (Figure 4c), but the subsequent administration of prazosin abolished these 
responses (p<0.05; Figure 4d).
Cardiovascular effects of (R)-isometheptene in rats pretreated i.p. with reserpine or 
its vehicle
As shown in Figure 5, in the animals pretreated with vehicle (5% w/v ascorbic acid, 1 ml⁄kg; 
i.p.), (R)-isometheptene induced dose-dependent tachycardic responses (Figure 5a) and 
small vasopressor responses (not dose-dependent; Figure 5b). In contrast, in the animals 
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pretreated with reserpine (5 mg/kg; i.p.), these tachycardic and vasopressor responses 
were practically abolished (p<0.05 when compared to those produced by the corresponding 
dose in the vehicle curve). 
Figure 4. Effects of i.p. pretreatment with vehicle (5% ascorbic acid), reserpine (Reserp), reserpine 
followed by i.v. administration of saline or reserpine followed by i.v. administration of prazosin (Praz) 
on the increases in heart rate (∆ Heart rate; upper panel) and diastolic blood pressure (∆ DBP; lower 
panel) produced by (S)-isometheptene (0.03-3 mg/kg, i.v.) in pithed rats. *p<0.05 vs. the corresponding 
dose in the vehicle curve; #p<0.05 vs. the corresponding dose in the reserpine curve; n=5 for each 
group.
Figure 5. Effects of i.p. pretreatment with vehicle (5% ascorbic acid) or reserpine on the increases in: 
(a) heart rate (∆ Heart rate); and (b) diastolic blood pressure (∆ DBP) produced by (R)-isometheptene 
























Apart from the implications discussed below, our study demonstrates the importance 
of investigating separately the enantiomers of a given compound. Indeed, the (R)- and 
(S)-enantiomers of a racemate may behave pharmacologically different from each other [21]. 
Thus, it is appropriate to consider each enantiomer as a separate pharmacological entity 
with different properties, unless proven otherwise [21]. In our study, the enantiomers of 
isometheptene displayed clear pharmacodynamic differences in their cardiovascular effects, 
and these differences could lead to the future usage of these enantiomers in different 
conditions.
Systemic hemodynamic effects produced by the different treatments in pithed rats
The fact that the baseline values of diastolic blood pressure and heart rate remained without 
significant changes after prazosin, rauwolscine, the combination prazosin plus rauwolscine 
or propranolol (not shown), as previously reported [3], may be due to the fact that pithed 
rats are devoid of central and peripheral nervous influences. On this basis, it is most likely 
that the effect of any of these antagonists on the tachycardic and vasopressor responses 
to the isometheptene enantiomers involves a direct interaction with their corresponding 
receptors.
Differential cardiovascular effects of the isometheptene enantiomers
In agreement with the sympathomimetic properties of isometheptene racemate in pithed 
rats [3], both enantiomers and the racemate produced dose-dependent increases in heart 
rate, although the tachycardic response produced by 3 mg/kg was not strictly dose-
dependent (Figure 1a) and apparently tachyphylactic. This finding implies a tyramine-like 
action (see below), as previously reported [3], and that such a high dose was supramaximal.
 In contrast, (R)-isometheptene produced only small vasopressor responses at 1 and 
3 mg/kg (which were not dose-dependent), while (S)-isometheptene and isometheptene 
racemate produced dose-dependent (and equipotent) vasopressor responses (Figure 1b). 
The simplest interpretation of these findings indicates: (i) a differential pharmacological 
profile between (R)-isometheptene and (S)-isometheptene; and (ii) that the vasopressor 
effects of isometheptene racemate are mostly mediated by the (S)-enantiomer (see below). 
Since, overall, (S)-isometheptene displayed a higher potency to produce cardiovascular 
responses, we proceeded to analyse, in the first instance, the pharmacological profile of 
the receptors/mechanisms involved in the responses to (S)-isometheptene.
The role of a tyramine-like action producing indirect stimulation of cardiac 
β-adrenoceptors in the tachycardic responses to (S)-isometheptene
The tachycardic responses to isometheptene racemate in pithed rats are mediated by an 
indirect tyramine-like action involving stimulation of propranolol-sensitive β adrenoceptors, 
most likely of the β1-subtype [3]. In keeping with this finding, the tachycardic responses 
produced by (S)-isometheptene: (i) were highly tachyphylactic as they were not 
reproducible when repeating a second dose-response after saline (Figure 2a); (ii) are 
mainly mediated by activation of propranolol sensitive β-adrenoceptors (Figure 2e); and 
47






(iii) do not involve activation of prazosin-sensitive α1-adrenoceptors and/or rauwolscine-
sensitive α2-adrenoceptors (Figures 2b, 2c and 2d). Most notably, the fact that these 
responses were practically abolished after reserpine (Figure 4a) reinforces the role of an 
indirect tyramine-like action in (S)-isometheptene-induced tachycardic responses (i.e. by 
displacing noradrenaline from sympathetic nerves which, in turn, would subsequently 
stimulate cardiac β-adrenoceptors). It is noteworthy that this dose-schedule with reserpine 
(i.e. 5 mg/kg, i.p.; -24 hrs) has been shown to abolish in pithed rats the tachycardic and 
vasopressor responses to the typical indirect sympathomimetic agent, tyramine [3].
The role of both an indirect tyramine-like action and a direct stimulation of 
α1-adrenoceptors in the vasopressor responses to (S)-isometheptene
Unlike its tachycardic responses (see above), the vasopressor responses to (S)-isometheptene: 
(i) were reproducible as they remained without significant changes after saline (Figure 3a); 
and (ii) are mainly mediated by α1-adrenoceptors as these responses were markedly blocked 
after prazosin (Figure 3b), but not (p>0.05) after rauwolscine (Figure 3c) or propranolol 
(Figure 3e) in doses high enough to completely block their respective receptors mediating 
cardiovascular responses [3]. Consistent with this suggestion, the combination prazosin 
plus rauwolscine produced a blockade (Figure 3d) that did not significantly differ (p>0.05) 
from that produced by prazosin alone (Figure 3b). Furthermore, the fact that reserpine 
markedly attenuated (but did not abolish) these vasopressor responses (Figure 4c), and 
that the subsequent administration of prazosin practically abolished these responses 
(Figure 4d) suggests the involvement of a mixed effect of (S)-isometheptene, namely: 
(i) a major indirect (tyramine-like) mechanism; and (ii) a minor direct sympathomimetic 
mechanism mediated by stimulation of α1-adrenoceptors. In keeping with these findings, 
and as implied by other studies at the neuro-vascular junction [3, 22, 23]: (i) neuronally-
displaced noradrenaline (i.e. by a tyramine-like action) primarily stimulates intrasynaptic 
α1-adrenoceptors; (ii) i.v. bolus of exogenous noradrenaline mainly activates extrasynaptic 
α2-adrenoceptors; and (iii) systemic vascular resistance (represented by diastolic blood 
pressure) is mainly modulated by α1-adrenoceptors.
 Interestingly, the fact that (R)-isometheptene-induced tachycardic (Figure 5a) and 
(weak) vasopressor (Figure 5b) responses were abolished by reserpine suggests the exclusive 
role of a tyramine-like action in both responses (with no role of direct sympathomimetic 
actions). This implies that (R)-isometheptene would produce stoichiometric displacement 
of noradrenaline from the sympathetic neurons innervating the heart and resistance blood 
vessels, resulting in tachycardic and vasopressor responses mediated by stimulation of 
cardiac β- and vascular α1-adrenoceptors [3, 22, 23].
Structure of the enantiomers and stereo-specificity of the α1-adrenoceptor
The different effects of the isometheptene enantiomers on the cardiovascular system 
in this study could also be explained by the chemical structures of these compounds. 
Indeed, there are some similarities between the molecular structures of isometheptene 
and noradrenaline, which may confer the capability of being recognized by the neuronal 
transporters, introduced into the synaptic vesicles and subsequently displace the stored 
catecholamines that, in turn, would interact with post-junctional adrenoceptors. The 
presence of an amine side chain in isometheptene provides the capability to stimulate 
directly the α1-adrenoceptor [23]. However, the presence of a chiral centre in the β carbon 
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of the amine group could explain the differences in the pharmacological profile of both 
enantiomers, suggesting that (R)-isometheptene cannot interact with the α1-adrenoceptor, 
probably due to a steric impediment.
Study limitations
The pithed rat model is a useful preparation for investigating the cardiovascular (side) 
effects of new developed antimigraine drugs (i.e. isometheptene enantiomers) and their 
mechanism of action. Since migraine-specific agents, namely triptans, are contraindicated 
for acute migraine attacks in patients with cardiovascular risk factors, new antimigraine 
drugs should ideally have a beneficial cardiovascular safety profile. The pithed rat model is 
appropriate to assess peripheral cardiovascular effects, however, it should be kept in mind 
that it excludes central nervous system mechanisms, which might be relevant in the clinical 
situation. 
 As migraine has a 2- to 3-fold higher prevalence in women, another limitation of our 
study is that we used only male rats. We deliberately chose to study male rats in this case 
since we wanted to limit experimental variation avoiding the effects of female hormones on 
vascular responsiveness, as it is known that noradrenaline vasopressor responses are altered 
in the presence of 17β-estradiol in this model [24]. Thus, future studies may focus on the 
antimigraine effects of the isometheptene enantiomers in female models during different 
hormonal cycle stages. 
Conclusions
Our findings show that both isometheptene enantiomers (R and S) are equipotent in 
producing tachycardic responses, and that these responses are mediated by a tyramine-
like action (abolished by reserpine). Moreover, (S)-isometheptene produced greater dose-
dependent vasopressor responses, while those produced by (R)-isometheptene were not 
dose-dependent. These effects are probably due to differences in their mechanism of 
action, namely: (i) a mixed sympathomimetic action for (S)-isometheptene (a tyramine-like 
action and a direct stimulation of α1-adrenoceptors); and (ii) exclusively a tyramine-like 
action for (R)-isometheptene.
 Therefore, (R)-isometheptene may be responsible for the therapeutic action of 
isometheptene racemate and (S)-isometheptene (producing greater vasopressor responses) 
might be associated with the vasospasm described with the racemate. Accordingly, 
(R)-isometheptene may represent a superior therapeutic benefit as an antimigraine agent. 
Undoubtedly, further studies with (R)-isometheptene in human preparations and in animal 
models of trigeminovascular activation will shed further light on the potential role of 
imidazoline receptors in the pathophysiology of migraine.
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Effects of two isometheptene enantiomersin isolated human 
blood vessels and rat middle meningeal artery 
– potential antimigraine efficacy
Based on: The Journal of Headache and Pain, 2019, 20: 47.
Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA, de Vries R, Dammers R, Bogers AJJC, 
van den Bogaerdt A, Daugherty BL, Danser AHJ, Villalón CM and MaassenVanDenBrink A.
Abstract
Background: Racemic isometheptene [(RS)-isometheptene] is an antimigraine drug 
that due to its cardiovascular side-effects was separated into its enantiomers, (R)- and 
(S)-isometheptene. This study set out to characterize the contribution of each enantiomer 
to its vasoactive profile. Moreover, rat neurogenic dural vasodilatation was used to explore 
their antimigraine mechanism of action.
Methods: Human blood vessel segments (middle meningeal artery, proximal and distal 
coronary arteries, and saphenous vein) were mounted in organ baths and concentration 
response curves to isometheptene were constructed. Calcitonin gene-related peptide (CGRP) 
induced neurogenic dural vasodilation was elicited in the presence of the enantiomers using 
a rat closed cranial window model.
Results: The isometheptene enantiomers did not induce any significant contraction in 
human blood vessels, except in the middle meningeal artery, when they were administered 
at the highest concentration (100 µM). Interestingly in rats, (S)-isometheptene induced 
more pronounced vasopressor responses than (R)-isometheptene. However, none of these 
compounds affected the CGRP-induced vasodilator responses.
Conclusion: The isometheptene enantiomers displayed a relatively safe peripheral vascular 
profile, as they failed to constrict the human coronary artery. These compounds do not 
appear to modulate neurogenic dural CGRP release, therefore, their antimigraine site of 
action remains to be determined.
Background
Migraine is a neurovascular disorder characterized by recurrent attacks of incapacitating 
unilateral headaches, recently interconnected with an overall increased risk of stroke and 
cardiovascular disease [1, 2]. Although its exact pathophysiology has not been elucidated 
completely, migraine headache has been associated with activation of the trigeminovascular 
system and increased release of calcitonin gene-related peptide (CGRP), resulting in 
dysfunctional nociceptive transmission and neurogenic dural vasodilatation [3]. 
 The triptans, serotonergic agonists with selective affinity for 5-HT1B/1D/(1F) receptors, 
are specific drugs for the acute treatment. Their mechanism of action has been attributed 
to a dural perivascular inhibition of CGRP release, an inhibition of central nociception 
and⁄or a postjunctional constriction of (cranial) blood vessels [4-6]. Because of the latter, 
the triptans are contraindicated in patients with cardiovascular risk factors or a history of 
cardiovascular disease. 
 Isometheptene is a sympathomimetic racemic drug available by prescription or over 
the counter in several countries, that has long been used for the acute treatment of primary 
headaches [7, 8]. Nevertheless, a few case reports of acute intracranial vasoconstriction 
after its use [9, 10] highlight its presumed vasoactive properties [11]. Given that the 
development of new antimigraine agents with a beneficial cardiovascular safety profile is 
crucial, Tonix Pharmaceuticals™ separated isometheptene racemate into its enantiomers, 
(S)-isometheptene and (R)-isometheptene, a mixed-acting (tyramine-like/minor direct 
α1-adrenoceptor) and an indirect-acting (tyramine-like) adrenergic receptor agonist, 








and previous studies have shown that: (i) imidazoline I1 receptor knockout mice have a 
potentiated nociceptive perception, suggesting that this receptor could be associated with 
an endogenous analgesia system [13]; (ii) (R)-isometheptene decreased trigeminal sensitivity 
in two rat models of chronic migraine [14]; and (iii) imidazoline I1 receptor agonists, like 
moxonidine and agmatine induced a prejunctional inhibition of the vasodepressor sensory 
CGRPergic outflow in pithed rats [15]. Together, these findings suggest that a potential 
antimigraine action of (R)-isometheptene could be mediated by inhibition of the trigeminal 
system. Hence, we hypothesized that the use of only (R)-isometheptene will maintain its 
antimigraine therapeutic effect, while the major side-effects associated with the racemate 
or (S)-isometheptene (i.e. cranial vasoconstriction) will be diminished [16]. 
 On this basis, the present study set out to analyse the effects of the isometheptene 
enantiomers and the racemate on human isolated blood vessels (i.e. middle meningeal 
artery, proximal and distal coronary arteries, as well as saphenous vein) and trigeminal 
CGRP induced neurogenic dural vasodilation in anaesthetized rats (through a closed cranial 
window).
Materials and Methods
Human isolated blood vessels
Middle meningeal arteries [internal diameter (ID) 0.5-1.5 mm] were obtained from 
11 patients (3 males, 8 females; mean age 53±5 years) who underwent neurosurgical 
interventions requiring a trepanation of the skull. During surgery, the dura mater together 
with a small piece of meningeal artery was collected in a sterile organ protecting solution 
and was immediately transported to the laboratory. The meningeal arteries were dissected 
and placed in a cold (4°C) oxygenated Krebs bicarbonate solution with the following 
composition (mmol/L): NaCl 119, KCl 4.7, CaCl2 1.25, MgSO4 1.2, KH2PO4 1.2, NaHCO2 25 and 
glucose 11.1; pH 7.4.
 Saphenous veins (ID 0.5-3 mm) were obtained from 11 patients (10 males, 1 female; 
mean age 71±2 years) who underwent coronary artery bypass surgery. Immediately after 
surgery, veins were placed in cold (4°C) oxygenated Krebs buffer solution with the following 
composition (mmol/L): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO2 25 and 
glucose 8.3; pH 7.4.
 Proximal (ID 2-3 mm) and distal (ID 0.5-1.0 mm) coronary arteries were obtained 
from 10 heart valve donors (6 males, 4 females; mean age 40±5 years) who died of non-
cardiac disorders: four traumatic brain injury, one benzodiazepine overdose, three anoxic 
encephalopathy and two cerebrovascular accident. The hearts were provided by the Heart 
Valve Bank Beverwijk (at that time still located in Rotterdam) from Dutch post-mortem 
donors, after donor mediation by The Dutch Transplantation Foundation (Leiden, The 
Netherlands), following removal of the aortic and pulmonary valves for homograft valve 
transplantation. All donors gave permission for research. Immediately after circulatory 
arrest, the hearts were stored at 4°C in a sterile organ protecting solution and were brought 
to the laboratory within the first 24 hours of death. The coronary arteries were dissected 
and placed in Krebs buffer with the same composition as the one used for the saphenous 
veins (see above). All blood vessels were used on the same day or stored overnight and used 
the following day for functional experiments.
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 The middle meningeal arteries and the distal coronary arteries were cut into ring 
segments of 1-2 mm length and suspended in Mulvany myographs on two parallel steel 
wires. The tension was normalized to 90% of the estimated diameter at 100 mm Hg [17]. 
The proximal coronary arteries and saphenous veins were cut into ring segments of 
about 3-4 mm length and suspended on stainless steel hooks in 15-mL organ baths. The 
vascular rings were stretched to a stable pretension of 10-15 mN, the optimal pretension 
as determined earlier [17], and changes in tissue force were measured with an isometric 
force transducer (Harvard, South Natick, MA, U.S.A.) and recorded on a flatbed recorder 
(Servogor 124, Goerz, Neudorf, Austria). The buffer was aerated with 95% O2 and 5% CO2 and 
was maintained at 37°C. The segments were allowed to equilibrate for at least 30 min and 
were washed every 15 min.
In vitro experimental protocols
Initially, segments were exposed to 30 mM KCl, followed by 100 mM KCl to determine the 
reference contractile response in each segment. Cumulative concentration response curves 
were constructed to (S)-isometheptene, (R)-isometheptene, isometheptene racemate, 
sumatriptan and noradrenaline, using whole logarithmic steps (1 nM to 100 μM). Sumatriptan 
and noradrenaline were used as positive controls, as previously reported [17]. Finally, 
the functional integrity of the endothelium was assessed by observing the relaxation to 
substance P (10 nM) in arteries or bradykinin (10 µM) in saphenous veins after precontraction 
with the thromboxane A2 analogue U46619 (10-100 nM). 
Animals
Twelve male Sprague-Dawley rats (300-350 g; 8-10 weeks of age), purchased from Harlan 
Netherlands (Horst, the Netherlands), were maintained at a 12/12 h light-dark cycle in a 
special room at constant temperature (22±2 °C) and humidity (50%), with food and water ad 
libitum. Only male rats were used to avoid crosstalk between CGRP and hormonal fluctuations 
of the oestrus cycle previously described in this model [18, 19]. Experimental protocols were 
approved by the Erasmus Medical Center’s institutional ethics committee (EMC permission 
protocol number 3393), in accordance with the European directive 2010/63/EU and the 
ARRIVE guidelines for reporting experiments in animals [20].
 After anaesthesia with sodium pentobarbital (60 mg/kg i.p. followed by 18 mg/kg 
i.v. per hour), the trachea was cannulated and artificially ventilated (58 strokes/min.; small 
animal ventilator SAR 830 series, CWE Inc., Ardmore, PA, U.S.A). The adequacy of anaesthesia 
was judged by the absence of ocular reflexes and a negative tail flick test.End-tidal pCO2 was 
monitored with a capnograph (Capstar 100 CWE Inc., PA, U.S.A.) and kept between 35-45 mm 
Hg. The left femoral vein and artery were cannulated for i.v. administration of drugs and 
monitoring of mean arterial pressure (MAP), respectively. The animals’ body temperature 
was maintained at 37°C by a homeothermic blanket (Harvard Instruments, Edenbridge, 
Kent, U.K.). The head of each rat was fixed in a stereotaxic frame and the parietal bone 
overlying a segment of the dural middle meningeal artery was drilled thin, applying cold 
saline until the artery was clearly visible. As skull drilling induces vasodilation, animals were 
allowed to rest at least for 1 hour before the experimental protocol started. The artery 
diameter was recorded with an intravital microscopy setup (MZ16, Leica microsystem Ltd., 
Heerbrugg, Switzerland) using a cyan blue filter on a cold light source. A zoom lens (80-450x 
magnification) and a camera were used to display images on a standard PC monitor. 
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The artery diameter (30-40 µm at baseline) was continuously monitored and measured 
with an intravital dimension analyser (IDA 1.2.1.10; U.K.). For periarterial electrical 
stimulation (ES), a bipolar stimulating electrode (NE 200X, Clark Electromedical, Edenbridge, 
Kent, U.K.) was placed on the surface of the bone approximately within 200 µm from the 
artery. The surface of the closed cranial window was stimulated at 5 Hz, 1 ms for 10 s 
(Stimulator model S88, Grass Instruments, West Warwick, RI, U.S.A.) with increasing voltage 
until maximum dilation was observed.
In vivo experimental protocols
After a stable hemodynamic condition for at least 60 min, baseline values of dural artery 
diameter and MAP were determined. Subsequently, the 12 rats were randomly divided into 
three sets (n=4 each). In each set, a control vasodilator response of the middle meningeal 
artery was produced by either endogenous [released by ES (150-300 µA) or capsaicin 
(10 µg⁄kg, i.v.)] or exogenous CGRP (1 µg/kg, i.v.). A 30-min interval between control 
and each subsequent vasodilation was allowed for the recovery of baseline values, and 
5 min before the next vasodilation, (R)-isometheptene, (S)-isometheptene or the racemate 
(3 mg/kg, i.v., each) were injected. The administration of the isometheptene enantiomers 
was alternated, and followed by racemate. In each case, there was a time interval of 
5 min to allow the dural artery diameter and MAP to return to baseline, before the next 
vasodilator was administered. We have previously shown that repeated (up to 5 times) 
ES and treatment with capsaicin or CGRP produced reproducible increases in dural artery 
diameter (data not shown). 
Statistical evaluation
All data are presented as mean ± SEM. The concentration response curves obtained in the 
vessels were analysed using GraphPad software (GraphPad software Inc., San Diego, CA, 
U.S.A.) to calculate the maximal effect (Emax) and pEC50 values. In case a concentration 
response curve did not reach a plateau, the contraction to the highest concentration was 
considered as Emax. Emax and pEC50 values were compared by unpaired t-test. The peak 
increases in dural artery diameter (measured in arbitrary units) in anaesthetised rats are 
expressed as percent change from baseline. Changes in MAP are expressed in absolute 
values (mm Hg). A repeated measures one-way analysis of variance (ANOVA) followed by 
Tukey’s test was performed to examine the different effects per se between isometheptene 
enantiomers and the racemate. The dural vasodilator differences between the variables 
within one group were compared using an ANOVA followed by Dunnett’s test. Statistical 
significance was accepted at p<0.05 (two-tailed).
Compounds
Apart from the anaesthetic (sodium pentobarbital), the drugs used in the present study were: 
isometheptene racemate, (R)-isometheptene and (S)-isometheptene (Tonix Pharmaceuticals 
Inc., New York, N.Y., U.S.A.); sumatriptan, bradykinin, noradrenaline, capsaicin, U46619 and 
substance P (Sigma Chemical Co., St. Louis, MO, U.S.A); and rat/human α-CGRP (NeoMPS 
S.A., Strasbourg, France). Capsaicin was dissolved in a mixture of tween 80, ethanol 70% 
and water (1:1:8), while the rest of the compounds were dissolved in either distilled water 
(in vitro) or physiological saline (in vivo). The doses mentioned in the text refer to the free 
base of substances in all cases.
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Vascular in vitro  responses in human middle meningeal artery
Middle meningeal artery relaxation to substance P (10 nM) was 51±17% of the precontraction 
induced by U46619. As shown in Figure 1, sumatriptan induced concentration-dependent 
contractions that appeared smaller (albeit non-significant) than those induced by 
noradrenaline at the highest concentrations (Emax 98±19 vs. 156±22%; p=0.070; n=6-7). 
In contrast, the pEC50 values were significantly higher for sumatriptan than for noradrenaline 
(7.0±0.2 vs. 5.8±0.2; p=0.001; n=6-7).
 Interestingly, isometheptene racemate and its enantiomers did not induce any 
significant contraction, except when they were administered at the highest concentration 
studied (100 µM, a supratherapeutic concentration), where the enantiomers only induced a 
modest contraction (20-40% of 100 mM KCl; p=0.002; n=7; Figure 1).
Figure 1. Concentration response curves to sumatriptan, noradrenaline, isometheptene enantiomers 
and isometheptene racemate on the middle meningeal artery (n=6-7), saphenous vein (n=7-10), as well 
as proximal (n=7-10) and distal (n=8-9) coronary arteries.
Vascular responses in human saphenous vein and coronary artery 
In saphenous vein, the endothelium-dependent relaxation to 10 µM bradykinin was 19±4% 
of the precontraction induced by U46619. Noradrenaline induced concentration-dependent 
contractions, which were larger and more potent than those induced by sumatriptan 
(Emax 111±9 vs. 51±10%; p<0.001 and pEC50 6.9±0.1 vs. 6.3±0.2; p=0.019; n=9-10). 
Isometheptene racemate, as well as its enantiomers, did not produce venocontraction, even 
at the highest concentrations tested (up to 100 µM). In the proximal and distal coronary 
segments, the endothelium-dependent relaxations to substance P were 31±3 and 83±7% of 
the precontraction induced by U46619, respectively. As shown in Figure 1, the contractile 
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responses to sumatriptan and the corresponding pEC50 values did not significantly differ 
between the proximal and distal segments of the coronary artery (Emax 19±6 vs. 45±17%; 
p=0.15 and pEC50 6.3±0.2 vs. 6.2 ± 0.1; p=0.65; n=9-10), respectively. Noradrenaline was 
devoid of contractile effects in both artery segments; the same was true for isometheptene 
racemate and its enantiomers. 
Effect of isometheptene enantiomers and racemate per se on MAP and dural artery 
diameter in vivo
In the closed cranial window experiments, the baseline value of MAP was 92±5 mm Hg (n=12). 
As shown in Figure 2 (left panel), i.v. injection of both isometheptene enantiomers and the 
racemate produced significant vasopressor responses (p<0.001; n=12 each). Remarkably, 
(S)-isometheptene produced more pronounced vasopressor responses than isometheptene 
racemate and (R)-isometheptene (39±7, 27±4 and 23±4 mm Hg, respectively; p=0.004; 
n=12).
Figure 2. Effect per se of i.v. bolus injections of (S)-isometheptene, (R)-isometheptene and the 
racemate (3 mg/kg each) on mean arterial pressure (MAP) and dural artery diameter; all compounds 
produced significant vasopressor responses and dural vasoconstriction (p<0.05); *p<0.05 as compared 
to (S)-isometheptene
In the dural artery, the administration of (S)-isometheptene, (R)-isometheptene or 
isometheptene racemate produced a significant (p<0.001, n=12) small, short-lasting decrease 
in dural artery diameter (12±2%, 13±2% and 10±2% of baseline diameter, respectively; 
Figure 2 right panel), which did not differ amongst the agonists (p=0.34; n=12). The dural 
artery diameter and MAP values restored to pre-injection levels by the time the next 
vasodilation was elucidated. At the end of the experiments, the value of MAP (88±5 mm Hg) 
was not significantly different from the initial baseline value (p=0.53; n=12).
Effect of ES, capsaicin or CGRP on MAP and dural diameter 
In none of the experiments ES (150-300 μA) affected MAP. The i.v. administration of 10 µg/kg 
capsaicin or 1 µg/kg CGRP produced, as compared to baseline, a similar decrease in MAP of 
19±7 and 24±8 mm Hg (p=0.68; n=4), respectively. Regarding dural artery diameter, a similar 
vasodilation was produced after ES and administration of capsaicin or CGRP (62±7, 42±5 and 
55±8% of baseline diameter, respectively; p=0.29; n=4 each). 
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Effect of isometheptene enantiomers and the racemate on the dural vasodilatory 
responses 
After pretreatment with (S)-isometheptene, (R)-isometheptene or isometheptene racemate, 
the increases in dural artery diameter (percent change from baseline) evoked by ES (49±9, 
56±6 and 44±11%, respectively; p=0.48), capsaicin (34±5, 28±2 and 26±13%, respectively; 
p=0.42), or CGRP (49±9, 56±6 and 44±11%, respectively; p=0.84) were similar (n=4 each) to 
their respective controls in all groups (Figure 3). 
Figure 3. Effect of i.v. bolus injections of isometheptene enantiomers or the racemate (3 mg/kg) on 
dural vasodilation induced by periarterial electrical stimulation (150-300 μA, upper panels), capsaicin 
(10 μg/kg, middle panels) or α-CGRP (1 μg/kg, lower panels) in anesthetized rats (n=4 in each group); 
(S)-IMH, (S)-isometheptene; (R)-IMH, (R)-isometheptene; (RS)-IMH, isometheptene racemate.
Discussion 
Apart from the implications discussed below, the present study shows the importance of 
analysing, in an integrative way, the properties of novel antimigraine drugs (namely the 
isometheptene enantiomers) in different experimental models. Within this context: the use 
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of different human isolated blood vessels allows us to discern possible vascular side-effects 
induced by potential antimigraine agents; and the rat closed cranial window is an in vivo 
neurovascular migraine model that focuses on the pathophysiological interaction of the 
trigeminal system with neurogenic dural vasodilation [21].
Human vascular (side) effects
A limitation of the current specific antimigraine drugs (i.e. triptans and ergots) is their 
theoretical risk of coronary vasoconstriction, consequently all vasoactive antimigraine 
agents are contraindicated in patients with cardiovascular risk factors or coronary artery 
disease [22]. With this in mind, we investigate the vasomotor effects of the isometheptene 
enantiomers in different human blood vessels, including the proximal and distal coronary 
arteries; additionally, the human saphenous vein was included as a positive control of 
peripheral venoconstriction that is sensitive to α-adrenergic stimulation [23]. Importantly, 
the isometheptene enantiomers and the racemate were devoid of vasoconstrictor 
properties in the proximal and distal coronary arteries, as well as the saphenous veins at all 
concentrations tested. 
 Similarly, the isometheptene enantiomers were devoid of meningeal contractile 
effects, except when they were administered at the highest concentration (100 µM, 
Figure 1), a supratherapeutic concentration that would never be reached in the clinical 
situation.  Regarding the possible mechanism of action of this meningeal vasoconstriction, it 
is tempting to speculate that it is mediated by an indirect (tyramine-like) action, resulting 
in noradrenaline displacement from perivascular sympathetic nerve terminals [24], as 
previously shown for (R)-isometheptene-induced vasopressor responses [25]. Admittedly, 
we did not test this hypothesis with experiments in the presence of neuronal reuptake 
inhibitors such as cocaine, because, as mentioned before, this phenomenon only happens at 
supratherapeutic concentrations and is thus unlikely to be clinically relevant.
 In contrast to the meningeal artery, there were no tyramine-like vasoconstrictor 
effects in coronary arteries, mainly because these vessels (via β2-adrenoceptors in vascular 
smooth muscle) normally dilate to (displaced) noradrenaline [26], as is evident from the lack 
of contraction after exogenous noradrenaline. Similarly, no tyramine-like responses were 
observed in saphenous veins; this may be attributed to a lesser sympathetic innervation 
(vs. arteries) and the possibility that an important amount of perivascular fibres [present in 
the loose connective tissue surrounding the vein, [27] were destroyed.
 Thus, on the basis of these results, the well-established antimigraine action of 
isometheptene racemate [7, 8, 11], and probably also of isometheptene enantiomers [in 
particular the antimigraine potential of (R)-isometheptene] would seem to be devoid of 
acute coronary side-effects.
In vivo effects of isometheptene on MAP
In this study, and in accordance with others [25, 28], isometheptene racemate and 
(S)-isometheptene are potent vasopressor compounds in rats. Their vascular responses 
are mediated by an indirect (tyramine-like action) and a minor direct stimulation of 
α1-adrenoceptors [28]. In contrast, vascular responses to (R)-isometheptene are exclusively 
indirect (tyramine-like action) and of less magnitude than its counterpart enantiomer [25]. 
Accordingly, (R)-isometheptene might produce fewer vascular side-effects as an antimigraine 
agent. 
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In vivo effects of isometheptene on dural artery diameter
In contrast to the lack of vasoconstriction in the isolated human middle meningeal artery, 
the isometheptene enantiomers and the racemate produced equipotent meningeal 
vasoconstrictor responses in vivo (Figure 2). This apparent in vitro/in vivo discrepancy 
suggests that isometheptene’s vasoconstriction is indeed mediated by a tyramine-like 
action mechanism, which is more evident when the perivascular sympathetic tone is higher 
(i.e. in vivo), whereas such neurogenic tone has been eliminated in vitro. Although it is 
believed that the marked dural vasoconstriction of ergots [17] and triptans [29], along with the 
inhibition of intracranial trigeminal afferents [21] contributes to the peripheral antimigraine 
mechanisms of these drugs, it is unlikely that isometheptene’s antimigraine action is related 
to this small, short-lasting decrease in dural artery diameter. Therefore, we proceeded to 
explore whether the attenuation of experimentally-activated trigeminovascular afferents 
could explain isometheptene antimigraine efficacy.
Modulation of perivascular CGRP release as antimigraine treatment 
The rat closed cranial window method is a highly predictive model of antimigraine action, 
in which triptans [21] and CGRP receptor antagonists [gepants and CGRP (receptor)-binding 
antibodies [30] have shown its ability to inhibit neurogenic (CGRP-mediated) vasodilation 
of the dural middle meningeal artery as one of their pharmacological sites of action. It is 
noteworthy that the isometheptene enantiomers and the racemate did not reduce the 
dural vasodilation evoked by the release of endogenous CGRP (by ES or i.v. capsaicin) or 
exogenous CGRP (Figure 3). Hence, inhibition of trigeminal CGRP release, as one of the 
mechanisms associated with antimigraine action (or vasoconstriction), does not appear to 
explain isometheptene’s antimigraine efficacy. Interestingly, it has previously been shown 
that imidazoline I1 and α2-adrenoceptor agonists are capable of inhibiting prejunctionally the 
sensory vasodepressor CGRPergic outflow in pithed rats [25, 31]. However, (R)-isometheptene, 
an imidazoline I1 receptor agonist with extremely low affinity for α2-adrenoceptors [12], did 
not inhibit the neurogenic dural vasodilation induced by trigeminal stimulation; suggesting 
a differential receptor expression between sensory and trigeminal afferents, as previously 
shown for α2-adrenoceptors [32]. This suggests that in the rat closed cranial window model, 
imidazoline I1 and α2 receptors do not play a role as prejunctional modulators of CGRP 
release in the trigeminovascular system. 
 Even though similar sample sizes have been used by two different research 
groups [32, 33], it could be argued that the statistical power of our in vivo experiments is low 
(and a limitation) due to the relatively small number of animals used per group. However, 
when comparing our current results with those of earlier findings using sumatriptan [21] 
and CGRP antagonists [30], the magnitude of inhibition of CGRP release is remarkably high 
(up to ca. 70%, and own experiments, data not shown). Thus, while we cannot categorically 
exclude that a higher number of animals could have produced statistically significant 
effects, such effects would be rather limited and, probably, devoid of clinical relevance, as 
an i.v. dose of 3 mg/kg isometheptene is already supramaximal in pithed rats [25].
Future perspectives for (R)-isometheptene
Isometheptene racemate as monotherapy or, as usual, combined with other drugs (e.g. 
analgesics), seems a cost-effective alternative (vs. the triptans) in some countries for the 
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acute treatment of mild-to-moderate primary headache [8, 10]. Whereas (R)-isometheptene 
has been shown not to be effective in the treatment of episodic tension-type headache [34], 
its antimigraine efficacy has not yet been clinically tested. Overall, after considering the 
above pharmacological profile of (R)-isometheptene, it is not unreasonable to suggest that 
its potential clinical use as an antimigraine agent may have superior therapeutic advantages 
over either isometheptene racemate or (S)- isometheptene. Most importantly, the fact that 
(R)-isometheptene produced only a slight increase in MAP suggests that it is not directly 
associated with the intracranial vasospasm previously described with the racemate [9, 10]. 
 As an imidazoline I1 receptor agonist, (R)-isometheptene should possess central 
antinociceptive properties, as previously shown for other imidazolines agonists [35]. This 
is supported by a preliminary study where high doses of (R)-isometheptene decreased 
trigeminal sensitivity in two rat models of chronic migraine, and this effect was associated 
with a reduced CGRP immunoreactivity in the trigeminal nucleus caudalis. Certainly, further 
experiments, falling beyond the scope of the present study, will be required to investigate 
whether: (i) (R)-isometheptene is capable of inducing central antinociception; (ii) activation 
of imidazoline receptors translates into acute or prophylactic antimigraine action; and 
(iii) selective imidazoline I1 receptor agonists can be developed as novel antimigraine 
agents. 
Conclusion
It is noteworthy that the isometheptene racemate and its enantiomers displayed a 
relatively safe peripheral vascular profile, as they failed to constrict the human coronary 
artery. Isometheptene’s antimigraine action appears unrelated to modulation of the 
trigeminovascular system and CGRP release, but most likely involves central mechanisms. 
The exact site and mechanism for antinociceptive modulation still remains to be elucidated. 
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Fig 1/2. Trigeminal nerve and ganglion.
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Part III. Dural neurovascular pharmacology
Chapter 6
Characterization of the trigeminovascular actions 
 of several adenosine A2A receptor antagonists 
 in an in vivo rat model of migraine
Based on: The Journal of Headache and Pain, 2018, 19: 41.
Haanes KA*, Labastida-Ramírez A*, Chan KY, de Vries R, Shook B,Jackson P, Zhang J, 
Flores CM, Danser AHJ, Villalón CM and MaassenVanDenBrink A. *Equal contributors.
Abstract
Background: Migraine is considered a neurovascular disorder, but its pathophysiological 
mechanisms are not yet fully understood. Adenosine has been shown to increase in plasma 
during migraine attacks and to induce vasodilation in several blood vessels; however, 
it remains unknown whether adenosine can interact with the trigeminovascular system. 
Moreover, caffeine, a non-selective adenosine receptor antagonist, is included in many over 
the counter anti-headache/migraine treatments.
Methods: This study used the rat closed cranial window method to investigate in vivo the 
effects of the adenosine A2A receptor antagonists with varying selectivity over A1 receptors; 
JNJ-39928122, JNJ-40529749, JNJ-41942914, JNJ 40064440 or JNJ-41501798 (0.3-
10 mg⁄kg) on the vasodilation of the middle meningeal artery produced by either CGS21680 
(an adenosine A2A receptor agonist) or endogenous CGRP (released by periarterial electrical 
stimulation).
Results: Regarding the dural meningeal vasodilation produced neurogenically or 
pharmacologically, all JNJ antagonists: (i) did not affect neurogenic vasodilation but 
(ii) blocked the vasodilation produced by CGS21680, with a blocking potency directly related 
to their additional affinity for the adenosine A1 receptor.
Conclusion: These results suggest that vascular adenosine A2A (and, to a certain extent, 
also A1) receptors mediate the CGS21680-induced meningeal vasodilation. These receptors 
do not appear to modulate prejunctionally the sensory release of CGRP. Prevention of 
meningeal arterial dilation might be predictive for antimigraine drugs, and since none of 
these JNJ antagonists modified per se blood pressure, selective A2A receptor antagonism may 
offer a novel approach to antimigraine therapy which remains to be investigated in clinical 
trials.
Background
Migraine is a neurovascular disorder associated with activation of the trigeminovascular 
system and release of calcitonin gene-related peptide (CGRP) from trigeminal sensory 
perivascular nerves, which results in cranial vasodilation and stimulation of sensory nerve 
transmission [1]. In line with these neurovascular mechanism: (i) plasma levels of CGRP, 
which increase during migraine, are normalized by triptans in parallel with amelioration 
of headache [2]; and (ii) CGRP receptor antagonists [1] and antibodies against CGRP or 
its receptor [3] are effective in migraine treatment. Although there seem to be some full-
responders, the average reduction in migraine days compared to placebo is only in the 
excess of 1 day per month when administering any CGRP antibody [4]. This limited efficacy 
resulting from inhibiting CGRP effects suggests that the pathogenesis of migraine could 
involve additional mechanisms.
 Interestingly, adenosine (released centrally and peripherally as a breakdown product 
of ATP) is another neuromodulator that seems to play a role in migraine pathophysiology [5]. 
Indeed: (i) adenosine plasma levels have been reported to be increased during migraine 
attacks [6]; (ii) exogenous adenosine may trigger migraine attacks [7]; (iii) dipyridamole, 
an adenosine uptake inhibitor, may increase the frequency of migraine attacks [8]; 








Accordingly, adenosine receptor antagonists may have potential therapeutic usefulness in the 
treatment of migraine; while caffeine, a non-selective adenosine receptor antagonist [5], 
is already present in several over-the-counter anti-headache/migraine medications [10].
 The conjunction of structural, transductional and operational criteria has shown 
that adenosine can activate four subtypes of G-protein-coupled receptors [11, 12], namely 
adenosine: (i) A1 and A3 receptors (coupled to Gi proteins), which mediate vascular smooth 
muscle constriction; and (ii) A2A and A2B receptors (coupled to Gs proteins), which mediate 
direct and endothelium-dependent vasodilation [13, 14]. Moreover, the A1 receptor can also 
mediate endothelium-dependent vasodilation [15, 16].
 Within this framework, it has been shown ex vivo that adenosine and CGS21680 
a stable A2A receptor agonist (with about 10-100-fold selectivity for A2A receptors over 
A1 and A3 receptors and poor affinity for A2B receptors [17]) dilate middle meningeal and 
cerebral arteries respectively, a response blocked by A2A receptor antagonists [13, 18]. 
The above findings, coupled to the demonstration that the trigeminal ganglion expresses 
A2A receptors [19] and the ability of this receptor to facilitate CGRP release in the 
hippocampus [20], beg the questions of whether adenosine A2A receptors can induce 
meningeal vasodilation in vivo, and also whether they could be involved in neurogenic 
vasodilation either per se or as modulators of CGRP release in the trigeminovascular system. 
 Hence, this study used the rat closed cranial window method, a model predictive 
of antimigraine action [21], to investigate the effects of five novel adenosine A2A receptor 
antagonists on the vasodilation of the middle meningeal artery produced by either CGS21680 
or endogenous CGRP (released by periarterial electrical stimulation). These antagonists 
(JNJ-41942914, JNJ-39928122, JNJ 40529749, JNJ-40064440 and JNJ-41501798) were 
developed as described by Shook et al. [22] and display a varying degree of selectivity for 
adenosine A2A over A1 receptors (Table 1).





CGS2168033 22 nM (7.6) 3100 nM (5.5) 141
Caffeine28 8,100 nM (5.1) 20,000 nM (4.7) 2.5
JNJ-39928122a 7.9 nMλ (8.1) 55.1 nMλ (7.3) 7
JNJ-40529749a 4.9 nM (8.3) 89.1 nM (7.1) 18
JNJ-41942914a 8.3 nM (8.1) 1093 nM (6.0) 132
JNJ-40064440a 8.2 nM (8.1) 1240 nM (5.9) 151
JNJ-41501798a 11.5 nM (7.9) 7997 nM (5.1) 695
Table 1. Affinity constants indicated as IC50 in nM (and the corresponding pIC50) for the compounds 
used in the present study. The JNJ antagonists were developed by Johnson & Johnson Pharmaceutical 
Research & Development, L.L.C. Hutchison et al. 1989 [33]; Fredholm et al. 1999 [28]; a, Paul Jackson 
(Johnson & Johnson, personal communication); λ, Indicates Ki values
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Materials and Methods
Intravital microscopy experiments 
Animals
Fifty-seven normotensive male Sprague-Dawley rats (300-400 g), purchased from Harlan 
(Horst, The Netherlands), were maintained at a 12/12 h light dark cycle (with light beginning 
at 7 a.m.) and housed at a constant temperature (22±2 °C) and humidity (50%), with food and 
water ad libitum. Only male rats were used to avoid crosstalk between CGRP and hormonal 
fluctuations during the female estrus cycle [23]. The animals were anaesthetized with an 
intraperitoneal (i.p.) injection of sodium pentobarbital (60 mg/kg, followed by 18 mg/kg 
i.v. per hour when necessary). The adequacy of anesthesia was judged by a negative tail 
flick test and the absence of ocular reflexes, amongst others. All experimental protocols of 
this study were approved by our Institutional Ethics Committee [Erasmus MC; permission 
protocol number EMC 1931 (118-09-04], in accordance with the NIH guide for the Care and 
Use of Laboratory Animals in U.S.A. and the ARRIVE guidelines for reporting experiments in 
animals [24]. All rats were randomly assigned into the different experimental protocols (see 
experimental protocol section).
General methods
After anesthesia, the trachea was cannulated and connected to a pressure ventilator (small 
animal ventilator SAR-830 series, CWE Inc., Ardmore, PA, U.S.A.). End-tidal pCO2 was 
monitored (Capstar-100 CWE Inc., PA, U.S.A.) and kept between 35 and 48 mm Hg. The left 
femoral vein and artery were cannulated for intravenous (i.v.) administration of drugs and 
continuous monitoring of blood pressure, respectively. Two or three samples of blood (at 
the beginning and at the end of the experiment) were withdrawn via the femoral artery 
to monitor blood gases and other parameters, which were kept between normal values 
(pH: 7.35-7.48; pCO2: 35-48 mm Hg; pO2: 100-120 mm Hg). The body temperature of each 
rat was monitored via a rectal thermometer and maintained throughout the experiment 
(36.5-37.5°C) by a homeothermic blanket system for rodents (Harvard Instruments, 
Edenbridge, Kent, U.K.). 
 The rats were placed in a stereotaxic frame and the parietal bone overlying a 
segment of the dural meningeal artery was carefully drilled thin, applying cold saline (4°C) 
until the artery was visible. Since skull drilling induces vasodilation, we allowed the animal 
to recover for 1 hour before the experimental protocol. The drilled area was covered with 
mineral oil to prevent drying and to facilitate visualization of the meningeal artery. The 
artery was captured with an intravital microscope (model MZ 16; Leica microsystem Ltd., 
Heerbrugg, Switzerland) using a cyan blue filter on a cold source of light. A zoom lens 
(80-450 × magnification) and a camera was used to display images with the blood vessel 
diameter (30-40 μm at baseline) being continuously monitored and measured with a video 
dimension analyzer (Living Systems Instrumentation Inc., Burlington, VT, U.S.A.). In rats 
where periarterial electrical stimulation was used to evoke dural vasodilation, a bipolar 
stimulating electrode (NE 200X, Clark Electromedical, Edenbridge, Kent, U.K.) was placed on 
the surface of the cranial window approximately within 200 µm from the vessel of interest. 
The cranial window surface was stimulated at 5 Hz, 1 ms for 10 s (Stimulator model S88, 
Grass Instruments, West Warwick, RI, U.S.A.). For neurogenic dural vasodilation, we initially 
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started with a current intensity (monitored on an oscilloscope, model 54601A, Hewlett 
Packard, Palo Alto, CA, U.S.A.) of 100 µA and increased with 50 µA steps until a maximal 
level of dilatation was achieved, usually at 200 µA. The resulting data were displayed and 
recorded using a WINDAQ data acquisition system (Version 2.54; DataQ Instruments Inc., 
Akron, OH, U.S.A.). 
Experimental protocols
First, 6 animals were used to determine the effect of i.v. adenosine and caffeine on 
the middle meningeal artery diameter.  The doses of adenosine (1 mg/kg) and caffeine 
(40 mg⁄kg) were based on previously published work [15, 25]. Further, 51 animals were 
divided into two groups which received, respectively, periarterial electrical stimulation 
(150-250 μA; n=27) and the adenosine A2 receptor agonist CGS21680 (10 μg/kg, i.v., n=24; 
the optimal dose as determined in 7 pilot experiments, data not shown). Dural vasodilator 
responses remained unchanged after repeated treatment for 4 times (data not shown) 
and in the presence of the vehicle captisol, which was used for dissolving most of the 
antagonists. Thirty min were allowed between each of these treatments for recovery to the 
baseline diameter. Subsequently, each of these groups was subdivided into five subgroups 
(n=3-6 each) which were given (after 30 min) i.v. bolus injections of, respectively, the 
adenosine A2A receptor antagonists JNJ 41942914 (0.3, 1, and 3 mg/kg), JNJ-39928122, 
JNJ-40529749, JNJ-40064440 and JNJ 41501798 (all 1, 3 and up to 10 mg/kg). Based on their 
binding affinities (see Table 1), only doses up until significant blockade, were tested for 
the CGS21580 response. Each antagonist dose was administered 5 min before periarterial 
electrical stimulation or CGS21680, except for caffeine (15 min) as previously reported [25]. 
The duration of each experiment was approximately 2.5 hours after stabilization.
Data presentation and statistical evaluation
All data are presented as mean ± SEM. The peak increases in dural meningeal artery diameter 
are expressed as percent change from baseline. Changes in mean arterial blood pressure 
(MAP) were expressed as absolute values (mm Hg). The difference between the variables 
within one group was compared by using a one-way repeated measures analysis of variance 
followed by Dunnet’s test. Dunnet’s test does not give individual P-values, hence statistical 
significance was accepted at p<0.05. When there was only one dose applied (for caffeine), 
two-tailed paired Student’s T-test was used.
Drugs
The compounds used in this study were: sodium pentobarbital (Nembutal; Ceva Sante Animale 
B.V., Maassluis, The Netherlands); caffeine, adenosine and CGS21680 hydrochloride hydrate 
(2-p-(2-Carboxyethyl)phenethylamino-5′-N-ethylcarboxamido adenosine hydrochloride 
hydrate) (Sigma Chemicals Co., Steinheim, Germany); JNJ 41942914, JNJ-39928122, 
JNJ-40064440, JNJ-40529749 and JNJ-41501798 (gift courtesy from Johnson & Johnson 
Pharmaceutical Research & Development, L.L.C., Raritan, NJ, U.S.A.). Caffeine, adenosine, 
CGS21680 and JNJ-40064440 were dissolved in distilled water, whereas JNJ-39928122, 
JNJ-41942914, JNJ-40529749 and JNJ-41501798 were dissolved in captisol (sulfobutylether 
β-cyclodextrin; Ligand Pharmaceuticals, San Diego, U.S.A.). The suspensions of JNJ-40529749 
and JNJ-41501798 were sonicated and filtrated. All solutions were further diluted in saline.
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In order to facilitate the interpretation of the following results, the five JNJ antagonists 
(Table 1) were sub-divided, a priori, into 3 groups (indicated in different grey-tones): 
(i) JNJ-39928122 and JNJ-40529749 have ~10-fold selectivity for A2A over A1 receptors; 
(ii) JNJ-41942914 and JNJ-40064440 are ~100 fold selective for A2A over A1 receptors; and 
(iii) JNJ-41501798 is ~700 fold selective for A2A over A1 receptors. It is also worth mentioning 
that caffeine has ~2.5-fold selectivity for the rat and ~5-fold selectivity for the human A2A 
vs. A1 receptors [KD values, [26]]; however, caffeine also inhibits A2B receptor with similar 
affinity as for A1, which is not the case for the JNJ antagonists.
Effects of i.v. adenosine and caffeine on dural diameter and MAP
We initially set out to determine the effect of adenosine on the dural diameter in vivo. 
Figure 1 shows that (i) 1 mg/kg adenosine caused a dural artery dilation of 50±6% and a 
drop in blood pressure to 53±4 mm Hg; (ii) 40 mg/kg caffeine caused a  non-significant dural 
artery dilation of 12±5%, while blood pressure was increased significantly by 14±3 mm Hg; 
(iii) after a stabilizing period post-caffeine, the second dural artery dilation produced by 
adenosine was reduced to 25±6% (n=6, p=0.003, which was accompanied by a significantly 
attenuated drop in blood pressure, to 69±5 mm Hg (p=0.004). 
Figure 1. The effect of caffeine on adenosine-induced dural vasodilation. Adenosine (1 mg/kg) was 
injected i.v. after a recovery period of 30 min. Then, caffeine (40 mg/kg) was injected slowly, and a 
second adenosine injection (1 mg/kg) was injected 15 min after the caffeine injection (adenosine after 
caffeine). Left panel illustrates increase in diameter and right panel changes in mean arterial blood 
pressure, in response to adenosine. Data are mean ± SEM, n=6, **p<0.01 compared to the control. 
Open circles represent baseline measurements before injections, B=Baseline.
Effect of the JNJ antagonists on the dural dilatation by periarterial electrical 
stimulation
In order to investigate whether the dural dilation induced by periarterial electrical 
stimulation could be in part dependent on adenosine release, either as direct activation 
of vascular adenosine receptors or prejunctional modulation of trigeminal CGRP release, 
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the JNJ antagonists (given i.v.) were investigated in their capability to modify the dural 
vasodilation produced by electrical stimulation. As shown in Figure 2 (left panels), 
neurogenic stimulation induced, overall, an immediate increase in dural artery diameter of 
83±7% (n=27). Surprisingly, none of the JNJ antagonists affected this neurogenic vasodilation 
(left panels). Suggesting that neither adenosine A1 nor A2A receptors are involved.
Figure 2. Effect of A2A antagonists on perivascular electrical stimulation of the dural artery. 
Perivascular electrical stimulation (150-250 µA) in the absence or presence of vehicle, or varying doses 
of JNJ-39928122 (A, n=4), JNJ-40529749 (B, n=4-5), JNJ-41942914 (C, n=6), JNJ-40064440 (D, n=4), 
or JNJ-41501798 (E, n=7-8). Data are presented as percentage of increase in diameter, left panels) 
and changes in mean arterial blood pressure (mm Hg, right panels) induced by periarterial electrical 
stimulation (ES). Note that none of the treatments produced any significant changes (p>0.05 compared 
to the vehicle). Open circles represent baseline measurements before injections/ES. JNJ-40064440 was 
dissolved in water, so vehicle measurements equal control.
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The effect of the JNJ antagonists on MAP before and during neurogenic dural stimulation
As shown in Figure 2 (right panels), both periarterial electrical stimulation and the 
JNJ antagonists were devoid of any effect per se on MAP.
Effects of CGS21680 on dural artery diameter and MAP
Although adenosine A2A or A1 receptors did not appear to be important in the vasodilation 
observed after neurogenic dural stimulation, adenosine vasodilates dural arteries in vivo 
(Figure 2), most likely via both A2A and A2B receptors as previously reported ex vivo [13]. 
Since our study set out to study specifically the role of the adenosine A2A receptor, we 
continued our study using CGS21680, which is a more biologically stable, highly selective for 
A2A over A2B receptor agonist [17]. 
 As shown in Figure 3, CGS21680 (10 µg/kg before administration of JNJ antagonists; 
n=24) mimicked adenosine in its capability to produce: (i) a marked dilation of the dural 
artery diameter (66±9%; left panels); and (ii) a drop in blood pressure (53±9 mm Hg; right 
panels) and hence excluding the involvement of A2B receptors.
The lower the selectivity (A2A over A1 receptors) the higher the potency of JNJ antagonists 
to block CGS21680-induced dural vasodilation
To further uncover the nature of the adenosine receptors in the dural vasculature, we 
explored the effect of the JNJ antagonist with varying selectivity (A2A over A1 receptors). 
Figure 3 (left panels) also shows that all JNJ antagonists significantly blocked the CGS21680-
induced dural vasodilation with varying degrees of potency. Specifically, the vasodilation to 
CGS21680 was: (i) abolished by 1 mg/kg (1±2%) of JNJ-39928122 (Figure 3A); (ii) abolished 
at 1 mg/kg (-2±1%) of JNJ-40529749 (Figure 3B); (iii) significantly attenuated (but not 
abolished) by 3 mg/kg (21±11%) of JNJ-41942914 (Figure 3C); (iv) significantly attenuated 
by 3 mg/kg (23±15%) and abolished (1±3%) by 10 mg/kg of JNJ-40064440 (Figure 3D); and 
(v) dose-dependently blocked, and practically abolished by 10 mg/kg (5±4%) of JNJ-41501798 
(Figure 3E). Clearly, the lower the selectivity of A2A vs. A1 (Table1) the higher the potency of 
JNJ antagonists to block CGS21680-induced dural vasodilation.
Effect of JNJ antagonists on CGS21680-induced vasodepressor responses
Similarly, the vasodepressor responses to CGS21680 were blocked by the JNJ antagonists as 
follows: (i) very potently by the less selective antagonists JNJ-39928122 and JNJ-40529749; 
and (ii) less potently by the highest doses of the more selective antagonists JNJ-41942914, 
JNJ-40064440 and JNJ-41501798, which display from low to very low affinity for the 
adenosine A1 receptor (Table 1). 
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Figure 3. Effect of i.v. CGS21680 on the dural diameter. CGS21680 (10 µg/kg) was injected followed by an 
injection of vehicle and varying doses of JNJ-39928122 (A, n=5), JNJ-40529749 (B, n=3-5) JNJ-41942914 
(C, n=4), JNJ-40064440 (D, n=3-4), or JNJ 41501798 (E, n=5-6). Data are presented as percentage of 
increase in diameter (left panels) and changes in mean arterial blood pressure (mm Hg, right panels) 
induced by CGS21680 (left lower panels).  CGS, 10 µg/kg CGS21680 i.v.; * p<0.05, ** p<0.01, *** p<0.001 
compared to the vehicle. #CGS in presence of vehicle. Open circles represent baseline measurements 
before injections. JNJ-40064440 was dissolved in water, so vehicle measurements equal control.
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Comparison between in vivo and in vitro vascular responses to adenosine
The adenosine receptor antagonists SCH58261 [478-fold A2A over A1 selective [27]] and caffeine 
[non-selective A1/2A/2B [28]] have been shown to block the ex vivo adenosine-induced dilation 
of endothelium-denuded middle meningeal arteries [18]. In these experiments, not only did 
caffeine (50 µM) or SCH58261 (1 µM) prevent the dural dilation, but a vasoconstriction to 
adenosine was unmasked. Interestingly, this effect was not observed in vivo, which could 
be due to the fact that the artery used for the myograph (outer diameter ~ 100 µm) had a 
larger diameter than in this study (outer diameter ~ 35 µm) and that there potentially are 
less adenosine A3 receptors expressed in smaller vessels, as we see no indirect involvement 
of A3 (i.e. vasoconstriction) in the current experiments. These differences require further 
investigation, but it is known that receptor expression changes along different vascular 
beds [29]. 
General considerations
In addition to the implications discussed below, the present study shows that: (i) both 
adenosine and CGS21680 produced rat dural vasodilation in vivo; and (ii) for JNJ antagonists, 
the lower the selectivity (A2A over A1 receptors) the higher the potency to block the dural 
vasodilation and vasodepressor responses induced by CGS21680 (implying that blockade 
of adenosine A1 receptors is also necessary to completely block the dural vasodilation 
in vivo). The latter finding is most likely due to endothelial A1 receptors, as the main 
difference between the in vivo (present study) and the ex vivo studies [18] is the absence of 
endothelium. Indeed, Honey et al. [21] have shown the presence of adenosine A1 receptors 
mediating vasodilation in the rat middle meningeal artery in vivo. 
The potential role of A2A and A1 receptors in the dural vasodilation as prejunctional 
modulators of neurogenic dural vasodilation or produced by CGS21680
The simplest interpretation of the fact that the JNJ antagonists had no effect on neurogenic 
dural vasodilation (Figure 2), which involves CGRP release [1], implies that: (i) adenosine 
is not released by periarterial electrical stimulation; (ii) A2A receptors do not constitute 
a positive feedback mechanism for CGRP release, as expected from its transductional 
properties [positive coupling to Gs proteins; [11]]; or (iii) cAMP increase, induced by 
CGRP, is so high that this could have masked the small increase in cAMP levels mediated 
by A2A receptors [26]. Interestingly, adenosine A1 receptors [coupled to Gi proteins; [11]] 
can produce a prejunctional inhibition of the neurogenic dural vasodilation in rats [21]. 
However, the weakly selective JNJ antagonists (JNJ-39928122 and JNJ-40529749), which 
would be theoretically expected to block (at least in part) this mechanism, did not increase 
neurogenic dural vasodilation (Figure 2).
 Several lines of evidence have previously shown in other systems that: (i) the 
vasodilation produced by adenosine and related agonists is mainly mediated by vascular 
and endothelial A2A receptors [13, 14] as well as by endothelial A1 receptors [16]; and 
(ii) the trigeminovascular system expresses adenosine A2A receptors [19]. In keeping with 
these findings, our results further demonstrate that the JNJ antagonists blocked CGS21680-
induced dural vasodilation (Figure 3), with a different profile of blockade (dependent on 
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A2A vs. A1 selectivity; see below). This reinforces the involvement of adenosine A2A and, 
probably to a lesser extent, of A1 receptors. In addition, based on the poor affinity of 
CGS21680 for the A2B receptors [17] and similar responses to adenosine, our data did not 
show any strong involvement of the A2B receptors.
Systemic effects of JNJ antagonists on A2A and A1 receptors
Caffeine is a non-selective adenosine A1, A2A and A2B receptor antagonist that does not 
affect adenosine A3 receptors at the doses used [28]. Accordingly, caffeine produced a slight 
increase in blood pressure (Figure 1), as previously reported [25]. Interestingly, the fact that 
none of the JNJ antagonists increased blood pressure (Figure 3, right panel), even at doses 
that blocked the dural vasodilation to CGS21680 (Figure 3, left panel) suggests that there 
is no strong “adenosine vascular tone”. In addition, it is worth emphasizing that adenosine 
A2B receptors are involved in the blood pressure effects of adenosine [30], which would 
explain the minor difference between caffeine and the JNJ antagonists in our study. 
 It is well established that A2A receptor agonists lower blood pressure [12, 31]. The 
A1 receptor agonists GR79236 and N6-cyclopentyladenosine (CPA), although less studied, 
also decrease blood pressure with higher potency than CGS21680, and both cause direct 
production of endothelial NO [15, 16, 31]. Hence, the vasodepressor response to adenosine 
in A1 -/- mice is reduced [32]. In the present study, the less selective (JNJ-39928122 and 
JNJ-40529749) A2A vs. A1 antagonists potently blocked the decrease in blood pressure, 
whereas the more selective (JNJ-40064440 and JNJ-41501798) A2A antagonists were less 
potent, and only effective at 10 mg/kg. These high doses of JNJ-4006440 and JNJ-41501798 
also induced inhibition of A1 receptors. Blockade of the adenosine A2A and A1 receptors 
prevents systemic vasodilation in response to adenosine, and therefore the block in blood 
pressure.
In vivo effects of CGS21680
In binding affinity studies, CGS21680 is 141-fold selective for A2A over A1 receptors [33]. 
However, our study raises the concern whether CGS21680 is a specific A2A receptor agonist 
in vivo in rats, as it appears that higher blocking affinities for the A1 receptor causes a 
more potent blockade of the vasodepressor and dural vasodilator responses. For the human 
adenosine receptors, the selectivity for A2A over A1 receptors is minimal [34]. 
 The most obvious explanation for the apparent discrepancy between the binding 
affinity selectively and the in vivo effects, is the location of adenosine receptors, as 
A1 receptors are on the endothelium, whereas the A2A receptors are mainly located 
on vascular smooth muscle [12]; hence the endothelium will be directly exposed to an 
apparently higher concentration. In addition, there are opposing findings on the selectivity 
of CGS21680. For example CGS21680 binds with high affinity (around 1 nM) to  adenosine A1 
receptors in the hippocampus of A2A -/- mice [35], in contrast, in the same mice CGS21680 
had no effect on blood pressure [36]. 
 Comparing our findings with previous studies in rats, the vasodepressor response 
to CGS21680 (10 µg/kg) was completely blocked by 3 mg/kg of the A2A receptor antagonists 
ZM241385 [319-fold A2A over A1; [15, 27]] or CGS15943 [9 fold A2A over A1; [37]]. Clearly, 
ZM241385 has a higher A2A over A1 selectivity, but its Ki for A1 receptors is 255 nM. Since these 
binding data are similar to those of our less selective compounds, A2A and also A1 receptors 
would be blocked in these studies.
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On the basis of the above lines of evidence, the antimigraine potential of selective adenosine 
A2A receptor antagonists would be of particular relevance in those patients whose adenosine 
plasma levels are markedly increased during a migraine attack. Although our findings 
indicate that adenosine is not released by perivascular electrical stimulation, inhibition of 
dural vasodilation is a shared mechanism of current (ergots and triptans) and prospective 
(CGRP (receptor) antagonists and antibodies) antimigraine drugs [1, 38]. Whether this 
(antimigraine) mechanism alone is sufficient to attenuate the trigeminal nociceptive 
transmission associated with migraine headache, remains to be determined. Additionally, 
other studies have shown that: (i) activation of A2A receptors facilitates the action of CGRP 
and VIP in the rat hippocampus [20]; (ii) A2A receptor knockout mice are hypoalgesic [36]; 
and (iii) A2A receptors are expressed in the rat trigeminovascular system [19] as well as in 
the rat trigeminal ganglion, together with A1, A2B and A3 receptors [18]. Furthermore, intra-
articular administration of adenosine and N6-cyclohexyladenosine (CHA, an adenosine A1 
receptor agonist), but not CGS21680, significantly increased ketorolac antinociception [39]. 
These findings, taken together: (i) argue in favor of selective blockade of adenosine A2 
receptors as a potential antimigraine strategy; and (ii) imply that blockade of A1 receptors 
would be a disadvantage in antimigraine treatment. Obviously, further clinical studies 
should evaluate the JNJ antagonist(s) with the optimal oral bioavailability based on their 
pharmacokinetic properties.
Conclusion
In conclusion, all the JNJ antagonists were capable of blocking CGS21680-induced dural 
vasodilation without affecting neurogenic dural vasodilation (suggesting no modulation of 
trigeminal CGRP release). This blockade was more potent when showing lower A2A over A1 
selectivity, and that both these receptors are involved in the dural artery vasodilation. 
On this basis, and considering that the JNJ antagonist were devoid of any effect per se on 
blood pressure, selective A2A receptor antagonism may offer a novel approach to antimigraine 
therapy that remains to be determined in clinical trials.
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Abstract
Background: The current understanding of mechanisms behind migraine pain has been 
greatly enhanced with the recent therapies targeting calcitonin gene-related peptide 
(CGRP) and its receptor. The clinical efficacy of CGRP-blocking drugs indicates that, at least 
in a considerable proportion of patients, CGRP is a key molecule in migraine pain. There are 
several receptors and molecular pathways that can affect the release of and response to 
CGRP. One of these could be purinergic receptors that are involved in nociception, but are 
greatly understudied with respect to migraine.
Objective: We aimed to explore purinergic receptors as potential antimigraine targets.
Methods: We used the human middle meningeal artery as a proxy for the trigeminal system 
to screen for possible antimigraine candidates. The human findings were followed by 
intravital microscopy and CGRP release measurements in rodents.
Results: We show that purinergic P2Y13 receptor fulfils all the features of a potential 
antimigraine target. The P2Y13 receptor is expressed in both the human trigeminal ganglion 
and middle meningeal artery and activation of this receptor causes: i) middle meningeal 
artery contraction in vitro; ii) reduced dural artery dilation following periarterial electrical 
stimulation in vivo and iii) a reduction of CGRP release from both the dura and the trigeminal 
ganglion in situ. Furthermore, we show that P2X3 receptor activation of the trigeminal 
ganglion causes CGRP release and middle meningeal artery dilation.
Conclusion: Both an agonist directed at the P2Y13 receptor and an antagonist of the P2X3 
receptor seem to be viable potential antimigraine therapies.
Background
The therapies for migraine patients have recently made a huge step forward with the 
arrival of the monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its 
receptor [1]. Apart from directly scavenging CGRP or blocking its receptor, future therapies 
could also be directed at regulating the cellular effect of CGRP or the neuronal release of 
CGRP or other neuropeptides. Currently available, acutely acting antimigraine drugs, the 
triptans, have also been demonstrated to inhibit CGRP release [2] which could be one of 
their most important therapeutic actions.
 Neither the origin of a migraine attack, nor the cause of migraine pain is fully 
understood. In contrast, the involvement of the CGRPergic system in migraine has been 
clearly recognized [1]. For example, CGRP is released during a migraine attack, and 
mitigation of the migraine pain after the use of triptans is accompanied by a normalization 
of CGRP levels [3]. Hence, molecular targets that can prevent CGRP release or counteract 
the effects of CGRP are viable targets for antimigraine therapy, as exemplified by the fact 
that all CGRP-targeted therapies thus far have been successful [4].
 An alternative approach to affect the CGRPergic system may be targeting the 
purinergic receptors because: i) purinergic receptors are involved in pain, ii) a subgroup 
of purinergic receptors initiates similar signaling pathways as the triptans and iii) in 
other systems, purinergic receptors have been shown to modulate neurotransmitter 
release. There are, in all, 19 purinergic receptors known today (18 in rodents), and there 








cellular responses [5]. Purinergic receptors are divided into two main groups: the adenine 
nucleoside receptors (A/P1 receptors) and the purine/pyrimidine nucleotide receptors 
(P2 receptors). Furthermore, the P2 receptors are divided into P2X receptors (P2X1-7), which 
are ligand-gated ion channels, and P2Y receptors (P2Y1,2,4,6,12-14), which are G protein coupled 
receptors [5]. The purinergic field is relatively new, which is exemplified by the presence 
of only one marketed drug that targets purinergic receptors, namely the anti-coagulant 
clopidogrel [6].
 Purinergic research in migraine has mainly been focusing on ATP and the role 
in neuronal sensitisation by acting on the low threshold ligand gated P2X3 receptor ion 
channel [7]. However, there is also data on the high ATP threshold P2X7 receptor in migraine 
models [8]. Focusing on the P2X3 receptor, increased expression in trigeminal ganglion (TG) 
neurons was observed in vitro after exposure to CGRP and in vivo following induction of 
trigeminal-associated pain [9, 10]. Activation of the P2X receptors might explain the painful 
sensation of ATP [11]. In contrast, the more modulatory P2Y receptors have been given little 
attention and to our knowledge only one in vitro study, investigating calcium signalling in 
primary neuron-glial trigeminal cultures, exists on the role of P2Y receptors [12]. 
 Activation of three purinergic receptors, the P2Y12, P2Y13 and P2Y14 receptors, leads 
to a decrease in intracellular cAMP [13], as these receptors are coupled to Gi proteins. This is 
similar to the activation of 5-HT1B/1D receptors, which are the pharmacological target of the 
triptans [14]. Activation of the 5-HT1B/1D receptors leads to vasoconstriction of the middle 
meningeal artery (MMA) and reduces the release of CGRP from peripheral C-fibers [15]. 
In contrast to the 5-HT1B/1D receptors, with an abundance of data available, there is limited 
evidence for the negative modulation of presynaptic transmission of sympathetic [16] and 
cholinergic nerves [17] following ADP-induced activation of the P2Y12 or P2Y13 receptors. It is 
not clear yet whether a similar action could exist for trigeminal nerves, which would have 
implications for the release of CGRP. We therefore embarked on a study with the aim to 
uncover purinergic targets in line with the neurovascular theory of migraine. 
 We hypothesized that P2Y receptors could play an important modulatory role in the 
pathophysiology of migraine and that P2X receptors might be important in the initiation of 
a migraine attack. Using the human MMA (hMMA), a potential direct target for antimigraine 
medication, as well as proxy for the trigeminal system, combined with intravital microscopy 
and CGRP release in rodents, we studied both a direct vasoactive effect, as well as a 
modulatory effect on CGRP release, by purinergic receptor stimulation in the trigeminal 
system.
Materials and Methods
All studies on animals were performed between 09:00 and 18:00, either on explanted organs 
or in the laboratory under anesthesia (see below).
Myograph studies in hMMA
Samples of dura mater were perioperatively obtained from 10 patients (two males and 
eight females; 48-69 years) undergoing neurosurgical procedures. Tissues were collected 
in a sterile organ-protecting solution and were immediately brought to the laboratory. 
Subsequently, hMMAs (internal diameter 0.5–1.5 mm) were dissected and used the same day 
or stored overnight in cold oxygenated Krebs solution of the following composition (mM): 
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119 NaCl, 4.7 KCl, 1.25 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3 and 11.1 glucose; pH 7.4. 
Study protocols were approved by the ethics committee at the Erasmus MC Rotterdam. 
 The hMMAs were cut into 1-2 mm long segments and mounted on stainless-steel 
wires (Ø 40 μm) in Mulvany myographs (Danish Myo Technology, Aarhus, Denmark) filled with 
carbogenated Krebs buffer solution at 37°C. The segments were stretched to their optimal 
lumen diameter (0.9 × L100), where L100 is an estimate of the diameter of the vessel 
under a passive transmural pressure of 100 mm Hg (13.3 kPa). Data were obtained through 
a Labchart data acquisition system (AD Instruments Ltd, Oxford, UK). hMMAs were exposed 
to 30 mM KCl, followed by 100 mM KCl to determine the reference contractile response. 
Using the indicated agonists, a cumulative concentration response curve (using half log-
steps unless otherwise indicated) was constructed. This cumulative approach might lead to 
an underestimation of the maximal contractions in case of desensitization, but in view of 
the scarcity of human tissue an alternative approach, using only one single concentration 
per vessel segment, is not feasible. The functional integrity of the endothelium was tested 
with substance P (10 nM) on arteries precontracted with the thromboxane A2 analogue 
U46619 (100 nM). The same precontraction was used to construct vasodilation curves.
Intravital microscopy on a closed cranial window in rats 
Twenty-seven normotensive male Sprague-Dawley rats (300-400 g), purchased from Harlan 
(Horst, The Netherlands), were maintained on a 12/12-h light-dark cycle (with light beginning 
at 7 a.m.) and housed at a constant temperature (22±2 °C) and humidity (50%), with food 
and water ad libitum. The animals were anaesthetized with sodium pentobarbital (60 mg⁄kg 
i.p., followed by 18 mg/kg i.v. per hour when necessary). The adequacy of anesthesia was 
judged by the absence of ocular reflexes and a negative tail flick test. The Institutional 
Ethics Committee approved all experimental protocols [Erasmus MC; permission protocol 
number EMC 1931 (118-09-04)]. 
 The protocol was identical to our previous studies [18]. Briefly, the left femoral 
vein and artery were cannulated for intravenous (i.v.) administration of drugs and continuous 
monitoring of blood pressure. Rats were placed in a stereotaxic frame and the skull was 
carefully drilled thin, until the MMA was visible. An intravital microscope (Leica MZ 16; Leica 
Microsystem Ltd, Heerbrugg, Switzerland), was used to record the artery diameter with 
a cyan filter on a cold source of light. A zoom lens (80 × magnification) and camera (DCx 
V3.52, Thorlabs LTD, Ely, UK) were used to capture the image of the dural artery, which was 
displayed and measured on a computer using a dedicated software package (IDA-Intravital 
Dimension Analyser; http://www.beneryx.co.uk) integrated with a ADC/DAC board (DI-158, 
DATAQ instruments, ‘s-Hertogenbosch, The Netherlands). For the periarterial electrical 
stimulation, a bipolar stimulating electrode (NE 200X, Clark Electromedical, Edenbridge, 
Kent, U.K.) was placed within 200 μm from the MMA. The cranial window surface was 
stimulated at 5 Hz, 1 ms for 10 s (Stimulator model S88, Grass Instruments, West Warwick, 
RI, U.S.A.). As we previously demonstrated, dural vasodilator responses are reproducible 
after repeated stimuli for at least for 4 times [18, 19]. Animals were randomized, and we 
allowed 30 min between stimulations/treatments for recovery to the baseline diameter.  
 MRS2211 (P2Y13 receptor antagonist) or ADPβS (ADP analogue, P2Y1/12/13 receptor 
agonist) was administered 15 min before periarterial electrical stimulation. The detection 
limit for arterial diameter was about 10 μm; in case an artery was not visible due to 




Twelve male Sprague-Dawley rats (300-400 g), purchased from Taconic (Ejby, Denmark) 
were maintained at a 12/12-h light-dark cycle (with dark beginning at 7 a.m.) and housed 
at a constant temperature (22±2°C) and humidity (50%), with food and water ad libitum. 
Rats were generally housed in Eurostandard cages (Type VI with 123-Lid) 2-6 together and 
single housed (Type III with 123-Lid) directly before undergoing the procedure.
 Rats were anaesthetized by CO2 inhalation and decapitated. All procedures were 
approved by the Danish Animal Experimentation Inspectorate. The protocol is described in 
detail elsewhere [19]. Shortly, the trigeminal nucleus caudalis (TNC) was excised from the 
brain stem, measuring approximately 6 mm in length. The skull was cut mid-sagittally and 
the brain halves were carefully removed while the cranial dura was left attached to the 
skull, and the trigeminal ganglion (TG) was dissected out. TGs and TNCs were immersed 
in 10 ml synthetic interstitial fluid (SIF, composition mM: 108 NaCl, 3.5 KCl, 3.5 MgSO4, 
26 NaHCO3, NaH2PO4, 1.5 CaCl2, 9.6 NaGluconate, 5.6 glucose and 7.6 sucrose; pH 7.4.) 
at 37°C for 30 min. Skull halves were transferred to a beaker containing SIF and washed 
2 times (each wash 15 minutes) in 250 ml SIF. 
 TGs and TNCs were randomized and placed in Eppendorf tubes in a heating block at 
37°C, they were washed again five times (each wash 10 minutes) with 300 μl SIF. Both skull 
halves were randomized and placed in a humid chamber above a water bath to maintain 
temperature at 37°C and washed five times (each wash 10 minutes) with 300 μl SIF. After 
10 min incubation with 300 μl SIF, 200 μl samples for measuring the basal CGRP release were 
collected from all the tissues, mixed with 50 μl enzyme immunoassay buffer (containing 
protease inhibitors) and stored at –20°C until analysis, within a week after the experiment 
was performed. Previous studies have shown that there is no significant difference between 
the basal CGRP release from the left and the right side of the tissues, thus, one side served 
as a control for the other, which has been shown to reduce the experimental and biological 
variations [19]. The release of CGRP from the skull halves, TG and TNC was induced by 
60 mM potassium. To maintain equal osmolarity, a proportional amount of Na+ was removed 
from the buffer. Experiments by others have shown that 10 min incubation is sufficient 
for a significant and reproducible release of CGRP over basal levels [19]. The tissues 
were pre- incubated for 20 minutes with different concentrations of inhibitors/vehicle 
and agonist⁄vehicle, and during the final KCl challenge the same concentrations were 
maintained. 
 The samples were processed using commercial EIA kits (SPIbio, Paris, France) to 
study CGRP release. From all tissues, 200 μl of sample was mixed with 50 μl of EIA buffer, 
which was also added to the CGRP standard. Determination of CGRP content was calculated 
based on this standard curve. Previous studies on the samples obtained from TNC showed 
that the amount of CGRP release was too high to fall in the linear range of the standard 
curve [19]. Therefore, TNC samples were diluted six times. Antibody in the CGRP EIA kit 
is directed against human-CGRP α/β, but it has 100% cross-reactivity with rat and mouse 
CGRP [19, 20]. The protocol was performed following the manufacturer’s instructions. 
Briefly, samples were incubated in at 4°C for 16–20 h, washed, and incubated with Ellman’s 
reagent. Following 60 min of incubation, the optical density was measured at 410 nm using 
a micro-plate photometer (Tecan, Infinite M200, software SW Magellan v.6.3, Männedorf, 
Switzerland). Samples (a total of two dura and one TNC) that did not generate any CGRP 







release in response to 60 mM potassium, and one TG with baseline over 100 pg/ml CGRP 
was not included in the analysis. Since data were paired, both the left and right side were 
excluded in the above cases.
Immunohistochemistry 
Human TGs were collected at autopsy, within 48 h post-mortem, from four patients 
(two males and two females; 68-82 years). The patients were without disorders related 
to the peripheral and central nervous system. The specimens were fixed after removal in 
2% paraformaldehyde (PFA) and 0.2% picric acid in 0.1 mol/L phosphate buffer, pH 7.2, tyrode 
solution. The tissue samples were kept at −80 °C until embedding and cryo-sectioning. 
The study followed the guidelines of the European Communities Council (86/609/ECC) in 
accordance with the Szeged University Medical School guidelines for ethics in human tissue 
experiments and was approved by the local Hungarian Ethics Committee. The hMMA was 
obtained from the same patients that were used for the myograph studies. Study protocols 
were approved by the ethics committee at the Erasmus MC, Rotterdam. 
 Human TGs and MMAs were cryosectioned. Details on immunohistochemistry 
are described elsewhere [21]. In short, slides with 10 μm sections were washed in PBS 
containing 2.5% Triton (PBS-T) for 15 min. Next, the primary antibody, rabbit anti-P2Y13 
receptor (Alomone, APR#017, 1:50), rabbit anti-P2X3 receptor (Alomone, APR#026, 1:200) 
or mouse anti-CGRP (Abcam Ab81887, 1:100) was added. Following incubation overnight 
in moisturized chambers (+8°C), cryosections were washed in PBS-T twice for 15 min and 
incubated for 1 hour with secondary antibodies (FITC anti-mouse, Jackson Immunoresearch 
1:200, and Cy3 anti-rabbit, Jackson Immunoresearch, 1:300) in the dark. After three 
washes for 15 min, the slides were mounted with Vectashield mounting medium containing 
DAPI (4′,6-diamidino-2-phenylindole, Vector Laboratories, Burlingame CA, USA). Negative 
controls were performed omitting the primary antibody. Immunofluorescence was observed 
using an epifluorescence microscope (Nikon 80i, Tokyo, Japan) combined with a Nikon 
DS-2MV camera. The images were then processed using Adobe Photoshop CS3 (v10.0 
Adobe 3 Systems, Mountain View, CA, USA). Potential co-localization was determined by 
superimposing the images taken with different wavelength filters.
Data presentation 
All quantitative data are presented as mean ± SEM. The n-number represents one rat or 
one human. The peak increases in dural meningeal artery diameter, as well as changes in 
mean arterial blood pressure (MAP, in vivo experiment) were expressed as percent change 
from baseline. The difference between two concentration response curves was determined 
by two-way ANOVA and the Bonferroni post-test. The difference between the variables 
within one group was compared by using a one-way repeated measures analysis of variance 
followed by Dunnet’s test. When only two variables were compared, a paired Student’s 
t-test was used.
Compounds 
The compounds used in this study were: sodium pentobarbital (Nembutal; Ceva Sante 
Animale B.V., Maassluis, The Netherlands); MRS2211, αβmetATP, olcegepant (Tocris); ADPβS, 
UDPβS, UTPγS, ATPγS (Biolog.de) and CGRP (NeoMPS S.A., Strasbourg, France). All other 
chemicals were from Sigma Chemicals Co. (Steinheim, Germany). All compounds were 
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dissolved in distilled water, with the exception of capsaicin and olcegepant, which were 
dissolved in DMSO. All solutions were further diluted in saline for in vivo studies or distilled 
water for in vitro studies.
Results
The MMA is an important component of the trigeminovascular system and may serve as a 
proxy for the neurovascular system and is therefore a good indicator of potential antimigraine 
therapies, also those acting primarily at neuronal components of the trigeminovascular 
system. We have previously fully characterized the contractility of the rat MMA (rMMA) to a 
number of purinergic agonists and therefore initially set out to compare these data to the 
hMMA.
In vitro relaxation of hMMA 
Since the hMMA has a much larger diameter than the rMMA it can therefore be mounted 
in myographs without damaging the endothelium, making it possible to investigate 
endothelium-dependent vasodilation. The presence of functional endothelium was checked 
with the addition of substance P (79±8% relaxation from 100 nM U46619) in the vessels 
used below. We investigated the main known purinergic vasodilators, UTPγS (P2Y2 and P2Y4 
receptor agonist), UDPβS (P2Y6 receptor agonist) and ADPβS (P2Y1, P2Y12, and P2Y13 receptor 
agonist). ADPβS (Figure 1(a), pEC50 6.82±0.28, Emax 72±10 %) had similar potency as UTPγS 
(Figure 1(b), pEC50 6.27±0.39, 84±9 %). UDPβS did not cause any vasodilation, but further 
contracted the artery by 45±21 % (Figure 1(c), pEC50 ~ 4).
In vitro contraction of hMMA 
For the contractile studies, we performed the experiment in endothelium-free hMMA, 
which was confirmed by a complete lack of dilation in response to substance P. Since the 
P2X receptors desensitize very fast, we constructed a two-log step concentration response 
curve to αβmetATP, an agonist at P2X receptors. αβmetATP was the most potent agonist 
(Figure 2(a), pEC50 6.40±0.20, Emax 117±11 %) on the hMMA, while ATPγS (Figure 2(b), 
pEC50 5.05±0.09, Emax 173± 47 %) was less potent than αβmetATP. For the pyrimidine receptors 
the most pronounced contraction was observed after activation of the P2Y2 receptor and 
P2Y4 receptor (Figure 2(c), UTPγS, pEC50 4.73±0.10, Emax 170±44 %). Since UTPγS and ATPγS 
had similar potency, this indicates that most of the effect is mediated by the P2Y2 receptors. 
A specific agonist for the P2Y6 receptor caused minor contraction (Figure2(d), UDPβS, 
pEC50 5.48±0.41, Emax 36±14%). 
 All of the above receptors have previously been investigated in human coronary 
and cerebral arteries where they induced contraction [22, 23], similar as for the triptans. 
Therefore, they are not preferable targets for antimigraine agonists. In contrast, ADPβS, 
an agonist for the P2Y1 receptor, P2Y12 receptor and P2Y13 receptor, has been shown to be 
devoid of contractile properties in human coronary and cerebral arteries [22, 23]. In contrast 
to the arteries above, in the hMMA, ADPβS caused a minor contraction (Figure 2(e), 
pEC50 5.99±0.20, Emax 19±4%). Due to the relatively low EC50 value, corresponding better to 
the P2Y12 receptor or P2Y13 receptor than the P2Y1 receptor, we applied a P2Y13 receptor 
antagonist (MRS2211, 10 μM) under two different conditions. First, in a pure contractile 
experiment, where MRS2211 prevented contraction from baseline (Figure 2(e)). 







Secondly, we added ADPβS with/without MRS2211 on arteries that were precontracted with 
30 mM KCl and had subsequently been relaxed with CGRP (Figure 2(f)). The results show that 
ADPβS agonism can revert the CGRP-induced relaxation by binding to the P2Y13 receptor, 
similar to what has been observed with sumatriptan [24].
Figure 1. Purinergic-induced relaxations of human middle meningeal (hMMA) artery with endothelium. 
Concentration-dependent relaxation induced by UTPγS (a), ADPβS (b), and UDPβS (c) on hMMAs 
precontracted with 100 nM U46619. The precontraction is set to be 100% above the baseline. Data are 
shown as mean ± SEM, n=5.
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Figure 2. Purinergic-induced contractions of human middle meningeal artery (hMMA) without 
endothelium. Concentration-dependent contraction induced by αβmetATP (a), ATPγS (b), UTPγS (c), 
UDPβS (d) and ADPβS (e) on hMMAs. f) Arteries were precontracted with 30 mM KCl, and relaxed with 
CGRP, followed by a concentration response curve to ADPβS. MRS2211, a specific antagonist against 
the P2Y13 receptor (10μM), was applied 30 min before performing the concentration response curve. 
Data are shown as mean ± SEM, n=5. (*p<0.05, **p<0.01, ***p<0.001; two-way ANOVA with Bonferroni 
post-test).







Effects on in vivo/in situ CGRP release in rat
Intravital microscopy – involvement of the P2Y13 receptor 
Our in vitro data show that P2Y13 receptor stimulation induces contraction in the hMMA. 
To confirm that a P2Y13 receptor agonist also can have effects in vivo, we continued with 
intravital microscopy in rats, a common method to assess the antimigraine potential of a 
compound that is supposed to act on the trigeminovascular system.
 Upon intravenous injection of ADPβS (330 μg/kg), we observed a transient decrease 
in blood pressure (Figure 3(a), 65±3%), which most likely was caused by stimulation of 
endothelial P2Y1 receptors followed by desensitization [25]. Subsequently, a long-lasting 
increase in blood pressure was observed (Figure 3(a), 23±4%), which, in contrast to the 
vasodilation, was dependent on the P2Y13 receptor, since the increase was only 7±4% in 
the presence of MRS2211 (1 mg/kg). MRS2211 did not have any significant effect the blood 
pressure per se. The direct effect of ADPβS on the artery was similar as observed for the 
blood pressure, with an acute dilation (56±21%) that returned to baseline. In contrast to the 
blood pressure, we did not observe any direct contraction following the ADPβS administration 
(data not shown).
 Using periarterial electrical stimulation (ES), which releases CGRP [19, 26], the 
rMMA dilated (Figure 3(b), 69±11%), according to our expectations, and vehicle did not 
affect this vasodilation (74±10%). In contrast, ADPβS caused a significant inhibition of the 
dilation (Figure 3(b), 37±7%). Furthermore, MRS2211 (1 mg/kg), which had no significant 
effects per se (Figure 3(c)), prevented the inhibitory effect of ADPβS and normalized 
the ES-induced dilation (Figure 3(c), 62±7%). Blood pressure could be of importance in 
relation to interpreting the diameter increase during electrical stimulation. There were no 
significant absolute differences during the third ES after ADPβS (130±4 mmHg) compared to 
ADPβS + MRS2211 (123±5 mmHg).
CGRP release from dura and TG – involvement of the P2Y13 receptor
 
To dissect the potential site of the P2Y13 inhibitory actions, we measured CGRP release 
ex vivo after individual stimulation of the trigeminal fibers in the dura mater and in the 
TG isolated from rats. ADPβS significantly inhibited CGRP release from both the dura mater 
(Figure 4(a) left panels, 172±15 vs 265±21 pg/ml, p=0.0003) and from the TG (Figure 4(a) 
right panels, 162±13 vs 278±36 pg/ml, p=0.0141). MRS2211 (10 μM) was without inhibitory 
effect per se (Figure 4(b)), but abolished the inhibitory response of ADPβS, illustrating that 
this is a P2Y13-dependent process (Figure 4(c)). Although not within the focus of the current 
study, ADPβS also inhibited CGRP release from the TNC (data not shown)
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Figure 3. In vivo effects of ADPβS on CGRP-induced dilation of the rat middle meningeal artery (rMMA). 
(a) Acute recordings of blood pressure upon infusion of 330 μg/kg ADPβS. The i.v. infusion of ADPβS 
caused a fast and short-lasting drop in the blood pressure followed by an increase that was prevented 
by the presence of 1 mg/kg of the specific P2Y13 receptor inhibitor MRS2211. (b) Inhibition of CGRP-
induced vasodilation of the rMMA by 330 μg/kg ADPβS. (c) In the presence of 1 mg/kg MRS2211, ADPβS 
does not cause inhibition of periarterial electrically-stimulated CGRP release and rMMA vasodilation. 
Data are shown as mean ± SEM, n=6. (*p<0.05, one-way ANOVA with Dunnett’s Multiple Comparison 
Test). ES: electrical stimulation.







Intravital microscopy – involvement of the P2X3 receptor
Previous research has shown that P2X3 receptors are co-expressed with CGRP in the 
trigeminal ganglion [9], and that P2X3 receptor-positive neurons innervate the dura 
mater [27]. Since purinergic research has been mainly focused on the P2X receptors, we 
continued to investigate the effect of the P2X receptor agonist αβmetATP on the rMMA 
in vivo, exemplified in a raw trace (Figure 5(a)). αβmetATP (150 μg/kg) caused a strong 
constriction of the rMMA (Figure 5(b), -70±7%), followed by a recovery dilation (Figure 5(b), 
54±10%). This dilation was completely prevented by the addition of the CGRP antagonist 
olcegepant (Figure 5(b), 1±4%, 100 μg/kg). Furthermore, olcegepant, as expected, prevented 
dilation both in response to capsaicin (10 μg/kg) and exogenous CGRP (1 μg/kg), but not 
to substance P (1 μg/kg). For the blood pressure data, we observed a similar response, 
with an initial increase in blood pressure (Figure 5(c), 34±7%), followed by a reduction of 
23±7% (Figure 5(c)). In contrast to the data from the rMMA, the drop in blood pressure was 
not inhibited by olcegepant. In addition, these data show that the response to exogenous 
CGRP on the rMMA is unaffected by the presence of ADPβS, unlike the endogenous release 
(Figure 3(b)).
 Since our data indicate that αβmetATP could trigger CGRP release, we hypothesized 
that ADPβS, via activation of the P2Y13 receptor, might be inhibitory also on the αβmetATP-
induced CGRP release. Surprisingly, we did not observe any significant inhibition on the 
maximum dilation (Figure 5(b), 35±13% vs 54±10%). However, there was a significant delay 
in the time to peak dilation, which is also visible in the illustrative raw-trace (Figure 5(a), 
216±27 sec vs. 147±8 sec, p=0.0307), illustrating the potential involvement of the 
P2Y13 receptor in αβmetATP-induced CGRP release.
CGRP release from dura mater and TG – involvement of the P2X3 receptor
The dilation observed after constriction of the rMMA could be caused by: i) CGRP release 
triggered at the synapse or ii) antidromic CGRP release triggered by P2X receptors in the 
TG. We therefore investigated the effect of αβmetATP on CGRP release in the dura mater 
and the TG. We observed that αβmetATP did not cause any CGRP release from the dura 
mater above baseline values (Figure 6 left panel, 31±5 vs 32±5 pg/ml), in contrast to when 
it was applied to the TG (Figure 6 right panel, 58±7 vs 102±15 pg/ml, p=0.0073).
Immunohistochemistry on human TG and hMMA: localization of P2Y13 receptor and 
P2X3 receptor, co-localization with CGRP
We have here presented strong functional evidence for the involvement of the P2Y13 receptor 
and P2X3 receptor in in vivo and in situ rat models. Similar experiments are not possible in 
humans, but we had access to human tissue. Although the samples were obtained post mortem 
and could have been subject to potential changes in protein expression, we investigated 
whether similar receptor components are present in the human trigeminovascular system. 
Although sparsely expressed, we did detect neurons expressing both the P2Y13 receptor 
and CGRP in the human trigeminal ganglion (Figure 7(a)). In contrast, the P2X3 receptor 
is strongly expressed together with CGRP (Figure 7(b)). In the hMMA, CGRP and the 
P2Y13 receptor co-localized, in what appear to be C-fiber nerve endings (Figure 8(a), white 
arrows), whereas the P2X3 receptor is sparsely, if at all, present in the hMMA (Figure 8(b)). 
In one of the samples of hMMA, we observed a meningeal nerve (Figure 8(c)). Here it is even 
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more evident that the P2Y13 receptor co-localizes with CGRP in the C-fibers, but this is not 
the case for the P2X3 receptor (white arrows).
Figure 4. In situ effects of ADPβS on CGRP release from the dura or trigeminal ganglion (TG).
(a) Addition of ADPβS or vehicle had no per se effect on CGRP release. The addition of 60 mM KCl CGRP 
release from both the dura (n=5) and the TG (n=6), which could be inhibited by the presence of 10 µM 
ADPβS. (b) Incubating with 10 µM of the specific P2Y13 receptor inhibitor MRS2211, had no effects 
per se (n=5). (c) 10 µM MRS2211 prevented the inhibition caused by ADPβS (n=4). Data are shown as 
mean ± SEM. (*p<0.05, **p<0.01, ***p<0.001; paired Student’s T-test)







Figure 5. In vivo effects of αβmetATP on the rat middle meningeal artery (rMMA). 
(a) Raw trace from single experiments showing the strong contraction induced by 150 μg/kg of 
αβmetATP and the following dilation in the presence of vehicle, Olcegepant (100 μg/kg) or ADPβS 
(330 μg/kg). (b) Inhibition of αβmetATP induced vasodilation of the rMMA by 100 μg/kg olcegepant. 
(c) Acute recordings of blood pressure upon infusion of 150 μg/kg αβmetATP. The i.v. infusion of 
αβmetATP caused a fast and short-lasting increase in the blood pressure followed by a short-lasting 
decrease that was unaffected by the presence of 100 μg/kg olcegepant or 330 μg/kg ADPβS. When the 
rMMA was not visible its diameter was set to be 10 μm. Data are shown as mean ± SEM, n=6. (*p<0.05, 
**p<0.01, repeated measures one-way ANOVA, with Dunnett’s Multiple Comparison Test).
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Figure 6. In situ effects of αβmetATP on CGRP release from the dura or trigeminal ganglion (TG). 
The addition of 5 μM αβmetATP caused a strong release of CGRP from the trigeminal ganglion but not 
from the dura. 60 mM KCl caused CGRP release from both the dura and the TG, which was reduced 
following the release induced by αβmetATP. Data are shown as mean ± SEM, n=5. (*p<0.05, **p<0.01; 
paired Student’s t-test).
Figure 7. Immunohistochemical co-localization of P2Y13 receptor and P2X3 receptor in the human 
trigeminal ganglion. (a) Representative expression of P2Y13 receptor (green) and CGRP (red) in the 
human trigeminal ganglion co-localizes in some cells (merged). (b) Representative expression of 
P2X3 receptor (green) and CGRP (red) in the human trigeminal ganglion co-localizes in several of the 
cells (merged). DAPI was used to stain the nuclei for the merged picture. Scale bar is 100 μM.







Figure 8. Immunohistochemical co-localization of P2Y13 receptor and P2X3 receptor in the human middle 
meningeal artery. (a) Representative expression of P2Y13 receptor (green) and CGRP (red) in the hMMA, 
co-localizes in nerve endings, see arrows (merged). (b) Representative expression of P2X3 receptor 
(green) and CGRP (red) in the hMMA did not co-localize at the nerve endings, see arrows (merged). 
(c) Insert of a nerve following the hMMA, further illustrates the co-localization of P2Y13 receptor (green) 
and CGRP (red), but not any co-localization of CGRP with the P2X3 receptor. DAPI was used to stain the 




Direct effects on the MMA 
Until CGRP receptor antagonists were developed, all acutely acting specific antimigraine 
drugs induced direct vasoconstriction. Although direct vasoconstriction of the MMA may 
not be an essential requirement in treating migraine [1], it still might play a relevant 
role [28]. In addition, the MMA may serve as a proxy of the trigeminal system, where 
potential antimigraine compounds can be tested. In the current study, we started with 
a characterization of purinergic receptors on the hMMA. The data show that purinergic 
receptors have important effects. Particularly, their activation on the endothelium may 
induce strong dilation (Figure 1), while their activation in smooth muscle cells may induce 
a strong contraction (Figure 2). Only the contractile responses can be compared to our 
previously obtained data in the rat, as there were no endothelial responses in the rMMA due 
to their limited diameter [29].
Vasoactive properties of purinergic ligands on the hMMA 
The P2X receptor agonist αβmetATP caused the most potent contraction in the hMMA 
(pEC50 6.40±0.20, Figure 2(a)). This is expected as the P2X1 receptor is known to mediate 
potent contractions in smooth muscle cells [30]. The main pyrimidine receptor in the hMMA 
is the P2Y2 receptor (Figure 1(b) and Figure 2(b)/(c)). When activated in the endothelium 
of the hMMA, it causes a strong vasodilation, with higher potency than in the human 
internal mammary artery [31]. The P2Y2 receptor is also the receptor that leads to the 
strongest contraction of the MMA, similar to human coronary and omental arteries [22, 23]. 
Activation of the P2Y6 receptor caused a pure contractile effect (Figure1(c) and Figure 2(d)). 
The Emax was not very high, which is similar to the human omental artery [22]. In human 
coronary arteries, there was no contraction to UDPβS [23], which contrasts to the cerebral 
arteries, where UDPβS is a strong constrictor [22]. ADPβS was a strong vasodilator 
(Figure 1(a)), which is typically attributed to the P2Y1 receptor [31]. The contraction to 
ADPβS in the hMMA was potent, but with a relatively low Emax (Figure 2(e)). In conclusion, 
the functional purinergic profile of the hMMA is most similar to human omental arteries 
and shares strong similarities to the coronary arteries. The profile in hMMA contrasts with 
that in human cerebral arteries, where the main difference is strong contractility to UDPβS 
(P2Y6 receptor agonist). Contractions to ADPβS are not described in any of other human 
arteries, making the hMMA unique.
Focus on the P2Y13 receptor in the hMMA 
We were further particularly interested in ADP and its stable analogue ADPβS, since it is known 
that this does not cause contraction in the human coronary or cerebral vasculature [22, 23]. 
The side-effect of coronary vasoconstriction is a current caveat of the current acutely 
acting antimigraine treatments such as the triptans [32]. The contractile response to ADPβS 
in hMMA is small but significant. Furthermore, the response to ADPβS on the hMMA seems 
to be mediated purely by the P2Y13 receptor, as it is blocked by its antagonist MRS2211 
(Figure 2(e)/(f)), at a concentration that should be devoid of effects on the P2Y1 and P2Y12 
receptors [33]. Although the contraction to ADPβS was minor, ADPβS and P2Y13 receptor 
activation could reverse the dilation caused by CGRP (Figure 2(f)). This has a strong link 









to antimigraine potential, and the data are very similar to what has been observed for the 
triptans [24].
Comparison between hMMA and rMMA 
In our previous study on rMMA, ADPβS caused a strong contraction compared to the current 
data on the hMMA. We did not explore the functional pharmacological identity of the ADPβS 
response in the rat study, but we detected a strong P2Y13 receptor signal in the rMMA by PCR, 
combined with some P2Y1 receptor expression, but no expression of the P2Y12 receptor [29]. 
Regarding the difference in contraction between rMMAs and hMMAs, it appears that in both 
human and rat, fast acting and short-lasting effects are mediated via ATP on P2X receptors. 
In humans, long-term effects of purines are effectuated by ATP on the P2Y2 receptor, in 
contrast to rats where ADP is acting on P2Y1 receptor [29]. For pyrimidines, UTP through 
P2Y2 receptor activation is important in humans, while the breakdown product UDP acts on 
the P2Y6 receptor in rodents. It therefore seems that the human artery is more sensitive 
to ATP. In conclusion, the purinergic contractions in hMMA is caused by ATP/UTP, in contrast 
to the rMMA, which contracts to their breakdown-products UDP/ADP. Nevertheless, in vivo, 
the response is most likely similar, as the breakdown of UTP/ATP into UDP/ADP is nearly 
instantaneous [34], exemplified by studies on P2Y2 receptor and P2Y6 receptor knock out 
mice [35] and functional data from rat meningeal arteries [36].
Trigeminovascular effects 
In the light of the recent advances in migraine research, investigating, the in vivo effects 
of potential antimigraine compounds on CGRP release is a highly relevant approach. 
We therefore used an established method to study the in vivo effects of ADPβS and αβmetATP, 
which activate P2Y13 and P2X3 receptors, respectively
Inhibitory effects of P2Y13 receptor agonism 
Our data show that ADPβS, through activation of the P2Y13 receptor, inhibits vasodilation 
caused by periarterial electrical stimulation (Figure 3(b)/(c)). Periarterial stimulation 
has been shown to cause in vivo release of CGRP [19, 26]. Therefore, our experiments 
are the first to show that P2Y receptors, coupled to Gi proteins, can have prejunctional 
inhibitory effects on CGRP release in vivo. Similar observations have been made on other 
prejunctional nerve endings, where P2Y13 receptor activation was demonstrated to inhibit 
noradrenaline release from sympathetic neurons [16] and cholinergic transmission on the 
neuromuscular junction [17]. Importantly, we also show the direct inhibitory effect of ADPβS 
on CGRP release from both the dura and the TG in situ (Figure 4(a)). ADPβS is activating 
the P2Y13 receptor, as the specific P2Y13 receptor inhibitor MRS2211 was without effects 
per se, but reversed the inhibitory effect of ADPβS (Figure 4(b)/(c)). This is similar to the 
experiments by Honey et al., where an adenosine A1 receptor antagonist (DPCPX) blocked 
the inhibitory effect of an adenosine A1 agonist (GR79236) on meningeal vasodilation, but 
had no effects per se [37]. Since inhibiting CGRP release (or CGRP signaling) is now believed 
to be the most important hallmark of all acute antimigraine treatments [1], our data clearly 
demonstrate the therapeutic potential of a specific P2Y13 receptor agonist.
  Purinergic receptors as pontential antimigraine targets
Trigeminal activation by P2X receptor activation 
αβmetATP injections caused an activation of the trigeminovascular system, starting with 
a strong, short-lasting contraction of the rMMA, followed by a relaxation (Figure 5(a)). 
The relaxation is mediated by CGRP, as demonstrated by the blockade induced by the 
CGRP receptor antagonist olcegepant (Figure 5(b)). This is highly similar to the experiment 
by McCulloch and colleagues that was performed over 30 years ago, who showed that 
trigeminal nerve lesion prevented the relaxation following a constriction of the meningeal 
artery [38]. Our data show that αβmetATP-induced activation of P2X receptors on the TG is 
the most likely mechanism of action, leading to CGRP release (Figure 6). Indeed, Yegutkin 
et al. showed that αβmetATP triggered trigeminal nerve fiber activity [36] and Eroli et al, 
has shown that αβmetATP evokes neuronal firing in trigeminal cultures [39]. Therefore, 
stimulation of P2X3 receptors using αβmetATP could be a model of trigeminal activation, 
particularly for antidromic CGRP release occurring at the MMA. This is supported by: i) the 
relative long time from stimulation until observable dilation (Figure 5(a)), as the signal 
to release CGRP might travel from the TG and ii) the ability of αβmetATP to trigger CGRP 
release only from the TG and not in the dura mater (Figure 6).
Expression in human TG and clinical relevance  
We investigated whether the purinergic receptors found to be important in the rat 
trigeminovascular system are also expressed in the human TG. The P2X3 receptor was 
strongly expressed in CGRPergic neurons (Figure 7(a)), similar to what has been shown 
before in rats [9]. There are also neurons that are positive for both the P2Y13 receptor 
and CGRP, although we only sporadically observed these (Figure 7(b)). In addition, we 
investigated the hMMA and its innervation. Here we found that, in contrast to the TG, the 
P2Y13 receptor is co-localized with CGRP (Figure 8(a)), in contrast to the P2X3 receptor 
(Figure 8(b)). Combined with the findings in the TG, these data match the functional data 
that we observed in the rat. Both the functional data and the immunohistochemistry indicate 
that P2X3 receptor activation and expression mainly occurs in the TG (Figures 5-8), and that 
P2Y13 receptor inhibition and expression can both exist in the TG (Figures 3/4 and 7) and 
on the nerve endings at the dura/MMA (Figures 3/4 and 8). Combined, the above findings 
suggest that there are similarities in the purinergic aspects of the trigeminovascular system 
between humans and rats.
 The clinical applications and potential antimigraine effects need to be further 
investigated; for this purpose, there is a particular need for the development of specific 
agonists. The main concern regarding the use of agonists based on ADP is their potential 
thrombotic activity. ADP activating P2Y1 or P2Y12 receptors is considered a relatively weak 
platelet aggregation agonist by itself (we did not observe any acute thrombotic events in the 
current experiments). Unfortunately, ADP still works as an amplifier of platelet aggregators 
such as thrombin [40], which is not compatible with treatment of patients. This potential 








In the current study, we performed a thorough investigation of the purinergic receptors in 
the hMMA and compared it to our previous data on the rMMA. Interestingly, the expression 
and regulation of contractile responses are mediated by different receptors in human and 
rat. P2Y2 receptors (activated by ATP/UTP) are mediating most of the G-protein coupled 
purinergic function in hMMA compared to a combined effect of the P2Y1 receptor (ADP) and 
P2Y6 receptor (UDP) in rMMA. 
 The P2Y13 receptor was important in counteracting the effects of CGRP on the 
hMMA and P2Y13 receptor activation also inhibited CGRP release, both in vivo and in situ. 
Therefore, the P2Y13 receptor could therefore be a novel antimigraine target, particularly 
when considering the intracellular pathway activated by this receptor in light of the migraine 
pathophysiology. Furthermore, activation of the P2X3 receptor caused specific CGRP release 
originating from the TG and a consequent olcegepant-sensitive dilation at the rMMA. 
Our findings contribute to further understanding of the pathophysiology of migraine. 
To investigate the full clinical potential of targeting the P2Y13 receptor, a pharmacologically 
specific agonist is clearly needed.
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Abstract
Familial hemiplegic migraine type 1 (FHM1) is a rare migraine subtype. Whereas transgenic 
knock-in mice with the human pathogenic FHM1 R192Q missense mutation in the Cacna1a 
gene reveal overall neuronal hyperexcitability, the effects on the trigeminovascular system 
and calcitonin gene-related peptide (CGRP) receptor are largely unknown. This gains 
relevance as blockade of CGRP and its receptor are therapeutic targets under development. 
Hence, we set out to test these effects in FHM1 mice. We characterized the trigeminovascular 
system of wild-type and FHM1 mice through: (i) in vivo capsaicin- and CGRP-induced dural 
vasodilation in a closed cranial window; (ii) ex vivo KCl induced CGRP release from isolated 
dura mater, trigeminal ganglion and trigeminal nucleus caudalis; and (iii) peripheral vascular 
function in vitro. In mutant mice, dural vasodilatory responses were significantly decreased 
compared to controls. The ex vivo release of CGRP was not different in the components 
of the trigeminovascular system between genotypes, however, sumatriptan diminished 
the release in the trigeminal ganglion, trigeminal nucleus caudalis and dura mater but 
only in wild-type mice. Peripheral vascular function was similar between genotypes. These 
data suggest that the R192Q mutation might be associated with trigeminovascular CGRP 
receptor desensitization. Novel antimigraine drugs should be able to revert this complex 
phenomenon. 
Background
Migraine is a disabling neurovascular brain disorder that is characterized by severe attacks 
of throbbing headache, which can be accompanied by nausea, vomiting, osmo-, photo- and 
phonophobia [1]. In one-third of patients, attacks may be preceded by neurological symptoms 
(migraine with aura), the likely consequence of a wave of neuronal and glial depolarization 
with subsequent temporary inactivity, called cortical spreading depression [2]. Migraine 
headache is associated with activation of the trigeminovascular system and calcitonin gene-
related peptide (CGRP) release from sensory nerves [3]. Monogenic familial hemiplegic 
migraine, a rare subtype of migraine with transient hemiparesis during the aura, has shown 
validity as a genetic model of migraine [4]. Familial hemiplegic migraine type 1 (FHM1) is 
caused by specific missense mutations in the CACNA1A gene that encodes the α1A subunit of 
neuronal voltage-gated CaV2.1 (P/Q-type) calcium channels [5, 6]. 
 A transgenic knock-in mouse model was generated by introducing the human 
FHM1 R192Q mutation into the mouse Cacna1a gene using a gene targeting approach [7]. 
The mutation results in a gain of CaV2.1 channel function with enhanced cortical 
glutamatergic neurotransmission [8], an increased susceptibility to cortical spreading 
depression [7, 9], and signs of spontaneous unilateral head pain, as evidenced by increased 
head grooming and eye blinking [10]. Few studies have investigated CGRP expression and 
function in the trigeminovascular system of FHM1 R192Q mice, however, the results are 
inconsistent and mostly only the trigeminal ganglion was investigated [11-13], making it 
difficult to understand the exact role of this mutation in the different components of the 
trigeminal system. Furthermore, the effect the R192Q mutation may have on perivascular 
CGRP release and CGRP-induced (dural artery) vasodilation has not been investigated. Also, 
it is not known whether the R192Q mutation could affect the peripheral vascular function. 
 Hence, to study the effects of the R192Q mutation on the trigeminovascular system, 








by endogenous and exogenous CGRP in vivo, (ii) CGRP release in the trigeminovascular 
components including the trigeminal nucleus caudalis, trigeminal ganglion and dura mater 
ex vivo, and (iii) peripheral vascular CGRP receptor function in vitro. We hypothesized 
that the R192Q mutation will increase dural vasodilation and CGRP release in the 
trigeminovascular system but will not disturb peripheral vascular function.
Material and Methods
Experimental animals
Experiments were performed in 13- to 14-week-old homozygous FHM1 R192Q mice (“R192Q”) 
and wild-type littermates (“wild-type”) of both sexes. Mice were backcrossed for at least 
five generations with C57BL/6J mice so that the genetic background is >97% C57BL/6J, 
as described before [7]. All mice were bred at the Leiden University Medical Center and 
transported to our animal facility at least 14 days before the start of the experiment to 
allow for sufficient equilibration time at the Erasmus MC. Animals were housed under 
a 12-hr dark-light cycle and given free access to food and water. All experiments were 
approved by the Erasmus University Medical Center’s institutional animal ethics committee 
and in accordance with the European directive 2010/63/EU and ARRIVE (Animal Research: 
Reporting In Vivo Experiments) reporting guidelines for the care and use of laboratory 
animals.
In vivo: Intravital microscopy and dural artery vasodilation
Animals (n=32; 13 wild-type and 19 R192Q) were anaesthetized throughout the experiment 
using intraperitoneal (i.p.) sodium pentobarbital (80 mg/kg, i.p. and then 20 mg/kg/h, 
i.p.). The trachea was cannulated and connected to a pressure ventilator (small animal 
ventilator SAR-830 series; CWE, Inc., Ardmore, PA, USA). The jugular vein was cannulated 
for intravenous (i.v.) administration of drugs and the femoral artery for continuous 
monitoring of mean arterial pressure. During the experiment, the core temperature of the 
animal was monitored via a rectal thermometer and maintained between 36.5 and 37.5°C 
using a homeothermic blanket system for rodents (Harvard Instruments, Edenbridge, UK). 
Subsequently, the mouse was placed in a stereotaxic frame, and the parietal bone was 
drilled thin until the dural artery was clearly visible. As the mouse skull is very thin, care 
was taken to drill with constant application of ice-cold saline. In four out of 32 mice, 
bleeding was observed underneath the skull, making visualization of the artery difficult; 
these animals were excluded from the study. The drilled area was covered with mineral oil 
to prevent drying of the skull and to facilitate visualization of the artery. The dural artery 
was captured with an intravital microscope (Leica MZ 16; Leica Microsystem Ltd, Heerbrugg, 
Switzerland), using a cyan filter on a cold source of light. A zoom lens (80x magnification) 
and camera (DCx V3.52, Thorlabs LTD, Ely, UK) were used to capture the image of the 
dural artery, which was displayed and measured on a computer using a dedicated software 
package (IDA-Intravital Dimension Analyser; http://www.beneryx.co.uk) integrated with a 
ADC/DAC board (DI-158, DATAQ instruments, ‘s-Hertogenbosch, The Netherlands). Data of 
dural artery diameter, mean arterial pressure and exhaled CO2 were recorded using Labchart 
data acquisition system (AD Instruments Ltd, Oxford, UK).
 As described in a previous study [14], mice dural arteries were first constricted 
with endothelin-1 (ET-1) before other pharmacological interventions, as it is not possible 
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to observe significant vasodilation in mouse dural arteries without artery preconstriction. 
ET-1 (1-6 µg/kg i.v.) was titrated to induce vasoconstriction, reducing the diameter to 30-40% 
of its original diameter. Capsaicin (30 µg/kg) and α-CGRP (10 µg/kg) were administrated i.v. 
as a bolus after the constriction induced by ET-1 was stable (around 5 minutes). The arterial 
diameter was recorded for another 10 minutes. 30 min were allowed to elapse after each of 
the treatments for the recovery of baseline diameter.
Ex vivo: CGRP release in trigeminal nucleus caudalis, trigeminal ganglion, and dura 
mater 
Mice were anesthetized using sodium pentobarbital (80 mg/kg, i.p.) and decapitated at the 
atlanto-occipital joint. The skin and galea aponeurotica were retracted from the skull, which 
was divided into halves by a clear cut along the sagittal suture. The brain halves, together 
with the brainstem, were carefully removed while the cranial dura was left attached to the 
skull [15]. The trigeminal nucleus caudalis (Sp5C), which runs caudally from approximately 
9-13 mm from bregma, was isolated from the brainstem. The trigeminal ganglia were 
harvested by dissection 1 mm proximal and distal to the point where the mandibular nerve 
branches off and the dura mater around the trigeminal ganglion had been carefully removed 
[16]. All other tissues, except for the dura mater, were extracted from the skull without 
damaging the dura. The isolated trigeminal nucleus caudalis, trigeminal ganglion and the 
skull with the dura mater were immersed and washed in carbogenated synthetic interstitial 
fluid, containing (mM): NaCl (108), KCl (3.48), MgSO4 (3.5), NaHCO3 (26), NaH2PO4 (11.7), 
CaCl2 (1.5), sodium gluconate (9.6), glucose (5.55) and sucrose (7.6) for 30 minutes at 37°C. 
 Isolated trigeminal nucleus caudalis, trigeminal ganglion and dura mater were 
placed in a 24 well plate containing 500 μL synthetic interstitial fluid. The 24-well plate was 
fixed in a water bath that formed a closed humid chamber of 37°C. To induce CGRP release, 
tissues were stimulated with 60 mM KCl, this concentration was chosen based on previous 
literature on CGRP release in rats and mice [17]. To test reproducibility, a second stimulation 
with 60 mM KCl was done after two wash steps of 10 minutes each. In the experiments 
with sumatriptan (30 μM), the agonist was applied 10 minutes prior to the challenge with 
60 mM KCl. For every sample, including basal, the solution was collected after 10 minutes 
incubation and mixed with aprotinin (500 KUI/mL; n=6-12). For the assessment of CGRP 
content, samples were stored at  80°C until processed with a commercial CGRP RIA kit 
according to the manual (Phoenix Pharmaceuticals, Burlingame, CA, USA). The assay has a 
detection level of ~0.1 pg/mL, if the CGRP content of a sample was below the detection 
limit, the value for that sample was set at 0.1 pg/mL.  
In vitro: Peripheral vascular function
Aortas and mesenteric arteries were dissected from the mice and placed in a carbogenated 
Krebs bicarbonate buffer solution containing (mM): NaCl (118), KCl (4.7), CaCl2 (2.5), 
MgSO4 (1.2), KH2PO4 (1.2), NaHCO3 (25) and glucose (8.3); pH 7.4. The arteries were cut 
in small segments of about 2-4 mm each, which were suspended in Mulvany myographs 
(ADinstruments, Danish Myograph Technology, Aarhus, Denmark) containing oxygenated 
Krebs bicarbonate solution at 37°C. After equilibration for at least 30 minutes, with two 
changes of solution at 15-minute intervals, blood vessel segments were subsequently 
stretched to a tension normalized to 90% of l100 [18]. Then, the vessels were exposed to 
30 mM KCl. The maximum contractile response to KCl was determined using 100 mM KCl. 
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After washout and stabilisation, concentration response curves to α-CGRP, acetylcholine, 
sodium nitroprusside and 5-hydroxytryptamine (5-HT) were constructed in a parallel 
design [19], U46619 (10-300 nM) was used to induce precontraction of the vessel segments, 
before constructing relaxation curves to acetylcholine, sodium nitroprusside and α-CGRP. 
After the concentration response curves to acetylcholine, a single concentration of sodium 
nitroprusside (0.1 mM) was administered.
Data analysis
Dural artery diameter was calculated from the area under the curve of the intensity 
measured and expressed in arbitrary units (AU). Vasodilation induced by capsaicin or α-CGRP 
was corrected for diameter change before induction of vasodilation to compare differences 
between wild-type and mutant mice. Changes in mean arterial pressure were expressed in 
mm Hg [20]. Paired and unpaired student t-tests and one-way ANOVA were conducted to 
compare changes in dural diameter and blood pressure after each experimental intervention, 
followed by the Bonferroni Multiple Comparisons post-test. 
 CGRP samples were measured in duplicate and total CGRP release was calculated 
as the average of the duplicates. CGRP release was expressed as relative stimulated CGRP 
release, which was calculated by the ratio of KCl-induced CGRP release and basal CGRP 
release [12]. Statistical differences of the relative CGRP release between genotypes were 
calculated using one-tailed Mann-Whitney test for unpaired observations and Friedmann 
test, followed by Dunns multiple comparison post hoc test. For the repeated stimulation 
with KCl and the sumatriptan experiments, a one-tailed Wilcoxon matched pairs test for 
non-parametric analysis of paired data was used.
 Vasorelaxant responses to α-CGRP, acetylcholine and sodium nitroprusside were 
expressed relative to the contraction induced by U46619 (10-100 nM). Contraction by 5-HT 
was expressed relative to the contraction induced by KCl (100 mM). For each agonist, the 
maximal effect (Emax) was calculated. The concentration response curves of the agonists 
were analyzed using nonlinear regression analysis, and the potency of the agonists was 
expressed as pEC50 (i.e., negative logarithm of the molar concentration of agonist inducing 
half maximum response) using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, 
CA, USA.). Statistical differences of the Emax and pEC50 were calculated using the unpaired 
student t-test [21]. While the experimenter was aware of the genotype of the animals 
during the experiment because of logistic reasons, all analyses were performed in a manner 
blinded to the genotype. All data are expressed as mean ± SEM. Statistical significance was 
accepted at p<0.05.
Compounds
The compounds used in the present study (obtained from the sources indicated) were: 
rat α-CGRP and ET-1 (NeoMPS S.A., Strasbourg, France), sumatriptan succinate, capsaicin, 
acetylcholine, sodium nitroprusside and 5-HT (Sigma Chemical Co., Steinheim, Germany). 
α-CGRP, ET-1, sumatriptan, acetylcholine, sodium nitroprusside and 5-HT were dissolved in 
water. Capsaicin (1 mg/mL) was dissolved in a mixture of Tween-80, ethanol 70% and water 
(1:1:8). All stock solutions were stored at -80°C until required. Just before use, the stock 
solutions were further diluted to appropriate concentrations in isotonic saline for injection 
and in water for application.
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There was no difference in body weight between the wild-type (22.4±1.0 g) and R192Q 
(24.6±1.2) mice included in our study (p=0.807). Also, in none of the experiments there 
was a difference between the results obtained in male and female animals. Therefore, the 
results from both sexes were pooled for further analysis.
In vivo: Effect on dural artery dilation induced by capsaicin and CGRP
Diameter changes induced by ET-1, capsaicin or CGRP are shown in Figure 1. 
Figure 1. Trigeminovascular dural artery vasodilation.
Diameter change (%) induced by endothelin-1 (ET-1), capsaicin or CGRP in wild-type (WT, white bars) 
and R192Q (grey bars) mice. ET-1 induced comparable dural vasoconstriction in all groups (upper left 
and right panels). Capsaicin induced significant dural vasodilation in both genotypes (upper left panel), 
while CGRP only induced dural vasodilation in the wild-type group (upper right panel). The vasodilation 
induced by capsaicin and CGRP, corrected for the ET-1 baseline, is significantly lower in the R192Q 
groups than in the wild-type groups (lower left and right panel). Data are expressed as mean ± SEM, 
n=9-16, *p<0.05 vs the corresponding dose to ET-1, #p<0.05 between genotypes.
Blood vessel baseline diameter before any pharmacological intervention was significantly 
higher in the wild type (721±48 AU; n=12) than mutant (560±53 AU; n=16, p<0.05) mice. 
Administration of ET-1 reduced the dural artery diameter in the capsaicin-treated group 
to 40±3% and 31±4% of its original diameter in wild-type and mutant mice, respectively. 
In the CGRP-treated group, ET-1 reduced the diameter to 37±6% of its original diameter 
in wild-type mice and to 34±9% of its original diameter in the mutant mice. There was no 
significant difference between the two genotypes in the dose of ET-1 required to reach this 


















Capsaicin induced significant (p<0.001) dural vasodilation in wild-type (88±4%) and mutant 
(53±6%) mice compared to the preconstriction. Capsaicin-induced vasodilation corrected for 
the diameter change before induction of vasodilation, was significantly lower in the mutant 
mice (22±4%; n=16) than in the wild-type (48±5%; n=11; p<0.001). 
 CGRP-induced dural vasodilation was significantly different compared to the 
preconstriction in wild-type (68±6%; n=11; p<0.01), showing a tendency for significance in 
mutant mice (46±9%; n=11; p=0.06). In accordance, CGRP-induced vasodilation corrected 
for the diameter change before induction of vasodilation, was also significantly lower in 
mutant mice (11±5%; n=11) than in the wild-type (31±7%; n=11; p<0.05). 
In vivo: Effect on mean arterial pressure of capsaicin and CGRP 
As shown in Figure 2, baseline mean arterial pressure was comparable between the two 
genotypes (wild-type: 80±3 mm Hg; n=10 vs R192Q: 72±4 mm Hg; n=14; p=0.11). 
Figure 2. Effect of pharmacological intervention on mean arterial pressure.
Mean arterial pressure (MAP; mm Hg) after administration of endothelin-1 (ET-1), capsaicin  or CGRP in 
wild type (white bars) and R192Q (grey bars) mice. ET-1 increased the MAP compared to the baseline in 
both genotypes, and this increase was reverted after administration of only CGRP. Data are expressed 
as mean ± SEM, n=9-14, *p<0.05.
ET-1 increased the mean arterial pressure similarly in both genotypes (wild-type: 
111±7 mm Hg; n=10 vs R192Q: 107±6 mm Hg; n=14; p<0.001 vs baselines). Capsaicin did 
not reverse the elevated blood pressure caused by ET-1 in either genotype (wild-type: 
100±7 mm Hg; n=10 vs R192Q: 102±5 mm Hg; n=14). Administration of CGRP caused a 
normalization of the elevated blood pressure in both genotypes (wild-type: 80±5 mm Hg; 
n=9, vs R192Q: 89±5 mm Hg; n=10; p<0.001 vs baselines). Mean arterial pressure changes 
induced by ET-1, capsaicin or CGRP were not different between wild-type and mutant mice.
Ex vivo: Relative stimulated CGRP release after KCl stimulation
Basal CGRP release (in absolute values) in trigeminal caudal nucleus (wild-type: 4.9±1.0; 
n=11 vs R192Q: 6.2±1.3 n=12; p=0.203), trigeminal ganglion (wild-type: 1.3±0.3; n=11 vs 
R192Q: 1.3±0.2 n=12; p=0.367) and dura mater (wild-type: 0.9±0.6; n=12 vs R192Q: 1.0±0.2 
n=12; p=0.321) was not different between wild-type and mutant mice. Relative stimulated 
CGRP release (measured as the ratio of KCl-induced CGRP release and CGRP release at 
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basal) was used to compare the effect of KCl in the different trigeminal components of 
wild-type and mutant mice (Figure 3). 
Figure 3. CGRP release in the trigeminovascular system.
Relative stimulated CGRP release in the trigeminal nucleus caudalis (TNC), trigeminal ganglion (TG) and 
dura mater of wild-type (WT, white bars and circles) and R192Q (grey bars and squares) mice. There is 
no statistical difference in CGRP release between wild-type and R192Q mice in the trigeminal nucleus 
caudalis, trigeminal ganglion or dura mater. Data are expressed as mean ± SEM, n=11-12. 
Relative stimulated CGRP release induced by KCl was comparable between wild-type and 
mutant mice in the trigeminal nucleus caudalis (wild-type: 3.6±0.5; n=12 vs R192Q: 4.1±0.8; 
n=11; p=0.415), trigeminal ganglion (wild-type: 3.6±0.8; n=12 vs R192Q: 3.4±0.9; n=12; 
p=0.375), and dura mater (wild-type: 9.0±2.7; n=12 vs R192Q: 5.6±1.3; n=12; p=0.425). 
Moreover, there was no difference in relative stimulated CGRP release between the different 
trigeminovascular components of wild-type and mutant mice. 
Ex vivo: Relative stimulated CGRP release after repeated stimulation with KCl 
CGRP release was measured after the first and second stimulation with KCl to test the 
reproducibility of CGRP release. The relative stimulated CGRP release of wild-type mice 
was similar for the first and second stimulation for trigeminal nucleus caudalis (1st: 3.7±0.8 
vs 2nd: 1.8±0.3; n=6; p=0.156), trigeminal ganglion (1st: 3.9±1.7 vs 2nd: 3.0±1.2; n=6; 
p=0.281) and dura mater (1st: 2.4±0.7 vs 2nd: 2.2±1.5; n=6; p=0. 281) (Figure 4, top panel). 
 Also for the mutant mice, no statistical differences were observed between the 
first and second stimulation for trigeminal nucleus caudalis (1st: 4.3±1.1 vs 2nd: 3.8±2.2; 
n=6; p=0.406), trigeminal ganglion (1st: 3.7±1.6 vs 2nd: 6.3±3.2; n=6; p=0.422) and dura 
mater (1st: 3.6±0.8 vs 2nd: 6.4±2.6; n=6; p=0.156) (Figure 4, top panel), although there 
was a trend for increased release in trigeminal ganglion and dura mater, with means 77% 







































































































































































Figure 4. Effect of repeated stimulation and sumatriptan on CGRP release.
Relative stimulated CGRP release after a first (1st) and second (2nd) stimulation with KCl (panels a, b, c) 
or in the absence (-) or presence (+) of sumatriptan (panels d, e, f) in trigeminal nucleus caudalis (TNC), 
trigeminal ganglion (TG) and dura mater of wild-type (WT, circles) and R192Q (squares) mice. There 
were no statistically significant differences between the first and second stimulation with KCl in either 
genotype. Sumatriptan significantly reduced the relative stimulated CGRP release in the trigeminal 
nucleus caudalis, dura mater and trigeminal ganglion of wild-type, but not in all the trigeminovascular 
components of the R192Q mice tested. Data are expressed as mean ± SEM, n=5-6, *p<0.05 vs. response 
in the absence of sumatriptan.
Ex vivo: Relative stimulated CGRP release in the absence and presence of sumatriptan 
The effect of pretreatment with sumatriptan (30 µM) on CGRP release in the trigeminovascular 
components is shown in Figure 4 (lower panel). In the presence of sumatriptan, relative 
stimulated CGRP release in wild-type mice was significantly attenuated in trigeminal nucleus 
caudalis (4.7±1.1 vs 2.6±1.0; n=6; p<0.05), dura mater (2.4±0.4 vs 0.8±0.1; n=5 p<0.05) and 
in the trigeminal ganglion (3.7±1.1 vs 1.6±0.3; n=6; p<0.05). However, in mutant mice, 
sumatriptan did not significantly reduce the relative stimulated CGRP release in trigeminal 
nucleus caudalis (5.3±1.3 vs 3.4±1.0; n=6; p=0.078), trigeminal ganglion (1.8±0.2 vs 7.0±3.0; 
n=6; p=0.078) or dura mater (4.8±2.2 vs 5.6±3.2; n=6; p=0.422), although, in contrast to our 
hypothesis there was a trend for increased release in trigeminal ganglion and dura mater, 
with means 390%  and 16% higher, whereas sumatriptan lowered release for the other tissues 
in wild-type or mutant. 
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In vitro: Peripheral vascular function in aortas and mesenteric arteries
In the aortas, KCl-induced contraction was not different between both genotypes (wild-type: 
8.3±0.4 mN; n=12 vs R192Q: 7.9±0.5 mN; n=11; p=0.560), while in mesenteric arteries the 
KCl-induced contraction was significantly lower in mutant mice (wild-type: 5.7±0.8 mN; 
n=9 vs R192Q: 3.4±0.3 mN; n=13; p<0.01). There were no significant differences between 
full concentration response curves to CGRP, sodium nitroprusside or acetylcholine in 
aortas or mesenteric arteries of both genotypes (Figure 5). To determine the endothelial 
function, the maximal effect of acetylcholine was corrected for the maximal effect 
induced by sodium nitroprusside (0.1 mM) in the same vessel segment. No differences were 
found in the acetylcholine/sodium nitroprusside ratio between genotypes in the aortas 
(wild-type: 0.76±0.05; n=11 vs R192Q: 0.77±0.03; n=10; p=0.812) or in the mesenteric 
arteries (wild-type: 0.73±0.10; n=6 vs R192Q: 0.77±0.06; n=9; p=0.714). 5-HT induced a 
concentration-dependent contraction, which was not different in aortas of both genotypes. 
In mesenteric arteries, the maximal effect induced by 5-HT seemed to be lower in wild-type 
than in mutant mice, but this was not statistically significant (p=0.13; Figure 5). 
Figure 5. Peripheral vascular function.
Concentration response curve to different agonists in isolated aortas and mesenteric arteries of wild-
type (WT, open circles) and R192Q (closed circles) mice. There were no differences between wild-type 
and R192Q mice in relaxant responses to acetylcholine (a, e), sodium nitroprusside (SNP, b, f) and CGRP 
(c, g), which are expressed relative to the contraction induced by U46619, in the aortas (a, b, c) and 
mesenteric arteries (e, f, g). Contractile responses to 5-hydroxytryptamine (5-HT, d, h), which are 
expressed relative to 100 mM KCl, in the aortas (d) and mesenteric arteries (h) were also not different 


















































































































   !




The mechanisms underlying migraine pathophysiology are not completely elucidated. 
It seems that migraine is a disorder of brain sensory processing, characterized by a 
generalized neuronal hyperexcitability [22], while the head pain is thought to be the 
consequence of activation of the trigeminovascular system, CGRP release and sensitization 
of trigeminal nociceptors. Transgenic mice harboring the FHM1 R192Q mutation revealed an 
overall hyperexcitability phenotype and increased susceptibility to CSD [4], but whether this 
mutation could affect the normal physiology of the trigeminovascular system is unknown. 
Therefore, the functionality of the trigeminovascular system was investigated in transgenic 
mice that express the FHM1 R192Q missense mutation in the α1A subunit of voltage-gated 
CaV2.1 calcium channels that leads to a gain of function of these channels by studying: 
(i) dural artery vasodilation induced by endogenous and exogenous CGRP in vivo, (ii) CGRP 
release in various components of the trigeminovascular system ex vivo, and (iii) peripheral 
vascular function in vitro.
 Several aspects of the CGRP-related trigeminovascular function were abnormal 
in the mutant mice. First of all, the trigeminovascular dural artery vasodilation in vivo, 
either by endogenous (induced by capsaicin) or exogenous CGRP, was reduced. A priori 
we expected an increased vasodilation in mutant mice. After all, as CaV2.1 channels are 
also expressed on perivascular nerve endings [23], given the gain of function of the R192Q 
mutation on CaV2.1 channels [7], activation of the channels would lead to release of CGRP, 
a potent vasodilator, and increased vasodilation [24].  
 One possible explanation for the reduced effects on dural vasodilation, is that CGRP 
release may already be elevated at basal in mutant mice, due to the increased activity of 
mutant CaV2.1 channels as proposed in previous studies [11, 25]. Therefore, administration 
or release of CGRP from an exogenous or endogenous source, may no longer exert an effect 
in response to a stimulus. However, more complex mechanisms seem to be involved, since 
we observed a lower baseline dural diameter in the mutant mice in our in vivo study; 
and no genotypic differences in CGRP release, at basal or after KCl stimulation, in the 
trigeminovascular components in our ex vivo study.
 On the other hand, hyperactivity of mutant CaV2.1 channels, could potentially lead 
to CGRP depletion – already at baseline – as may be concluded from an immunohistochemistry 
study that showed reduced CGRP immunoreactivity in the trigeminal ganglia and 
trigeminocervical complex of these mice [13]. However, our data do not seem to support 
CGRP depletion, since no statistical differences in basal CGRP release or CGRP release after 
repeated stimulation between the genotypes were observed. Still, a reduction in response, 
in their case for intracellular Ca2+ response, was observed after somatosensory stimulation 
when studying the same R192Q mouse model, which was ascribed to reduced neurovascular 
coupling [26]. 
 An alternative explanation for the in vivo reduced dural artery vasodilation 
response to capsaicin may be mediated by a change in CGRP receptor function or expression, 
since we also observed reduced dural vasodilation induced by exogenous CGRP in the 
mutant mice, which might suggest a desensitization or downregulation of this receptor. 
Receptor desensitization, as suggested before for CGRP-mediated ATP-gated P2X3 signaling 
in FHM1 R192Q mice [25] is more likely given that CGRP receptor expression on trigeminal 
ganglion neurons was shown to be similar between genotypes in culture and in situ [27]. 
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Hypothetically, the different in vivo effects on dural vasodilation between wild-type 
and mutant mice could have been due to changes in mean arterial pressure associated 
with the administration of drugs. However, this is unlikely as changes in blood pressure 
during intravenous injection of ET-1, capsaicin or CGRP, are below the level affecting dural 
vasodilation in this experimental model [28] and, more importantly, they were not different 
between wild-type and mutant mice. 
 When considering the present and previous studies on FHM1 R192Q mice, the 
basal release of CGRP and functionality of the CGRP receptor may change with age. It is 
noteworthy that in 11-day-old mutant mice there is an increased basal and KCl stimulated 
CGRP release from trigeminal ganglia [11]; in 2-week-old animals an increased basal CGRP 
release was identified [25]; whereas in 4-week-old mice an increased stimulated CGRP 
release but unaffected basal CGRP release was identified [12]. Remarkably, in the present 
study of 13- to 14-week-old mutant mice, which are young adult mice, neither an increase in 
basal nor in KCl-stimulated CGRP release in the components of the trigeminovascular system 
(including trigeminal ganglia) was observed, while in our in vivo experiments, CGRP-induced 
dural artery vasodilation was decreased. Moreover, a reduced CGRP expression was found 
in the trigeminal ganglion of 5  to 8 month old mutant mice in an immunohistochemistry 
study [13]. Therefore, it is tantalizing that the age of the mutant mice may be a determining 
factor that could reconcile the different findings of CGRP release in these studies. 
 An alternative explanation for the apparent discrepancy between our FHM1 R192Q 
mice data and the previously studies mentioned, where an increased CGRP release was 
observed in the trigeminal ganglion [12], may be the concentration of KCl employed in the 
different experiments. While Fioretti et al. [12] used 35 mM KCl to stimulate CGRP release, 
we used 60 mM KCl based on studies showing that this concentration activates calcium 
channels (including the CaV2.1 channels) [29]; and this induces a significant increase in 
CGRP release without reaching the maximal effect in the trigeminal ganglion, trigeminal 
nucleus caudalis and dura mater [17], which are essential characteristics for our study. 
However, we cannot exclude that using lower concentrations, a difference in sensitivity to 
KCl between wild-type and mutant mice might have been unmasked. 
 To assess systemic vascular CGRP receptor desensitization, we performed 
concentration response curves to CGRP in isolated aortas and mesenteric arteries, to 
understand the effect of the R192Q mutation on peripheral CGRP receptor function. 
Interestingly, no differences in the relaxant responses were found between genotypes, so 
it is unlikely that the R192Q mutation affects CGRP-induced vasodilation in these vessels. 
Though, if desensitization of CGRP receptors occurs due to a structurally elevated CGRP 
release (caused by the gain of function of the CaV2.1 calcium channel), it may only be 
occurring in dural arteries. Unfortunately, it is not possible to do functional studies with a 
Mulvany myograph, due to the small size of those vessels (outer diameter < 30 µm). 
 The general vascular function of the aortas and mesenteric arteries was also 
investigated by performing concentration response curves to acetylcholine, sodium 
nitroprusside, 5-HT and a single dose of KCl. Between genotypes, there were no differences 
in the acetylcholine and sodium nitroprusside responses, or the acetylcholine/sodium 
nitroprusside ratio, suggesting that the R192Q mutation does not influence peripheral nitric 
oxide (NO) endothelium-dependent and -independent pathways, which seems in line with a 
lack of effect on the baseline mean arterial pressure in vivo.
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 Instead, a decreased KCl-induced contraction in the mesenteric arteries of mutant 
mice was observed, which might suggest that the R192Q mutation (in the CaV2.1 calcium 
channel) indirectly influences other channels. This might also be the case with other voltage-
dependent calcium channels, disturbing the levels of cytoplasmic [Ca2+], the activation 
of the Ca2+-calmodulin-dependent myosin light chain (MLC) kinase, MLC phosphorylation, 
and overall contraction of the smooth muscle cells [30].The latter seems to be supported 
by findings, although not confirmed by other research groups, that the CaV2.1 calcium 
channel may be present in smooth muscle cells of murine aortas, rat renal vessels and 
rabbit renal afferent arterioles [31, 32]; and may contribute to contraction by regulating 
intracellular calcium concentrations [32].The fact that this effect was only observed in 
mesenteric arteries and not in aortas, suggests that the R192Q mutation in CaV2.1 channels 
might play a more prominent role in resistance arteries than in conductance arteries. This 
could be related to the channel expression levels in different vascular beds. Since the 5-HT 
induced contraction was related to the KCl response in vitro, the trend of increased 5-HT 
induced contraction observed in the mesenteric arteries of the R192Q mice, might rather 
be due to biological differences in the KCl responses, than differences in the function of the 
5-HT1B receptors, which is responsible for the 5-HT induced contraction [33]. 
 The ex vivo CGRP release experiments demonstrated in wild-type mice, that 
the presence of sumatriptan significantly reduced CGRP release upon stimulation in the 
trigeminal nucleus caudalis, dura mater and in the trigeminal ganglion. This seems in line 
with a finding that naratriptan and sumatriptan prevented the induction of sensitization in 
central trigeminovascular neurons, but not from peripheral terminals innervating the dura 
mater [34].However, there was also a trend of lower CGRP release in the trigeminal nucleus 
caudalis of wild-type mice after a second stimulation with KCl (Figure 4, top panel), which 
might suggest that the effect of sumatriptan observed is a result of lower release in response 
to the second stimulation, rather than inhibition of CGRP release by sumatriptan. This is 
unlikely since delta CGRP release in the sumatriptan experiments (CGRP release in the 
presence of sumatriptan – CGRP release in the absence of sumatriptan) were significantly 
different from the hypothetical value of zero (p=0.05); which was not the case for the delta 
CGRP release in the repeated experiments (CGRP release after second stimulation – CGRP 
release after first stimulation), indicating that the lower CGRP release in the trigeminal 
nucleus caudalis of wild-type mice in the sumatriptan experiments is indeed an effect of 
sumatriptan.  
 Notably, in the mutant mice, sumatriptan did not show a statistically 
significant change in CGRP release upon stimulation on the different components of the 
trigeminovascular system. This might be explained by the gain of function effect on the 
CaV2.1 calcium channels that influence the modulation properties of sumatriptan, since 
activation of the 5-HT1 receptor modulates calcium channels to control CGRP release [35]. 
Conclusion
In conclusion, our data do not support the a priori hypothesis that the FHM1 R192Q mutation 
increases dural artery vasodilation and CGRP release in the trigeminovascular system; 
instead, a decrease in dural vasodilation and no effect on CGRP release was observed, 
possibly involving trigeminovascular CGRP receptor desensitization. Thus, our data reinforce 
the findings of previous studies that the R192Q mutation does not only affect central aspects 
of migraine pathophysiology, but also the normal functioning of the trigeminovascular 
129






system. Moreover, the effects of the mutation on CGRP release in the trigeminovascular 
system may not just be an ‘on’ or ‘off’ phenomenon but rather of a modulatory nature, 
involving multiple mechanisms. Although it is still undefined whether the trigeminovascular 
effects of the R192Q mutation are the consequence of a direct neurovascular effect, a 
central neuronal dysfunction, or a combination of both; our results clearly indicate that the 
FHM1 R192Q mice display trigeminovascular abnormalities, underlining their relevance for 
migraine research. 
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Part IV. Summary, conclusions and future perspectives
Chapter 10
Summary, conclusions and future perspectives
Summary and conclusions
Migraine is a chronic neurovascular disorder characterized by recurrent severe attacks 
of throbbing headache, which can be accompanied by nausea, vomiting, photo- and 
phonophobia. It has been estimated that migraine affects about 15% of the adult population 
worldwide, furthermore, it is the second most prevalent neurological disorder and the 
first cause of disability in people aged under 50 years [1, 2]. While the exact mechanisms 
underlying the onset of a migraine attack remain unclear, it is now accepted that its headache 
phase results from activation and sensitization of trigeminal afferent fibers from meningeal 
nociceptors, neuropeptide release and dysfunctional nociceptive transmission [3, 4]. 
 Calcitonin gene-related peptide (CGRP) is a key neuropeptide, widely expressed in 
the peripheral and central trigeminovascular system, involved in craniofacial nociceptive 
modulation [5]. In migraine patients, infusion of CGRP triggers migraine-like headaches [6], 
and during spontaneous attacks this peptide is released in the extracerebral circulation [7]. 
The treatment of choice currently available for terminating migraine attacks are the triptans, 
5-HT1B/1D receptor agonists, some of which also display affinity for the 5-HT1F receptor [5]. 
These drugs have the ability to normalize elevated CGRP plasma levels by inhibiting further 
release from trigeminal afferents and consequently decreasing nociceptive transmission 
from the periphery to the central nervous system [7]. However, due to their coronary 
vasoconstrictor potential, they are contraindicated in migraine patients with cardiovascular 
disease.
 This concern has resulted in the development of new drugs devoid of vascular side 
effects, such as monoclonal antibodies targeting CGRP or its receptor. Moreover, these drugs 
have shown that migraine attacks can be prevented via exclusively peripheral blockade of 
CGRP. This thesis focused on the pharmacological modulation of the peripheral CGRPergic 
projections of the trigeminovascular system.
 Chapter 3 provides a comprehensive review about the current knowledge on the 
effects of triptans and CGRP-blocking molecules on the cranial vasculature. It summarizes 
not only classical concepts like extracerebral, intracerebral and extracranial vessel anatomy 
and the different imaging techniques to measure them, but also the possible site of action 
and mechanism(s) of novel antimigraine drugs being developed. 
 Chapter 4 describes in pithed rats the cardiovascular effects of the isometheptene 
enantiomers, (S)-isometheptene and (R)-isometheptene, and the pharmacological profile 
of the more potent (S)-enantiomer. We found that compared to (R)-isometheptene, 
(S)-isometheptene produced greater vasopressor responses, whilst both compounds 
equipotently increased heart rate. These different cardiovascular effects are probably due 
to differences in their mechanism of action, namely a mixed sympathomimetic action for 
(S)-isometheptene (a tyramine-like action and a direct stimulation of α1-adrenoceptors), 
and exclusively a tyramine-like action for (R)-isometheptene. In Chapter 5, we describe 
the contribution of each of the isometheptene enantiomers to its human vasoactive profile, 
moreover, rat neurogenic dural vasodilatation was used to explore their antimigraine site 
and mechanism of action. Our in vitro study revealed that the isometheptene enantiomers 
displayed a relatively safe peripheral vascular profile, as they failed to constrict the human 
coronary artery; further, these compounds do not appear to modulate neurogenic dural CGRP 
release in vivo. Thus, (R)-isometheptene may represent a superior therapeutic benefit as an 








 Chapter 6 investigates the involvement of adenosine A2A receptors as prejunctional 
modulators of the trigeminovascular system using the rat closed cranial window method. 
In regard to the dural meningeal vasodilation produced neurogenically, different adenosine 
A2A receptor antagonists with varying selectivity over adenosine A1 receptors did not 
affect neurogenic vasodilation. These purinergic receptors do not appear to modulate 
prejunctionally the sensory release of CGRP. In Chapter 7 we investigate the modulation of 
trigeminal CGRP release by additional (P2X and P2Y) purinergic receptors using the human 
middle meningeal artery as proxy for the trigeminal system, and intravital microscopy and 
CGRP release measurements in rodents. We showed that the purinergic P2Y13 receptor fulfills 
all the features of a potential antimigraine target. The P2Y13 receptor is expressed in both 
the human trigeminal ganglion and middle meningeal artery and activation of this receptor 
causes: i) middle meningeal artery contraction in vitro, ii) reduced dural artery dilation 
following periarterial electrical stimulation in vivo, and iii) a reduction of CGRP release 
from both the dura and the trigeminal ganglion in situ. Furthermore, we show that P2X3 
receptor activation of the trigeminal ganglion causes CGRP release and middle meningeal 
artery dilation. Both an agonist directed at the P2Y13 receptor and an antagonist of the P2X3 
receptor seem to be viable potential antimigraine therapies.
 In Chapter 8 we investigated the modulation of trigeminal CGRP release 
by lasmiditan, a highly selective 5-HT1F receptor agonist, and comparatively studied 
sumatriptan. CGRP release was similarly diminished by sumatriptan and lasmiditan 
in all the trigeminovascular system components (dura mater, trigeminal ganglion and 
trigeminal nucleus caudalis) ex vivo.  In vivo, lasmiditan or higher doses of sumatriptan 
significantly attenuated endogenous CGRP release, but not exogenous CGRP effects. These 
findings suggest that selective 5-HT1F receptor activation by lasmiditan is sufficient to 
prejunctionally inhibit CGRP release in peripheral and central trigeminal nerve terminals, 
and, consequently, attenuate nociceptive transmission in the trigeminovascular system. 
Since activation of 5-HT1F receptors is not associated with vasoconstriction, lasmiditan may 
represent a cardiovascular safety advantage over the current vasoactive triptans.
 Chapter 9 investigates whether transgenic knock-in mice with the human 
pathogenic familial hemiplegic migraine type 1 (FHM1) R192Q missense mutation have a 
dysfunctional trigeminovascular CGRPergic system. In mutant mice, in vivo capsaicin- and 
CGRP-induced dural vasodilation in a closed cranial window was significantly decreased 
compared to controls. The ex vivo release of CGRP was not different in the components 
of the trigeminovascular system between genotypes, however, sumatriptan diminished 
the release in the trigeminal ganglion, trigeminal nucleus caudalis and dura mater only in 
wild-type mice. Peripheral vascular function was similar between genotypes. These data 
suggest that the R192Q mutation might be associated with trigeminovascular CGRP receptor 
desensitization. Novel antimigraine drugs should be able to revert this complex phenomenon. 
Future perspectives
Although migraine pathophysiology has not been elucidated completely, since the last 
years several drugs that target the peripheral and/or central CGRPergic projections of 
the trigeminovascular system are becoming clinically available. Importantly, since acute 
CGRP administration triggers migraine-like attacks without crossing the blood-brain barrier 
and prophylactic therapeutic antibodies are unlikely to reach the brain, recent data argue 
strongly for a key role of peripheral CGRP in migraine pathophysiology [6]. However, there 
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have been patients that do not develop migraine-like attacks after CGRP administration 
or that do not respond to CGRP (receptor) blockade, which suggests that the pathogenesis 
of migraine involves additional mechanisms [8]. In addition to CGRP, a wide variety of 
neurotransmitters, neuromodulators and (hetero- and auto-) receptors are expressed in the 
peripheral and central projections of the trigeminovascular system, which could contribute 
to additional mechanisms of action of current (and prospective) antimigraine drugs [9, 10]. 
 As an imidazoline I1 receptor agonist, (R)-isometheptene should possess central 
antinociceptive properties, as previously shown for other imidazolines agonists [11]. This 
is supported by a preliminary study where high doses of (R)-isometheptene decreased 
trigeminal sensitivity in two rat models of chronic migraine, and this effect was associated 
with a reduced neuronal nitric oxide synthase and CGRP immunoreactivity in the trigeminal 
nucleus caudalis [12]. Moreover, imidazoline I1 receptor agonists potentiated oxycodone 
analgesia, a selective agonist of the µ-opioid receptor [13]. Therefore, further experiments 
are required to investigate whether (R)-isometheptene is capable of attenuating supraspinal 
nociceptive behaviors in different animal models (e.g. hot plate test) or whether this 
imidazoline I1 agonist can induce a synergistic antinociceptive effect with opioids. Ultimately, 
additional clinical studies with (R)-isometheptene will shed further light on the potential 
role of imidazoline receptors in the pathophysiology of migraine.
 In addition to the trigeminovascular CGRP release inhibition by lasmiditan, further 
(antimigraine) mechanisms of action described with previous 5-HT1F receptor agonists include 
modulation of glutamate release from trigeminal sensory fibers and enhanced mitochondrial 
biogenesis [14, 15]. The co-localization of 5-HT1F receptors with glutamate in the vestibular 
nuclei of rats, suggests that the 5-HT1F receptor might also modulate glutamate release in 
other CNS structures [16]. Moreover, since glutamate receptor antagonism prevents the 
induction of cortical spreading depressions (CSDs), a key pathogenic event in migraine with 
aura, 5-HT1F receptor agonism could attenuate CSDs via a central modulation (inhibition) 
of glutamate. Mitochondria are present at high concentrations in the presynaptic terminals 
of trigeminal meningeal nociceptors, suggesting a (dys)functional role of mitochondria in 
nociception; and several studies have suggested mitochondrial dysfunction in migraine 
patients [17]. Therefore, after taking into account these additional mechanisms, future 
experiments are needed to determine whether lasmiditan can: (i) inhibit glutamatergic 
neurons in the central nervous system, (ii) attenuate CSDs initiation and its associated 
hyperaemia or, (iii) enhance mitochondrial biogenesis; and if all or none of these mechanisms 
are associated with its clinical antimigraine efficacy. Furthermore, a randomized controlled 
clinical trial with a hydrophilic 5-HT1F receptor agonist, which does not enter the brain 
and could still be effective in migraine without CNS side effects, seems justified and would 
reinforce the relevance of the peripheral pathophysiological mechanisms of migraine. 
Finally, a clinical trial comparing the efficacy of lasmiditan with triptans (i.e. sumatriptan) 
in terminating migraine attacks, will reveal the therapeutic importance of activating a 
different subset of 5-HT1 receptors in migraine. 
 The antimigraine potential of the selective adenosine A2A receptor antagonists 
would be of particular relevance in those patients whose adenosine plasma levels are 
markedly increased during a migraine attack. Although our findings indicate that adenosine 
is not released after trigeminal activation (by perivascular electrical stimulation), inhibition 
of dural vasodilation is a shared mechanism of current (ergots and triptans) and prospective 




(antimigraine) mechanism alone is sufficient to attenuate the dysfunctional trigeminal 
nociceptive transmission associated with migraine headache remains to be determined. 
Obviously, further clinical studies are needed to evaluate the antimigraine potential of the 
JNJ adenosine receptor antagonists with the optimal doses based on their pharmacokinetic 
properties.
 Since our functional data and immunohistochemistry revealed that P2Y13 receptor 
expression and activation (inhibition of CGRP release) occurs in the trigeminal ganglion and 
on the nerve endings at the dura mater/middle meningeal artery, the clinical applications 
and potential anti-migraine effects need to be further investigated. For this purpose, there 
is a particular need for the development of specific agonists. The main concern regarding 
the use of agonists based on ADP is their potential thrombotic activity. ADP activating P2Y1 
or P2Y12 receptors is considered a relatively weak platelet aggregation agonist by itself. 
Unfortunately, ADP still works as an amplifier of platelet aggregators such as thrombin [18], 
which is not compatible with the treatment of patients. This potential side-effect should 
not be an issue for a selective P2Y13 receptor agonist.
 The generation of transgenic knock-in mice with the human pathogenic FHM1 
R192Q missense mutation in the Cacna1a gene affects the central aspects of migraine 
pathophysiology (overall neuronal hyperexcitability), but also results in peripheral CGRP-
trigeminovascular desensitization. In addition to these effects, our study suggests that this 
mutation alters the peripheral vascular function of resistance blood vessels (e.g. reduced 
KCl-induced contraction of the mesenteric artery), which could contribute to the generalized 
vascular dysfunction that has been associated with migraine [19]. Further experiments in 
these mice are needed to elucidate the effects of the FHM1 mutation on the peripheral 
CGRPergic fibers at the neurovascular junction and if this contributes to peripheral vascular 
dysfunction. This could clarify whether this is one of the mechanisms that leads to the 
increased cardiovascular risk of migraineurs.
 Migraine is three times more prevalent in women of reproductive age than in men 
and previous studies have provided insight into the effects of female sex hormones on the 
pathophysiology of migraine, suggesting that the reactivity of the trigeminovascular system 
in migraine patients, in response to varying levels of female hormones, differs from that in 
healthy women without migraine [20]. Moreover, a crosstalk between CGRP and hormonal 
fluctuations of the estrus cycle has previously been described [21]. Therefore, in the 
present thesis the pharmacological characterizations were limited to male rodents. Future 
experiments should test whether there are any differences in CGRP release between male 
and female rodents, and how ovarian steroid hormones fluctuation modifies these responses 
during the different stages of the estrous cycle. It has recently been shown that application 
of CGRP to the cranial meninges causes behavioral responses consistent with headache, only 
in female rodents [22], supporting a thorough pharmacological characterization in female 
rodents during the different stages of the estrous cycle.







Migraine is een chronische neurovasculaire aandoening die bij circa 15% van de wereldwijde 
populatie volwassenen voorkomt [1]. Het is de tweede meest voorkomende neurologische 
aandoening en de meest invaliderende aandoening bij mensen in de leeftijd onder de 50 
jaar [2]. Terwijl de  exacte onderliggende mechanismen die het begin van een migraineaanval 
veroorzaken nog steeds onbekend zijn, wordt nu algemeen geaccepteerd dat de 
hoofdpijnfase veroorzaakt wordt door de activatie en sensitisatie van trigeminale afferente 
vezels vanuit meningeale nociceptoren, neuropeptide afgifte en verstoorde nociceptieve 
transmissie [3, 4]. Calcitonin gene-related peptide (CGRP) is een belangrijk neuropeptide, 
dat veel tot expressie komt in zowel het perifere als centrale trigeminovasculaire systeemen 
dat tijdens een migraine aanval vrijkomt in de extracerebrale circulatie [5]. Bovendien is 
aangetoond dat door blokkade van CGRP of de receptor met monoclonale antilichamen 
migraine aanvallen voorkomen kunnen worden door een perifere remming van CGRP. In dit 
proefschrift ligt de focus op de farmacologische regulatie van de perifere CGRP projecties 
van het trigeminovasculaire systeem.
 Hoofdstuk 3 geeft een uitgebreid overzicht van de huidige kennis over de effecten 
van triptanen en CGRP-blokkerende moleculen op de craniële vasculatuur. Het bevat niet 
alleen een samenvatting van de klassieke concepten als de extracerebrale, intracerebrale 
en extracraniële vasculaire anatomie en de verschillende beeldvormingstechnieken om 
deze te meten, maar ook de mogelijke plaats van activiteit en mechanisme(n) van nieuwe 
antimigrainemiddelen die in ontwikkeling zijn. 
 Hoofdstuk 4 beschrijft de cardiovasculaire effecten van de isomethepteen 
enantiomeren, (S)-isomethepteen en (R)-isomethepteen in ratten onder anesthesie, 
en het farmacologisch profiel van het meest potente (S)-enantiomeer. Vergeleken met 
(R)-isomethepteen vonden we dat (S)-isomethepteen een grotere bloeddrukverhogende 
respons opleverde, terwijl beide stoffen in gelijke mate de hartslag verhoogden. Deze 
verschillende cardiovasculaire effecten worden waarschijnlijk veroorzaakt door verschillen 
in hun werkingsmechanismen, namelijk een gemengd sympathomimetische werking 
bij (S)-isomethepteen (een tyramine-achtige werking en een directe stimulatie van 
α1-adrenoceptoren), en een exclusief tyramine-achtige werking bij (R)-isomethepteen. 
In Hoofdstuk 5 beschrijven we bijdrage van elk van de isomethepteen enantiomeren aan 
het humane vasoactieve profiel. Daarnaast is het neurogene durale vasodilatatie rat model 
om hun antimigraine aangrijpingspunt en werkingsmechanisme te onderzoeken. Onze 
in vitro studie liet zien dat de isomethepteen enantiomeren een relatief veilig perifeer 
vasculair profiel vertoonden, aangezien zij geen vernauwing in de humane kransslagader 
veroorzaakten; bovendien lijken deze stoffen niet de durale afgifte van CGRP in vivo te 
reguleren. Samengevat lijkt (R)-isomethepteen het beste profiel te hebben als antimigraine 
middel, maar het locatie van het antimigraine effect en het centrale actiemechanisme 
dienen nog te worden vastgesteld. 
 Hoofdstuk 6 onderzoekt de betrokkenheid van adenosine A2A receptoren als 
prejunctionele modulatoren van het trigeminovasculaire systeem, waarbij gebruik gemaakt 
is van de ‘closed cranial window’ methode in ratten. Verschillende adenosine A2A receptor 
antagonisten met variërende selectiviteit over adenosine A1 receptoren hadden geen invloed 
op de neurogeen ge:induceerde dural meningeal vaatverwijding. Deze purinerge receptoren 




onderzochten we de regulatie van trigeminale CGRP afgifte door additionele (P2X and P2Y) 
purinerge receptoren, gebruik makend van de humane  a. meningea media als graadmeter 
voor het trigeminale systeem, en intravitalemicroscopie en metingen van de CGRP afgifte 
bij ratten en muizen. We toonden aan dat de purinerge P2Y13 receptor alle kenmerken 
bezit van een mogelijk antimigraine doelwit. De P2Y13 receptor komt zowel in het humane 
trigeminale ganglion als in de a. meningea media tot expressie en activatie van deze 
receptor veroorzaakt: i) in vitro vernauwing van de a. meningea media, ii) verminderde 
verwijding van de durale arterie na peri-arteriële electrische stimulatie in vivo, en iii) een 
verminderde afgifte van CGRP vanuit zowel de dura als het trigeminale ganglion in situ. 
Voorts toonden we aan dat activatie van de P2X3 receptor in het trigeminale ganglion CGRP 
afgifte en verwijding van de a. meningea mediaveroorzaakt. Zowel een agonist gericht op 
de P2Y13 receptor als een antagonist van de P2X3 receptor lijken geschikte kandidaten voor 
antimigraine behandelingen te zijn.
 In Hoofdstuk 8 onderzochten we de regulatie van trigeminale CGRP afgifte door 
lasmiditan, een zeer selectieve 5-HT1F receptor agonist, en bestudeerden deze in vergelijking 
met sumatriptan. Ex vivo was CGRP afgifte was verminderd op gelijke wijze door zowel 
sumatriptan als lasmiditan in alle componenten van het trigeminovasculaire systeem (dura 
mater, trigeminale ganglion en trigeminale nucleus caudalis). In vivo zorgden lasmiditan 
of hogere doses sumatriptan voor een significant verminderde endogene CGRP afgifte, 
maar werd de respons op exogeen CGRP niet beïnvloed. Deze bevindingen suggereren 
dat selectieve 5-HT1F receptor activatie door lasmiditan voldoende is om CGRP afgifte 
prejunctioneel te remmen in perifere en centrale trigeminale zenuwuiteinden, waardoor 
als gevolg hiervan de nociceptieve transmissie in het trigeminovasculaire systeem afzwakt. 
Aangezien de activatie van 5-HT1F receptoren niet betrokken is bij vasoconstrictie, heeft 
lasmiditan mogelijk een cardiovasculair veiligheidsvoordeel ten opzichte van de bestaande 
vasoactieve triptanen.
 Hoofdstuk 9 is onderzocht of transgene knock-in muizen met de humane 
pathogene familiaire hemipleigische migraine type 1 (FHM1) R192Q missense mutatie 
een verstoordefunctie van het trigeminovasculaire CGRP systeem hebben. In mutante 
muizen was in vivo capsaïcine- en CGRP-geïnduceerde durale vaatverwijding in een  het 
‘closed cranial window’significant verminderd in vergelijking met controle muizen. Er was 
geen verschil tussen genotypen wat betreftj ex vivo afgifte van CGRP in de verschillende 
componenten van het trigeminovasculaire systeem. Sumatriptan verminderde echter de 
afgifte in het trigeminale ganglion, de trigeminale nucleus caudalis en dura mater in alleen 
de wild-type, en niet de mutante muizen. Perifere vasculaire functie was in alle genotypes 
hetzelfde. Deze uitkomsten wijzen erop dat de R192Q mutatie wellicht betrokken is bij 
desensitisatie van de trigeminovasculaire CGRP receptor. Nieuwe antimigraine middelen 
zouden dit complexe fenomeen moeten kunnen herstellen.
Toekomstperspectief
Hoewel de pathofysiologie van migraine nog niet volledig is opgehelderd, zijn de laatste 
jaren verscheidene middelen op de markt gekomen die aangrijpen op perifere en/of 
centrale CGRP-projecties van het trigeminovasculaire systeem. Aangezien acute toediening 
van CGRP een migraine-achtige aanval oproept zonder de bloed-hersenbarrière te passeren 
en het onwaarschijnlijk is dat profylactische therapeutische antilichamen de hersenen 
bereiken, pleiten recente onderzoeksresultaten sterk voor een belangrijke rol van perifeer 






CGRP in migraine [6]. Er zijn echter patiënten die geen migraine aanval ontwikkelen na 
het toedienen van CGRP, of die niet reageren op de remming van CGRP (receptor), hetgeen 
er op wijst dat ook andere mechanismen dan CGRP betrokken zijn bij de pathogenese van 
migraine [7]. Naast CGRP komt een groot aantal neurotransmitters, neuromodulatoren 
en (hetero- en auto-) receptoren tot expressie in perifere en centrale projecties van het 
trigeminovasculaire systeem, die bij kunnen dragen aan aanvullende werkingsmechanismen 
voor huidige (en toekomstige) antimigraine middelen [8, 9]. 
 Als een imidazoline I1 receptor agonist zou (R)-isomethepteen centrale anti-
nociceptieve eigenschappen moeten bezitten, zoals eerder is aangetoond bij andere 
imidazoline agonisten [10]. Deze theorie wordt ondersteund door een voorstudie waarbij 
een hoge dosering van (R)-isometheptene de trigeminale gevoeligheid verminderde in twee 
rattenmodellen met chronische migraine, dit effect ging gepaard met een verminderde 
neuronale stikstof oxide synthase en CGRP immunoreactiviteit in de trigeminale nucleus 
caudalis [11]. Bovendien werken imidazoline I1 receptor agonisten versterkend op de 
analgesie geïndueerd door oxycodon, een selectieve agonist van de µ-opioïde receptor [12]. 
Om deze reden is nader onderzoek vereist om vast te stellen of (R)-isometheptene in staat 
is om supra-spinale nociceptieve gedragingen in verschillende diermodellen (bijvoorbeeld 
de hete plaattest) af te zwakken of dat de imidazoline I1 agonist een synergetisch anti-
nociceptief effect teweeg kan brengen met opioïden. 
 Naast de remming van trigeminovasculaire CGRP afgifte met lasmiditan worden 
andere (antimigraine) actiemechanismen beschreven met voorgenoemde 5-HT1F receptor 
agonist, waaronder modulatie van glutamaat afgifte vanuit de trigeminale sensorische vezels 
en verbeterde mitochondrische biogenese [13, 14]. De co-lokalisatie van 5-HT1F receptoren 
met glutamaat in de vestibulaire kernen van ratten suggereert dat de 5-HT1F receptor 
wellicht ook de glutamaat afgifte in andere structuren van het centrale zenuwstelsel 
reguleert [15]. Aangezien remming van de glutamaat receptor de opwekking van ‘cortical 
spreading depressions’ (CSDs),  een belangrijke pathogeen fenomeen bij migraine met aura, 
voorkomt, zou remming van de 5-HT1F receptor CSDs kunnen verminderen door middel van 
een centrale regulatie (remming) van glutamaat. Mitochondriën zijn in hoge concentraties 
aanwezig in de presynaptische uiteinden van trigeminale meningeale nociceptoren, hetgeen 
wijst op een (ont)regelende rol van mitochondriën in nociceptie; inderdaad bevatten 
verschillende onderzoeken aanwijzingen voor een verstoring in de mitochondriën bij 
migrainepatiënten [16]. Deze aanvullende mechanismen in beschouwing nemend is meer 
onderzoek nodig om vast te stellen of lasmiditan in staat is om: (i) glutamatergec neuronen 
in het centraal zenuwstelsel te remmen, (ii) beginnende CSDs en de daarmee gepaard gaande 
hyperemie te verminderen  of, (iii) mitochondriële biogenese te verbeteren; en of deze 
mechanismen samenhangen met hun klinische effectiviteit in het  tegengaan van migraine. 
Bovendien lijkt een gerandomiseerde gecontroleerde klinische studie met een hydrofiele 
5-HT1F receptor agonist, die niet de hersenen binnendringt en desondanks effectief kan zijn 
bij migraine zonder centrale bijwerkingen, gerechtvaardigd. Een dergelijke studie zou de 
inzichten in de relevantie van de perifere pathofysiologische mechanismen van migraine 
vergroten. 
 Aangezien onze functionele data en immunohistochemie lieten zien dat 
P2Y13 receptorexpressie en -activatie (remming van de CGRP afgifte) plaatsvindt in het 
trigeminale ganglion en op de zenuwuiteinden van de dura mater/a. meningea media, 




worden. Hiervoor is in het bijzonder de ontwikkeling van specifieke agonisten noodzakelijk. 
De voornaamste zorg met betrekking tot het gebruik van op ADP gebaseerde agonisten is hun 
potentiële trombotische activiteit. ADP dat P2Y1 of P2Y12 receptoren activeert, wordt op 
zichzelf als een relatief zwakke agonist beschouwd voor samenklontering van bloedplaatjes. 
Helaas werkt ADP nog steeds als een versterker van aggregatie van bloedplaatjes zoals 
trombine [17], wat niet verenigbaar is met de behandeling van patiënten. Deze mogelijke 
bijwerking zou geen probleem vormen bij het gebruik van een selectieve P2Y13 receptor 
agonist.
 Migraine komt drie keer zo vaak voor bij vrouwen in de reproductieve leeftijd dan 
bij mannen en eerdere studies hebben inzicht verschaft in de effecten van vrouwelijke 
geslachtshormonen op de pathofysiologie van migraine, en suggereren dat de reactiviteit 
van het trigeminovasculaire systeem bij migrainepatiënten in reactie op wisselende 
vrouwelijke hormoonspiegels, anders is dan bij gezonde vrouwen zonder migraine [18]. 
Daarnaast is in het verleden een wederzijdse beïnvloeding van CGRP en hormonale 
schommelingen in de vruchtbaarheidscyclus beschreven in de literatuur [19]. Om deze 
redenen zijn in dit proefschrift de farmacologische typeringen beperkt tot mannelijke 
knaagdieren. Toekomstig onderzoek zal moeten uitwijzen of er verschillen bestaan in de 
afgifte van CGRP bij mannelijke en vrouwelijke knaagdieren, en hoe de schommeling van 
steroïd hormonen  in de eierstokken op deze reactie inwerkt tijdens de verschillende stadia 
van de vruchtbaarheidscyclus. Recentelijk is aangetoond dat het toedienen van CGRP in het 
hersenvlies gedragsreacties veroorzaakt die overeenkomen met hoofdpijn, wat alleen bij 
vrouwelijke knaagdieren plaatsvindt [6]. Dit vraagt om een grondige farmacologische typering 
bij vrouwelijke knaagdieren tijdens de verschillende stadia van de vruchtbaarheidscyclus.
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